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Every day the human body encounters various pathogens such as bacteria and viruses. 
If these pathogens break through the initial physical and chemical barriers of the body, 
the immune system is recruited to eliminate them. To achieve this, the immune system 
uses tightly regulated innate and adaptive defense mechanisms. Rapid recognition and 
elimination of the pathogen is mediated by the innate immune response, while the adap-
tive immune response is slower but more specic and generates immunological memory 
for a quicker response if re-exposure occurs. The intricate balance between eector and 
regulatory immune cells ensures an optimal immune response. This balance also prevents 
immune responses against self-antigens through a phenomenon called immune toler-
ance. However, the interplay between intrinsic (genetic) and extrinsic (environmental) fac-
tors likely causes breakdown of self-tolerance, eventually resulting in autoimmune disease. 
Adaptive immunity (B and T cells) plays a fundamental, but yet incompletely understood 
role in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder 
(NMOSD). MS and NMOSD are inammatory and demyelinating diseases of the central 
nervous system (CNS) that are mediated by autoimmune-related processes. In this chapter, 
we introduce how B and T cells develop and interact in healthy individuals and what could 
trigger particular subsets to become pathogenic instead of protective in such patients. 
This sets the stage for the current thesis, which addresses the underlying mechanisms and 
clinical impact of human B and T cells on inammatory CNS demyelinating disease. 
ADAPTIVE IMMUNITY
B and T cells initially develop in the bone marrow and originate from hematopoietic 
stem cells (HSCs) committed to the lymphoid lineage [1]. Depending on the cytokine 
milieu and distinct transcription factors [1-3], lymphoid progenitor cells will either remain 
in the bone marrow to mature into B cells or migrate to the thymus to mature into T cells. 
During these processes, highly specic and unique B- and T-cell receptors are generated, 
making it possible to recognize a large variety of antigens. Both central and peripheral tol-
erance checkpoints are exploited to prevent recognition of self-antigens and to promote 
the development of functional subsets with non-self-reactive receptors [4]. Such B and 
T cells recirculate in the blood until an antigen is encountered within lymphoid organs. 
Upon encounter with antigens, B and T cells are activated and dierentiate into eector 
and memory cells in order to remove the pathogen through antibody-mediated humoral 
and cytotoxic cellular immunity [5, 6]. To reach these eector and memory stages, B and T 
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cells undergo a series of well-regulated developmental steps, which are further explained 
below.
B-cell development and eector functions
In the bone marrow, HSC-derived precursors develop into immature B cells with a B cell 
receptor (BCR) that is generated by random gene recombination of their immunoglobulin 
(Ig) heavy and light chain loci, known as V(D)J rearrangements [7, 8]. Two main central 
tolerance mechanisms ensure that immature B cells expressing high anity BCRs for 
self-antigens are removed. Receptor editing occurs when a self-reactive BCR is expressed 
during the early stages of B-cell development and certies that this specicity is lost 
through a second round of V(D)J rearrangements [9]. This mechanism involves the removal 
of an autoreactive BCR by deleting the self-reactive light-chain gene and replacing it with 
another sequence. If receptor editing fails, clonal deletion in the bone marrow removes 
self-reactive B cells [9]. The cells that survive these checkpoints exit the bone marrow and 
enter the circulation as transitional B cells (CD38high CD24highIgM+IgD+), which then further 
dierentiate into naive mature B cells (CD38-/dimIgM+CD27- IgD+; Fig. 1) with a functional 
BCR [7, 8]. At this particular stage, peripheral tolerance mechanisms including apoptosis, 
anergy and T regulatory cell (Treg)-mediated suppression are important to control autore-
active B cells that have escaped negative selection in the bone marrow [10].
Within secondary lymphoid organs such as the lymph nodes, mature naive B cells 
encounter antigens via the BCR, internalize, process and present these antigens on human 
leukocyte antigen (HLA) class II molecules to CD4+ T cells [11]. This can initiate either germi-
nal center (GC)-dependent or –independent dierentiation of naive B cells into memory B 
cells and antibody-secreting cells (ASCs; Fig. 1) [12, 13]. In GC-dependent responses B cells 
receive signals from CD4+ T follicular helper (Tfh) cells via CD40 ligand (CD40L[CD40]), CD28 
(CD80/CD86) and interleukin (IL)-21 to undergo clonal expansion, class switch recombina-
tion and somatic hypermutations of the VH genes [6]. During class switch recombination, 
the constant region of the BCR Ig heavy chain is replaced by other isotypes that have vary-
ing properties and functions. Somatic hypermutations take place at the variable regions 
of both the Ig heavy and light chains and comprises of single-nucleotide exchanges, 
deletions and point mutations [14]. Both these processes increase the anity of B cells 
for antigens. Somatic hypermutations in the GC can lead to formation of self-reactive B 
cells as well, however the tolerance mechanisms involved here to regulate their removal 
remains poorly understood [15]. Strong HLA-II antigen presentation and co-stimulation 
via CD40L/CD40 are key processes for maintaining peripheral tolerance [9, 16]. B cells that 
survive peripheral tolerance checkpoints and enter GCs develop into class switched IgG+, 
IgA+ or IgE+ memory B cells and long-lived plasma cells (CD38highCD27highCD138+) [17, 18]. 




in a GC-independent manner via the marginal zone in the spleen giving rise to natural 
eector B cells (CD27+IgM+IgD+) or in a GC-dependent manner that results in the devel-
opment of ‘IgM-only’ (CD27+IgM+IgD-) B cells (Fig. 1) [20]. Furthermore, GC-independent 
responses can lead to the generation of short-lived plasmablasts (CD38highCD27high) when B 
cells interact with CD4+ T cells in extra-follicular regions [12, 13]. Memory B cells function to 
act as antigen-presenting cells (APCs) and secrete pro- or anti-inammatory cytokines [21, 



























































Figure 1. Peripheral B-cell development.
Immature B cells that have survived central tolerance egress from the bone marrow into the circulation as 
transitional B cells (CD38highCD24highIgM+IgD+). When an antigen is encountered, naive mature B cells (CD38-/
dimCD27-IgM+IgD+) can take three pathways of dierentiation. Outside the germinal center (GC), B cells are able 
to directly mature into antibody-secreting cells (ASC; i.e. short-lived plasmablasts [PB; CD38highCD27highCD138-]). 
Natural eector B cells (CD27+IgM+IgD+) develop in the marginal zone of the spleen and are triggered in a GC-
independent manner [20]. Inside the GC, B cells are induced by T follicular helper (Tfh) cells via HLA class II, co-
stimulatory molecules (CD40-CD40L, CD80/CD86-CD28) and IL-21 to dierentiate into IgM-only/class-switched 
memory B cells as well as antibody-secreting cells (short- and long-lived plasma cells [PC; CD38highCD27highCD138+]).
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[23] that produce specic antibodies to neutralize the pathogen, activate the complement 
system and mediate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis
[24].
Besides for BCR signaling, B-cell intrinsic Toll-like receptor (TLR) activation also plays 
a role in shaping antibody responses against pathogens [25, 26]. TLRs directly sense 
microbes by recognizing pathogen-associated molecular patterns [25]. Human B cells 
express TLR1, TLR6, TLR7, TLR9 and TLR10 [25, 27, 28]. TLR1 and TLR6 are present at the 
plasma membrane and sense extracellular microbes, whereas TLR7 and TLR9 are localized 
in endosomal compartments and respond to pathogen-derived nucleic-acids such as 
single-stranded RNA and CpG-ODN (also referred to as CpG-DNA), respectively [29, 30]. 
BCR and CD40 stimulation enhance TLR expression on GC B cells and induce proliferation, 
somatic hypermutations and class switching before developing into high anity ASCs [27, 
31]. TLR9 is of particular interest since in vitro studies show that B cell dierentiation via 
CpG-ODN requires additional BCR, CD40 or cytokine signaling [26, 32]. This seems only to 
be the case in humans and not in mice [33, 34]. Through this interaction, TLRs cooperate 
with antigen-specic signals to generate optimal B-cell responses after an infection [25]. 
TLR signaling is also able to enhance the APC function of B cells [35] as well as their secre-
tion of a wide range of inammatory cytokines depending on the triggers [36, 37]. 
T-cell development and eector functions
Within the thymus, HSC-derived T-cell precursors (i.e. thymocytes) further mature by
undergoing rounds of positive and negative selection, and T-cell receptor (TCR) gene rear-
rangement [5, 38]. However, thymic deletion does not eliminate all self-reactive T cells. 
After leaving the thymus, these cells are further kept in check via intrinsic (ignorance, 
anergy, phenotype skewing, apoptosis) and extrinsic (Tregs, tolerogenic dendritic cells 
[DCs]) peripheral tolerance mechanisms [39]. These central and peripheral mechanisms 
both contribute to regulate or eliminate autoreactive T cells which are generated in the 
thymus by the stochastic nature of TCR rearrangement. In the end, non-autoreactive naive 
T cells enter secondary lymphoid organs for antigen-driven activation [38]. Here, naive T 
cells are primed by DCs to dierentiate into eector and memory subsets. There are two 
major types of T cells: CD4+ T helper (Th) and CD8+ cytotoxic T cells (CTLs). Based on the 
type of cytokines produced, CD4+ Th cells can be classied into functionally distinct sub-
populations. Th1 cells are required to generate an optimal CD8+ CTL response [40] and 
mount an immune response against intracellular bacteria and viruses [41]. Th2 cells are 
involved in removing extracellular parasites and helminthes, while Th17 cells normally 
respond to extracellular bacteria and fungi [5]. The capacity of macrophages and B cells 
to respond to extracellular antigens is stimulated by Th1 and Th2 cells, respectively [41]. 




presented. Th1 typically induces IgG antibody responses, Th2 promotes IgE and Th17 cells 
are able to trigger all subclasses including IgM, IgA, IgG and IgE [42, 43]. Also important 
in driving germinal center and antibody responses are Tfh cells, which are mainly found 
within follicles and produce IL-21 that induces such responses [44, 45].
CD4+ Th cell dierentiation involves the interplay of certain cytokines and transcrip-
tion factors (Fig. 2). Th1 cells are induced by IL-12 and interferon gamma (IFN-γ), which 
activate downstream signaling molecules signal transducer and activator of transcription 
(STAT)4 and STAT1 respectively [5, 46]. The T-box transcription factor (T-bet) is the master 
regulator of Th1 development and enhances IFN-γ production [47]. IFN-γ secretion creates 
a feedforward loop where IFN-γ induces STAT1 and T-bet expression which in turn leads 
to increased production of IFN-γ [5, 48]. Th2 cells are induced by IL-4. IL-4-mediated STAT6 
expression enhances the master transcription factor GATA-binding protein 3 (GATA3) [5, 
49]. The development of Tfh cells involves IL-6 and IL-21 that drive STAT3 and B cell lym-
phoma 6 (BCL-6) expression [5].
Th17 dierentiation is more complex and involves three distinct phases, including 
1) dierentiation, 2) self-amplication and 3) stabilization [5]. Th17 cell development is 
induced by transforming growth factor beta (TGF-β), IL-1β and IL-6, IL-21 or IL-23 [5, 50]. 
These cytokines activate downstream STAT3 signaling, which induces the master tran-
scription factor retinoic acid receptor-related orphan gamma t (RORγt). Interestingly, IL-1β 
together with IL-23 induces both T-bet and RORγt expression in murine and human Th17 
cells [51, 52]. Th17 cells are known to be highly polyfunctional, being able to additionally 
express transcription factors that are typical for Th1. These dierences in signaling path-
ways and transcription factors result in distinct expression of chemokine receptors and 
cytokines, which can be used to dene the phenotype of Th cells (Fig. 2). While Th1 and 
Th2 cells can be simply dened by their classical chemokine receptor proles, Th17 cells 
are more heterogeneous and consist of dierent phenotypes depending on the chemok-
ine receptor combinations used to dene them. C-C chemokine receptor (CCR)6-negative 
Th cells consist of Th1 cells that are positive for C-X-C chemokine receptor (CXCR)3 and 
Th2 cells that express CCR4 [53, 54]. Th17 cells are positive for CCR6 and can be further 
dened based on CXCR3 expression into Th1-like Th17 cells (CCR6+CXCR3+). Th17 cells also 
express CCR4 that can be used to subdivide these cells into Th17.1 (CCR6+CXCR3+CCR4-/
dim) and Th17 double positive (DP; CCR6+CXCR3+CCR4+) cells (Fig. 2) [55]. The expression 
of these receptors reects the pro-inammatory cytokines produced by each Th subset. 
Human Th17 (CCR6+CXCR3-CCR4+) cells produce high levels of IL-17A and lack IFN-γ, while 
GM-CSF is moderately expressed [55]. This is in contrast to mice where IL-17A is typically 
co-expressed with GM-CSF [56]. Th17.1 (CCR6+CXCR3+CCR4-/dim) cells secrete high levels of 
IFN-γ and GM-CSF but only low levels of IL-17A [55], while Th17 DP (CCR6+CXCR3+CCR4+) 





MS is a heterogeneous chronic inammatory demyelinating disease of the CNS. The 
pathological hallmark of MS is lesions within dierent CNS compartments including 
the brain, optic nerve and spinal cord [57, 58]. These lesions are initiated by immune 
cell-mediated inammation and contribute to demyelination and axonal loss [59]. 
Neurodegeneration is the main cause of clinical disability in MS patients [60]. The diag-





























Figure 2. Functional characteristics of human CCR6- and CCR6+ eector/memory Th cells. 
CD4+ Th0 cells dierentiate into distinct eector Th subsets based on the cytokine milieu that triggers certain 
transcription factors. Transcription factor, chemokine receptor and cytokine proles can also be used to classify 
these Th subsets. Both Th1 (CXCR3+) and Th2 (CCR4+) cells do not express CCR6. CCR6+ cells bear three major 
subsets: Th17(CCR4+), Th17.1 (CXCR3+CCR4-/dim) and Th17 double-positive (DP; CXCR3+CCR4+) cells [55]. Each of 





the presence of oligoclonal bands (immunoglobulins, Ig) within the cerebrospinal uid 
(CSF) that is obtained through lumbar puncture [61]. MS aects approximately 2.5 million 
people world-wide and is common in young adults between 20 and 40 years of age [60, 
62]. This disease is more frequent in women than in men with a ratio of 2.3:1 [63]. 
Disease course
The clinical and pathological heterogeneity of MS makes prognosis and treatment dif-
cult [60, 64]. Clinically isolated syndrome (CIS) refers to the rst neurological symptoms 
that last at least 24 hours and are suggestive of inammatory demyelinating diseases of the 
CNS [65-67]. Approximately 60% of CIS patients will experience subsequent relapses and 
convert to clinically denite MS (Fig. 3) [65, 68]. Relapsing-remitting MS (RRMS) is the most 
common subtype of MS, which is found in approximately 85% of patients and is dened by 
episodes of neurological dysfunction (relapses) followed by periods of relative clinical sta-
bility (remission) [60]. This subtype is characterized by waves of CNS-inltrating immune 
cells that contribute to demyelination during a relapse [60]. The remission phase of RRMS 
is dened by remyelination. Eighty percent of RRMS patients eventually convert to sec-
ondary progressive MS (SPMS), which is characterized by gradual increases in neurological 
decits with reduced numbers of inammatory relapses. There is a lack of biomarkers to 
accurately predict the conversion of CIS to RRMS and RRMS to SPMS. Approximately 10% of 
MS patients show a gradual neurological decline already from disease onset onwards [60]. 




















Figure 3. The heterogeneous disease course of MS. 
Symptoms for MS appear once the inammatory relapses go beyond the clinical threshold [60]. The rst clinical 
representation of MS is called clinically isolated syndrome (CIS), which transitions into relapsing-remitting MS 
(RRMS) after subsequent neurological attacks (relapses). RRMS is characterized by episodes of neurological 
dysfunction followed by remission. Secondary progressive MS (SPMS) evolves from RRMS, while primary 
progressive MS (PPMS) starts at disease onset. The progressive phase of the disease course involves gradual 




Over the last few decades, there have been remarkable advances in the treatment 
of MS (extensively reviewed and summarized in [69]). Most of these therapies target the 
immune system and networks involving B and T cells [69, 70]. Immunosuppressive drugs 
such as glucocorticoids are used to treat acute exacerbations in MS patients but are not 
disease-modifying [71]. First-line diseases-modifying drugs include dimethylfumarate, 
teriunomide, interferon β1a/b and glatiramer acetate [70]. Second-line disease-modify-
ing treatments show the strongest anti-inammatory eects, which are especially seen for 
alemtuzumab, ocrelizumab and natalizumab [69, 72]. The ecacy, tolerability and safety 
prole diers greatly across these treatments [70]. The benecial eects are often accom-
panied by serious side eects, which is particularly the case for second-line treatments. For 
example, clinical concerns during the use of natalizumab include the risk of progressive 
multifocal leukoencephalopathy (PML) [73] and severe rebounds of MS activity following 
treatment discontinuation [74]. Furthermore, these treatments are eective in dampening 
relapses, but are not able to prevent or stop the transition into progressive disease [70, 
75]. Since, relapse rates are associated with disease progression, it is crucial to unravel the 
(adaptive) immune mechanisms driving MS disease activity, especially during the early 
phases of the disease in order to allow earlier and thereby more eective treatment. 
Etiology: genetic and environmental factors 
Although the exact cause of MS is still unknown, both genetic and environmental fac-
tors have been described to increase the risk of developing MS. Genetic variation accounts 
for approximately 30% of the overall risk and large genome-wide association studies have 
now identied 233 dierent genetic regions that associate with MS [76]. Results from these 
studies underscore the role of disturbed adaptive immune responses in MS, which overlap 
and point to mechanisms shared with other autoimmune diseases [77]. The majority of 
gene variants associated with MS encode for proteins that are involved in functional path-
ways specically aecting B and CD4+ T cells [78]. The strongest genetic association with 
MS is HLA-DRB1*1501 [79]. Individuals who are carriers of the HLA-DRB1*1501 allele have 
an approximately three times higher risk of developing MS [69, 80]. 
Environmental factors such as low vitamin D, diet, sex hormones, infections and 
smoking can contribute to MS susceptibility [60, 63, 81]. Even though each of these fac-
tors increases the risk of MS, infection with the Epstein-Barr virus (EBV) is one of the best 
established contributors [82]. Individuals with high anti-EBV antibody titers or a history of 
infectious mononucleosis have an increased risk of developing MS [83-85]. Almost all MS 
patients are seropositive for EBV, which is the case for 90% of the healthy population [84, 




risk loci to cause MS. Consistently, the presence of the HLA-DRB1*1501 allele associates 
with increased levels of anti-EBV nuclear antigen (EBNA)1 IgG [88]. 
Immunopathology: B and T cells
Memory B and T cells are triggered in the periphery to inltrate and contribute to local 
inammation in the CNS of MS patients [89-91]. Pro-inammatory lymphocytes can enter 
the CNS through three main routes, i.e. the blood-brain barrier (BBB), the blood-cerebro-
spinal uid barrier (BCSFB) at the choroid plexus and the blood-meningeal barrier [92, 
93]. After their migration across the BBB, lymphocytes rst enter the perivascular space to 
interact with local APCs such as macrophages [92, 94]. Re-activated populations then have 
to cross the glia limitans to inltrate the CNS parenchyma [92, 94]. The BBB and BCSFB are 
thought to be dysfunctional, which is especially seen during the early phase of MS [57, 60, 
95, 96]. The exact mechanisms underlying the breakdown of BBB and BCSFB integrity are 
incompletely understood. Dierential expression of pro-inammatory cytokines, chemok-
ine receptors and integrins produced by inltrating lymphocytes are thought to facilitate 
this process in MS [57, 97]. This can be either through activation of brain endothelial or 
choroid plexus epithelial cells leading to upregulation of adhesion molecules or through 
disruption of tight junctions between these cells [96, 98-100]. CD4+ T cells are thought to 
initiate this damage [99, 101, 102] and subsequently allow the recruitment of other poten-
tially pathogenic immune cells into the CNS to cause damage to myelin sheaths. These 
cells can also inltrate the CNS through the BCSFB at the choroid plexus [97]. The success-
ful use of current treatment modalities in MS further highlight the role of B and T cells in 
the pathogenesis. For example, B-cell depletion (anti-CD20) therapies signicantly reduce 
disease activity and even slows down progression in MS patients. This is probably caused 
by reduced T-cell activation, as a result of the lack of antigen presentation, rather than 
antibody production by B cells [103]. Natalizumab is a monoclonal antibody that binds to 
α4β1 integrin (VLA-4) preventing T and B cells from binding to the vascular cell adhesion 
molecule (VCAM)-1 [104], thereby blocking their migration into the CNS. Yet, these thera-
pies target the bulk lymphocyte population and therefore have severe side eects. Earlier 
targeting of the exact Th and B cell subsets contributing to disease activity may circumvent 
this. 
T cells in MS
Based on human and experimental autoimmune encephalomyelitis (EAE) studies, the 
original view of MS is that increased activation or impaired regulation of eector T cells 
primarily mediate inammatory relapses [57]. CD4+ T cells are found deeper within lesions 
and CD8+ T cells are mostly found at the edges of lesions [95, 105]. Although CD8+ T cells 
outnumber CD4+ T cells within the CNS of late-stage MS patients [106], there are several 
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lines of evidence that CD4+ T cells contribute to MS disease onset [104, 107]. Consistently, 
an abundant number of CD4+ T cells are also visible in pre-active lesion sites [108], suggest-
ing an involvement of these cells in the early stages of lesion formation. Recently, it was 
demonstrated that in contrast to CD8+ T cells, brain-associated CD4+ T-cell TCR clonotypes 
are reduced in MS blood, indicating selective recruitment or, alternatively, local clonal 
expansion in the CNS [109]. Naive CD4+ T cells already seem to be more activated in CIS 
patients who rapidly develop CDMS, suggesting an increased ability to dierentiate into 
pathogenic subsets [110]. A potential cause of this increased activation is the lack of Treg 
control in the periphery [57, 111]. Tregs were shown to be abnormally enriched but func-
tionally impaired in MS [112-115]. This phenomena is associated with decreased FOXP3 
expression [114]. It is therefore thought that pro-inammatory CD4+ Th cells, triggered by 
APCs such as B cells or myeloid cells (macrophages, dendritic cells and microglia), escape 
Treg control and enter the brain.
Both Th1 and Th17 cells are associated with MS (Fig. 4) [104]. Prior to the identication 
of Th17 cells, Th1 cells were thought to be the critical autoreactive T-cell subset because 
IFN-γ induces EAE and is found in active MS lesions [116-118]. However, later studies 
challenged the involvement of Th1 cells by showing that genetic deletion of IFN-γ lead 
to increased severity of EAE [69, 119], indicating a protective role for IFN-γ instead. This 
controversy and identication of Th17 cells lead to their detection in the draining lymph 
nodes of mice with EAE, as well as in peripheral blood and CNS inltrates of patients 
with MS [107, 118, 120]. Th17 cells have also been shown to be enriched in the CSF of MS 
patients during a clinical relapse compared to patients in remission [121] and can directly 
induce neuronal dysfunction in the CNS [122]. Interestingly, Th17 cells do not only produce 
their signature cytokine, IL-17 (as explained in the section T-cell development and eector 
functions), but have been found to co-produce IFN-γ and/or GM-CSF depending on the 
cytokine milieu [123]. This is particularly true for myelin-reactive CCR6+ memory Th cells 
in MS patients. Furthermore, GM-CSF is an emerging cytokine that plays a crucial role in 
MS disease pathogenesis. The fact that CCR6+ cells responding to myelin produce dierent 
types of cytokines under diverse conditions indicates that further research is needed to 
dene distinct subsets in order to understand their exact role in MS and to better predict 
and treat the clinical course.
B cells in MS
A rst clue that B cells contribute to MS immunopathogenesis came from studies that 
identied oligoclonal bands in the CSF of MS patients [94, 124]. Oligoclonal bands are used 
as a diagnostic tool in MS and are present in the CSF of 90% of patients [125]. More recent 
studies identied meningeal follicle-like structures containing B cells and plasma cells 




demyelination [129]. Furthermore, similar B cell clones have been found in the periphery 
and CNS of MS patients [130, 131], indicative of their ability to migrate across the BBB and 
produce antibodies intrathecally (Fig. 4). Plasmablasts or plasma cells express little to no 
CD20 and as such are not targeted by anti-CD20 B-cell depletion therapies, which results 
in no eect on the amount of oligoclonal bands present within the CSF [57, 91]. This along 
with reduced T cell activation by such therapies indicates B cells can function as APCs in 
the periphery of MS patients (Fig. 4). Consistently, in mice, the antigen-presenting and not 
the antibody-producing function of B cells is essential for EAE induction [91]. Similarly, in 
MS patients, memory B cells have been shown to activate and induce auto-proliferation of 
CNS-inltrating IFN-γ-producing Th cells in an HLA-DRB1*1501-dependent manner [89]. 
B cells from MS patients also have an increased ability to produce pro-inammatory cyto-
kines, such as IL-6, GM-CSF, TNFα and lymphotoxin-α (LTα), which may contribute to local 
inammation and damage [103, 132-134]. Which peripheral mechanisms are required for 
the development of CNS-inltrating pathogenic B cells in MS patients remain elusive.
In contrast to other autoimmune diseases, only peripheral and not central tolerance 

































Figure 4. Model of peripheral triggering of CNS-inltrating B and T cells as underlying mechanism in early 
MS. 
In secondary lymphoid organs, CD4+ T helper (Th) and B cells interact to form germinal centers. In MS, yet unknown 
antigens are recognized and taken up by B cells, processed and presented via HLA-II molecules to CD4+ T cells. 
Together with costimulatory and cytokine signals, this causes a feedforward loop in which both B and T cells are 
activated. In early MS, pathogenic B- and T-cell subsets migrate across a dysfunctional blood-brain barrier into the 
perivascular space and likely become reactivated to cross the glia limitans into the CNS parenchyma. These cells 
can also cross the blood-CSF and blood-meningeal barrier to enter the CNS. Once in the CNS B- and T-cell subsets 
produce pro-inammatory cytokines that trigger demyelination along with other cells such as microglia. CD8+ T 
cells are also present in the CNS to induce local damage, although this is thought to be less during early MS. B cells 
develop into antibody-secreting cells (ASCs) to probably further mediate local pathology.
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of potentially autoreactive naive populations in the blood [112, 135, 136]. Similar to CD4+ 
Th cells, this may be attributed to the dysfunction of Tregs, allowing naive B cells to survive 
and develop into pathogenic memory B cells in peripheral lymphoid organs. After their 
escape from these checkpoints, naive B cells likely interact with Th cells in GCs to develop 
into memory populations capable of inltrating the MS brain (Fig. 4). Recent evidence from 
autoimmune mice show that autoreactive B cells are triggered by IFN-γ, which is likely 
produced by Tfh cells [18]. Moreover, pathogenic B-cell responses in autoimmune dis-
eases such as systemic lupus erythematosus are enhanced after IFN-γ- and virus-mediated 
induction of T-bet- and CXCR3-expressing B cells [137-139]. Such IgG-switched T-bet+ B 
cells show increased antiviral responsiveness as well [140, 141]. However, in MS patients 
less is known about the signals coming from CD4+ Th cells to induce the development of 
such B cell subsets. 
EBV-related B- and T-cell responses in MS
EBV is a human DNA herpesvirus that establishes a lifelong latency within resting 
memory B cells [142]. During an acute infection, EBV is spread through saliva and infects 
naive B cells in the tonsils via binding of viral glycoproteins gp350/220 with CD21 and 
gp42/gH/gL with HLA-II expressed on B cells [142-144]. To accomplish latency in memory 
B cells, the virus uses a series of programs that drive B cells towards a GC response in a 
both antigen- and T cell-independent manner. Latent membrane protein (LMP)2A and 
LMP1 resemble signals coming from the BCR and CD40 receptor [142, 145]. In addition to 
their regulation of GC responses, [146], recent evidence shows that LMP2A and LMP1 can 
synergize with BCR and CD40 signaling as well [147]. 
Although denite evidence for EBV as a causal factor in MS is lacking, there are many 
hypotheses proposed on how EBV is involved in the immunopathogenesis of MS [148]. 
These include 1) molecular mimicry through cross-reactivity [149], 2) bystander activation 
and 3) infection of autoreactive B cells in the periphery [142, 150]. The rst hypothesis 
has been favored for many years and suggests that EBV antigens prime T cells, which 
cross-react with and instead attack cells expressing CNS antigens [151]. In line with this, 
IFN-γ-producing CD4+ Th cells in the blood of MS patients have been shown to respond to 
both myelin and EBV antigens [83, 87]. Also IFN-γ-producing T cells in MS CSF and brain 
tissue show increased EBV specicity and responses to EBV-infected B cells [152-155]. 
The second hypothesis suggests that immune cells respond to EBV infection and cause 
bystander damage to the CNS in the process of trying to eliminate the virus [142]. The third 
hypothesis postulates that EBV causes MS by infecting autoreactive B cells in genetically 
susceptible individuals [142, 144]. Here, the hypothesis is that EBV-infected memory B cells 
develop and escape CD8+ CTL control to inltrate the CNS and produce (auto)antibod-




EBV-specic T-cell responses [150]. Moreover, EBNA1-specic IgG antibodies are predictive 
for early disease activity [156] and are present in CSF from MS patients [152, 157]. Whether 
EBV is detected in the brain or solely recognized in the periphery and how this contributes 
to local pathology is still a matter of intense debate in the eld [158-163]. 
NEUROMYELITIS OPTICA SPECTRUM DISORDER
General features
NMOSD is a rare, but severe inammatory demyelinating disease of the CNS, which 
mostly aects the spinal cord, optic nerve and brainstem [94]. Approximately 80-90% of 
patients have relapses of optic neuritis and myelitis, most of which worsen over several 
days with slow recovery thereafter [164]. NMOSD has an estimated incidence and prev-
alence of 0.05-0.40 and 0.1-4.4 cases per 100,000 individuals [94, 165]. The mean age at 
onset ranges from 32-45 [165]. NMOSD is more common in females with a range of 66-88% 
of the patient population [165].
Initially, NMOSD was thought to be a clinical variant of MS. However, in 2004, aqua-
porin-4 (AQP4), a membrane-bound water channel expressed on astrocytes, was identied 
as a target antigen in approximately 75% of NMOSD patients [94, 166]. The detection of 
AQP4 antibodies allows NMOSD to be distinguished from MS [166]. Recent studies indi-
cate that within the subgroup of AQP4-IgG seronegative NMOSD patients, about 30-40% 
have antibodies specic for myelin oligodendrocyte glycoprotein (MOG) [167, 168]. MOG 
antibody-associated disorder (MOGAD) most frequently presents as acute disseminated 
encephalomyelitis (ADEM) in children under seven years and as optic neuritis in older 
children and adults [169, 170]. Currently, the diagnosis of AQP4-IgG-positive NMOSD 
and MOGAD is based on clinical manifestations, neuroimaging and serology [171]. Both 
anti-AQP4 and anti-MOG antibodies are of the IgG1 subtype and are more abundant in 
the serum than in CSF of these patients [166, 172]. Patients with MOGAD are predomi-
nantly males, have fewer relapses and show an improved recovery as compared to AQP4-
seropositive NMOSD patients [171, 173]. Clinical studies have also suggested reasons to 
include MOG-IgG-positive patients under the spectrum of NMOSD, but this remains a 
matter of debate since the exact pathology of disease is unknown [171]. For both progno-
sis and treatment decisions, it is important to understand the relation between the immu-
nopathogenesis and relapse occurrence in these patient groups. This is exemplied by the 
fact that eective MS treatments such as interferon-β and natalizumab can exacerbate 
NMOSD [174-176]. Steroids such as prednisolone are often used to dampen acute relapses, 
but does not prevent disease progression in both NMOSD and MS patients [173]. The exact 
cause of NMOSD is even less clear than in MS.
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Immunopathology: B and T cells
NMOSD is considered to be an autoimmune disease driven by autoantibodies that 
target astrocytes and/or oligodendrocytes in the CNS [94, 177-179]. Not much is known 
about how B cells are triggered, interact with T cells and develop into ASCs to cause local 
damage in this spectrum of diseases. It is highly likely that such specic ASCs are already 
induced in the periphery (Fig. 5) [94]. In contrast to MS, both central and peripheral B cell 
tolerance defects are present in patients with NMOSD, indicating that large numbers of 
autoreactive naive B cell clones accumulate in the periphery [180]. Moreover, B cell deple-
tion therapies with anti-CD20 [181, 182] and -CD19 [183] monoclonal antibodies are very 
eective in treating NMOSD. However, treatment response does not always correlate with 
reduced AQP4-specic antibody titers in the periphery [184]. Whether AQP4- or MOG-
specic antibodies are pathogenic or represent a bystander or epiphenomenon remains 
unclear [185], and together with B cell depletion therapy outcomes could suggest that 
similar to MS, also antibody-independent B-cell mechanisms are involved in the pathol-
ogy of NMOSD and MOGAD. In a few studies, increased frequencies of AQP4-specic Th17 
cells have been found in the peripheral blood of NMOSD patients [186, 187]. AQP4-specic 
Th cells are also able interact with B cells and induce dierentiation of ASCs within the 
peripheral lymph nodes [94]. Subsequently, peripherally produced anti-AQP4 or anti-MOG 
antibodies migrate into the CNS (Fig. 5) [188-190]. Within the brain, AQP4 is located at the 
foot of the astrocytes, which are CNS-resident cells that function to protect neurons and 
control the BBB and blood ow [173]. Binding of anti-AQP4 antibodies to astrocytes results 
in complement- and cell-mediated damage (Fig. 5) [173]. This largely involves the recruit-
ment of eosinophils and neutrophils [191]. The destruction of astrocytes is a primary event 
in NMOSD that eventually leads to a lack of support to myelin sheaths on neurons [173]. 
MOG, is a well-established autoantigen in EAE [192], which is expressed on the outermost 
lamellae of myelin sheaths and the cell body and processes of oligodendrocytes. Binding 
of anti-MOG antibodies to these structures causes demyelination (Fig. 5) [193]. Similarly, 
in a small number of encephalitis patients who are seropositive for anti-MOG antibody, 
demyelination by myelin-specic macrophages has been described [194, 195]. A role for 
complement-mediated demyelination in MOGAD remains unclear. Although complement 
is present in CNS lesions of MOGAD, MOG-specic antibodies have a limited ability to acti-









































Figure 5. Immunopathogenesis of AQP4-IgG-positive NMOSD and MOGAD. 
The rst part illustrates the dierent CNS-resident cells involved in neuronal support and maintenance in the 
healthy brain. The second part demonstrates a model of what pathogenic events may occur to induce AQP4-
IgG-positive NMOSD and MOGAD. In AQP4-associated NMOSD, AQP4 IgG enter the CNS and bind to its antigen 
and induces astrocyte damage. During initial disease there is relative myelin preservation but eventually lack 
of astrocyte support induces myelin damage. In contrast, MOGAD involves MOG IgG binding to its antigen on 
oligodendrocytes and causes demyelination. Adapted from Whittam et al., Journal of Neurology 2017 [198].
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THE SCOPE OF THIS THESIS
B and CD4+ Th cells are critically involved in the pathogenesis of CNS demyelinating dis-
eases such as MS and NMOSD. How human B- and CD4+ Th cell populations develop in the 
periphery in order to drive disease activity remains poorly understood. In this thesis, we 
set out to unravel the identity, mechanisms and triggers of disease-relevant lymphocyte 
subsets in MS and NMOSD patients. 
In Chapter 2, we studied human CCR6+ Th memory cells in detail and determined 
which Th17 eector phenotypes and functions correlate with early MS disease activity. The 
chemokine receptors CXCR3 and CCR4 were used to delineate subsets with high (Th17), 
dim (Th17 DP) and low (Th17.1) IL-17A levels in the blood (both pre- and post-natali-
zumab), CSF and brain tissue of MS patients. The expression of Th1 and Th17 transcription 
factors (T-bet, RORγt) and cytokines (IFN-γ, GM-CSF, IL-17A) by these cells were assessed 
to pinpoint their pathogenic potential. To further shed light on the dierences in CNS-
homing capacity of these Th17 subsets, we compared their recruitment to the CSF between 
patients with early MS and other types of neurological diseases. This capacity was related 
to their sensitivity to glucocorticoids as standard treatment of acute MS activity through 
the expression of multidrug resistance (MDR)1 and glucocorticoid receptor (GR) (Chapter 
3). MDR1 was used as a marker to detect glucocorticoid-resistant Th17.1 cells in MS brain 
compartments (both ex vivo and in situ). 
Chapter 4 focuses on which and how functional B-cell subsets are triggered to inltrate 
the CNS of MS patients. We assessed both their in vitro dierentiation and CNS inltration 
potential, as well as their ex vivo recruitment to MS brain compartments. IFN-γ and TLR9 
ligand CpG-ODN were used as triggers of naive and memory B cells in GC-like dierenti-
ation systems. In Chapter 5, the impact of EBV infection on the induction of B cells was 
assessed using PBMCs from MS patients who have received autologous bone marrow 
transplantation and patients treated with natalizumab. A highly sensitive qPCR was used 
to measure EBV DNA copy numbers in sorted B-cell subsets.
Since naive B cells have also been put forward as key contributors to NMOSD patho-
genesis, we compared both ex vivo and in vitro naive B-cell dierentiation between NMOSD 
and MOGAD patients with and without steroid treatment (Chapter 6), which is commonly 
used to dampen acute relapses. Results were compared to B cells from matched healthy 
controls and MS patients. Finally, in Chapter 7, the results obtained from this thesis are 
discussed and integrated with current knowledge into a model of how B and T cells could 
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Interleukin-17-expressing CD4+ T helper 17 (Th17) cells are considered as crit-
ical regulators of multiple sclerosis disease activity. However, depending on the 
species and pro-inammatory milieu, Th17 cells are functionally heterogeneous, 
consisting of subpopulations that dierentially produce interleukin-17, interfer-
on-gamma and granulocyte macrophage colony-stimulating factor. In the current 
study, we studied distinct eector phenotypes of human Th17 cells and their cor-
relation with disease activity in multiple sclerosis patients. Th memory populations 
single- and double-positive for C-C chemokine receptor 6 (CCR6) and CXC chemo-
kine receptor 3 (CXCR3) were functionally assessed in blood and/or cerebrospinal 
uid from a total of 59 clinically isolated syndrome, 35 untreated and 24 natalizum-
ab-treated patients with relapsing-remitting multiple sclerosis, and nine patients 
with end-stage multiple sclerosis. Within the clinically isolated syndrome group, 
23 patients had a second attack within 1 year and 26 patients did not experience 
subsequent attacks during a follow-up of >5 years. Low frequencies of T helper 
1 (Th1)-like Th17 (CCR6+CXCR3+), and not Th17 (CCR6+CXCR3-) eector memory 
populations in blood strongly associated with a rapid diagnosis of clinically de-
nite multiple sclerosis. In cerebrospinal uid of clinically isolated syndrome and 
relapsing-remitting multiple sclerosis patients, Th1-like Th17 eector memory 
cells were abundant and showed increased production of interferon-gamma and 
granulocyte macrophage colony-stimulating factor compared to paired CCR6+ 
and CCR6- CD8+ T cell populations and their blood equivalents after short-term 
culturing. Their local enrichment was conrmed ex vivo using cerebrospinal uid 
and brain single-cell suspensions. Across all pro-inammatory Th cells analyzed in 
relapsing-remitting multiple sclerosis blood, Th1-like Th17 subpopulation T helper 
17.1 (Th17.1; CCR6+CXCR3+CCR4-) expressed the highest very late antigen-4 levels 
and selectively accumulated in natalizumab-treated patients who remained free of 
clinical relapses. This was not found in patients who experienced relapses during 
natalizumab treatment. The enhanced potential of Th17.1 cells to inltrate the cen-
tral nervous system was supported by their predominance in cerebrospinal uid of 
early multiple sclerosis patients and their preferential transmigration across human 
brain endothelial layers. These ndings reveal a dominant contribution of Th1-like 
Th17 subpopulations, in particular Th17.1 cells, to clinical disease activity and pro-
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INTRODUCTION
Multiple sclerosis (MS) is mediated by eector T cells tracking from the periphery into 
the central nervous system (CNS) to trigger local inammation, demyelination and neuro-
degeneration [1]. Although current T cell-directed treatment attenuates disease activity, 
it often causes serious complications and does not prevent disease progression in MS [2]. 
To improve treatment ecacy and risk management, more in-depth insight into human 
eector T cells during MS onset is warranted. In the earliest clinical presentation of MS, clin-
ically isolated syndrome (CIS), increased peripheral CD4+ T cell activation is linked to the 
occurrence of a second attack [3]. However, substantial knowledge has been gained about 
specic human T helper (Th) functions, and the exact nature of the pro-inammatory Th 
subsets involved in MS is incompletely understood.
Both Th1 and Th17 cells are known to be encephalitogenic, but use distinct transmi-
gration routes to enter the CNS. In experimental autoimmune encephalomyelitis, Th1 cells 
preferentially migrate into the spinal cord, while Th17 cells mainly inltrate the brain [4].
This is facilitated by their dierential expression of pro-inammatory cytokines, chemo-
kine receptors and integrins [5-7]. Interleukin-17 (IL-17) and C-C chemokine receptor 6 
(CCR6) are key determinants for Th17 transmigration across the blood-brain barrier [8]. 
IL-17 is generally considered as the signature cytokine produced by CCR6-positive Th17 
cells. However, this greatly underestimates Th17 eector function, since subpopulations 
also (co-)produce interferon-gamma (IFN-γ) and granulocyte macrophage colony-stim-
ulating factor (GM-CSF). Next to IL-17, also IFN-γ and GM-CSF are strongly produced by 
myelin-specic CCR6-positive Th cells in MS [7, 9]. Th17 polyfunctionality is dierently reg-
ulated between species, as reected by the antagonistic regulation of IL-17 and GM-CSF 
expression in human compared to murine Th cells [10-12]. Particularly GM-CSF produced 
by Th cells is implicated as a critical mediator of MS onset [13, 14]. 
The surface expression of another chemokine receptor, CXCR3, denes Th17 cells with 
Th1-like features [15]. CCR6 and CXCR3 expression on CD4+ T cells is controlled by tran-
scription factors RORγt and T-bet, respectively, which were originally associated with IL-17/
IFN-γ double-production [15]. However, recent ndings demonstrate more heterogeneous 
IL-17, IFN-γ and GM-CSF expression proles in Th17 cells, depending on the inammatory 
milieu [16]. Besides CCR6 and CXCR3, also the presence of the α4β1 integrin very late 
antigen-4 (VLA-4), which is abundant on Th17 cells in MS cerebrospinal uid (CSF) [17], 
determines T-cell transmigration capacities. Anti-VLA-4 monoclonal antibody natalizumab 
is currently one of the most eective therapies in MS, but relapses are still encountered 
after one year in about one-third of treated patients [18]. Understanding which distinct 
pro-inammatory Th subsets are targeted by natalizumab will help to better predict treat-
ment response in MS [19].
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Here, blood and CSF samples from CIS and both untreated and natalizumab-treated 
relapsing-remitting MS (RRMS) patients were assessed for distribution, memory pheno-
type, activation and pro-inammatory capacity of Th17 subsets. We reveal that IFN-γ-/
GM-CSF-producing (CCR6+CXCR3+), but not IL-17-producing (CCR6+CXCR3-) Th17 eec-
tor cells are key regulators of MS onset. A Th1-like Th17 subpopulation termed Th17.1 
(CCR6+CXCR3+CCR4-) is selectively targeted by natalizumab in MS patients who remained 
free of clinical relapses. This work supports the design and early use of therapeutic strate-
gies against Th17.1 cells to prevent relapses in MS.
MATERIALS AND METHODS
Patients
Characteristics of patients and controls in the screening cohorts are summarized in Table 
1. Main experimental results were conrmed using additional cohorts (Supplementary
Table 1). All CIS and RRMS patients as well as controls were included at Erasmus MC
(Rotterdam, The Netherlands), which is a national tertiary referral center for patient with
MS (MS Center ErasMS). All primary material was collected between 2007 and 2017.
For blood analyses, we selected 23 patients with CIS who did not experience a second 
clinical attack for at least 5 years of follow-up (CIS-CIS) and 26 CIS patients who were 
diagnosed with clinically denite MS (CDMS) within 1 year after CIS (CIS-CDMS) from our 
prospective cohort. None of these patients were treated with disease-modifying therapies 
before or at time of sampling. CIS was dened as a rst clinical attack of demyelination 
in the CNS [20]. CDMS diagnosis was made when a patient experienced two attacks with 
clinical evidence of two separate lesions according to the Poser criteria [21]. A relapse was 
dened as sub-acute worsening of existing symptoms, or new symptoms after at least 30 
days of improvement or stable disease [22]. Fatigue scores were acquired at time of the 
rst attack using the self-administered Krupp’s Fatigue Severity Scale (FSS), as shown pre-
viously [23]. Anti-EBNA1 IgG levels were determined in plasma using a well-validated che-
miluminescent assay and analyzer (Liaison XL; both Diasorin, Saluggia, Italy) according to
manufacturers’ instructions at our local referral center for virus diagnostics (Erasmus MC).
Patients with RRMS were diagnosed according to the McDonald 2010 criteria [24]. 
Blood Th cell analyses were performed for 31 treatment-naive RRMS patients, as well as for 
24 RRMS patients before the start and after both 6 and 12 months of natalizumab therapy. 
The median time between the last clinical attack and rst administration of natalizumab 
was 2.8 months [interquartile range (IQR): 1.7-6.3]. Seventeen of these patients (70.8%) 
were treated with disease-modifying therapy before initiation of natalizumab (14 with 
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IFN-β, one with both dimethylfumarate and ngolimod, one with glatiramer acetate and 
one with mitoxantron). 
CSF with and without paired blood samples were obtained from 14 patients with ear-
ly-stage MS (ErasMS) and nine with late-stage MS (Netherlands Brain Bank, Amsterdam). 
In the early-stage MS group, 10 patients were CIS at the time of lumbar puncture and four 
patients were diagnosed with RRMS within 6 months before sampling. The median time 
between sampling and the last clinical attack was 2.8 months (IQR: 1.3-5.8). Additional 
autopsied brain tissues were obtained from ve patients with late-stage MS and two 
non-demented control subjects (Netherlands Brain Bank). All study protocols were 
Table 1. Characteristics of patients and controls in screening cohorts
aRRMS according to the McDonald (2010) criteria. 
bFourteen patients were included for in-depth analysis of Th17 subpopulations in blood. For three patients, Th 
subsets were only used for analysis of pro-inammatory cytokine expression. 
cAt the time of sampling.
dAt the time of pre-treatment sampling. 
eTime from CIS diagnosis to sampling.
fSamples obtained from either CIS and RRMS patients (‘early’) or deceased patients with MS and non-demented 
control subjects (‘late’). 
gThree patients were also used for ex vivo CSF/brain T cell analysis. 
HC = healthy control; MS = multiple sclerosis; NA = not applicable or available; NAT = natalizumab; NDC = non-
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approved by the medical ethics committee of the Erasmus MC (Rotterdam) and VUmc 
(Amsterdam, The Netherlands). Written informed consent was obtained from all included 
patients and controls. 
Mononuclear cell isolation from blood, CSF and brain tissue 
Blood from patients and matched controls was collected using Vacutainer CPT tubes 
(BD Biosciences, Erembodegem, Belgium) containing sodium heparin. Peripheral blood 
mononuclear cells (PBMC) were isolated according to manufacturer’s instructions. After 
centrifugation, cells were taken up in RPMI 1640 (Lonza, Verviers, Belgium) containing 
40% fetal calf serum (FCS) and 20% dimethyl sulfoxide (Sigma-Aldrich, Saint-Louis, MO) 
and stored in liquid nitrogen until further use. Surplus CSF of patients with early-stage MS 
was obtained through lumbar puncture for diagnostic purposes. Blood and CSF samples 
from patients with late-stage MS were acquired post-mortem through heart puncture and 
ventricle drainage, respectively. Collection tubes with CSF were centrifuged for 10 min at 
500g. Paired blood and blood from buy coats were diluted in phosphate-buered saline 
(PBS), after which mononuclear cells were isolated by density gradient centrifugation 
using Ficoll® Paque Plus (GE Healthcare, Freiburg, Germany). CSF and blood mononuclear
cell fractions were resuspended in RPMI 1640 containing 10% heat inactivated human AB 
serum (Sanquin, Rotterdam, The Netherlands) and 1% Pen/Strep (Lonza) and left to rest 
at 37oC until further use. Brain tissue samples were processed and single-cell suspensions 
were obtained as described previously [25]. 
Short-term CSF and blood T-cell cultures
Short-term culturing of CSF-derived T cells was required to obtain sucient cell num-
bers for uorescence-activated cell sorting (FACS) and intracellular cytokine staining of the 
Th subsets of interest. CSF and blood T cells were cultured as previously described [26]. In 
short, mononuclear cell fractions were treated for 13 to 15 days with γ-irradiated feeder 
cells (10×106 PBMC and 1×106 EBV- B-cell lines HAL-02 and RS-411), phytohemagglutinin-L 
(1 ng/ml; Sigma-Aldrich), IL-2 (25 U/ml; Erasmus MC) and IL-15 (12.5 ng/µl; Miltenyi Biotec, 
Leiden, The Netherlands) in RPMI 1640 containing L-glutamine (Lonza), 1% Pen/Strep and 
10% heat-inactivated human AB serum. IL-2 and IL-15 were added every 3 to 4 days. Post-
mortem CSF samples were re-stimulated using the same protocol. 
Antibodies and ow cytometry
Multicolor ow cytometric analysis was performed using the following uorochrome-la-
beled monoclonal anti-human antibodies: CD3 BV785 (SK7), CD8 FITC (SK1), CD45RA 
APC-H7 (HI100), HLA-DR FITC and BB515 (G46-6), VLA-4 BV711 and APC (9F10), CD45RO 
PerCP-Cy5.5 (UCHL1), CD25 BV605 and APC-R700 (2A3), CD226 BB515 (DX11), MCAM 
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PerCP-Cy5.5 (P1H12), PSGL-1 APC (KPL-1), GM-CSF BV421 and PE-CF594 (BVD2-21C11; all 
BD Biosciences), CD4 BV510 (OKT4), CD38 BV711 and PerCP-Cy5.5 (HIT2), CXCR3 BV421, 
PE-Cy7 and APC (G025H7), CCR6 PE (G034E3), CCR7 PE-CF594 (150503), CCR4 PE-Cy7 and 
PE-Dazzle (L291H4), CD161 BV605 (HP-3G10), IFN-γ BV421 and BV711 (4S.B3), and IL-17A 
APC (BL168; all Biolegend, London, UK). Cells were stained for 30 min at 4oC, measured 
with an LSRII-Fortessa ow cytometer and analyzed using FACSDiva 6.1.2 software (both 
BD Biosciences). Th1, Th17 and Th1-like Th17 cells were dened based on markers CCR6 
and CXCR3 with and without the use of CCR4. For analyses without CCR4, total CD4+ T cells 
were subdivided into CCR6-CXCR3+ (Th1), CCR6+CXCR3- (Th17) and CCR6+CXCR3+ (Th1-like 
Th17) subsets. In each Th subset, the proportion of eector memory (CCR7-CD45RA-) and 
central memory (CCR7-CD45RA+) cells was analyzed. CCR4 was used as a marker to discrim-
inate CCR6-CXCR3+CCR4- (Th1), CCR6+CXCR3-CCR4+ (Th17), CCR6+CXCR3+CCR4- (Th17.1) 
and CCR6+CXCR3+CCR4+ (Th17 double-positive, DP) subpopulations [27]. 
Intracellular cytokine staining
Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-), Th1-like Th17 (CCR6+CXCR3+), as well as CCR6- 
and CCR6+ CD8+ T cells were sorted from blood and CSF T cell memory pools (CD3+CD25-/
int CD45RO+CD45RA-) using a BD FACSAria™ III cell sorter. Prior to isolation of Th memory 
subsets from buy coats, CD4+ cells were puried from the mononuclear cell fraction 
using CD4 microbeads and the autoMACS Pro Separator (both Miltenyi Biotec). Cells were 
stimulated with phorbol 12-myristate 13-acetate (PMA; 1:2000) and ionomycin (1:500; 
both Sigma-Aldrich) for 5 h. GolgiStop™ (1:1500; BD Biosciences) was added during the last 
2.5 h of stimulation. Stimulated cells were xed and permeabilized using the BD Cytox/
CytopermTM kit (BD Biosciences) according to the provided protocol, and stained for IFN-γ, 
GM-CSF and IL-17A within the same tube. 
RNA isolation and quantitative PCR
Sorted T-cell subsets were washed with PBS and resuspended in RNA lysis solution with 
1% 2-ME. Total RNA was extracted using the GenElute™ Total RNA Purication kit (Sigma-
Aldrich) and treated with DNase I (Invitrogen, Carlsbad, CA). Complementary DNA (cDNA) 
was synthesized from total RNA using a reaction mix containing Tris-aminomethane (200 
mM), KCl (500 mM), MgCl2 (0.2 M; Sigma-Aldrich), DTT (100 mM; Invitrogen), random 
hexamers (50 µM; Invitrogen), oligo(dT) 15 primer (100 µg/ml; Promega, Madison, WI), 
dNTP mix (10 mM; Promega), RNAsin® (40 U/µl; Promega) and superscript™ II (200 U/µl;
Invitrogen). After incubation at 42oC for 50 min and inactivation at 99oC for 3 min, cDNA 
was diluted and stored at -20oC until use. For quantitative PCR, 0.2 µM forward and reverse 
primer (Sigma-Aldrich), 10 µM probe (Universal Probe Library; Roche Applied Science, 
Penzberg, Germany) and diluted cDNA were added to Taqman® Universal PCR Master Mix.
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Target gene expression was measured using optimal primer/probe assays and Taqman® 
7900HT (Applied Biosystems, Foster City, CA). We used the following thermal cycle pro-
tocol: 2 min at 50ºC and 10 min at 95ºC followed by 40 cycles of 15 s at 95ºC and 1 min at 
60ºC. CT values were analyzed using SDS 2.4.1 software (Applied Biosystems). Expression 
levels of target genes were normalized using 18S rRNA as a reference. Primer sequences 
are provided in Supplementary Table 2.
T-cell transmigration assays
CD4+CD25-/int memory T cells depleted from naive populations (CCR7+CD45RA+) were 
sorted by FACS and added at 2×105 cells/well to 3 μm pore size transwell plates (Corning, 
Amsterdam, The Netherlands). Migration of Th17 subsets towards medium or CXCL10 (900 
ng/ml; R&D Systems, Abingdon, UK) was analyzed after 3 h incubation at 37°C using FACS. 
To assess trans-endothelial migration of Th17 subsets, migration experiments were per-
formed across conuent monolayers of human brain endothelial cells (hCMEC/D3 cell line) 
[28] on collagen-coated 5 μm pore size Transwell® plate, as previously described [29]. In this 
system, 5×105 Th memory cells were added per well and migration was assessed after 4 h.
Statistical analyses
Statistical analyses were carried out using Graphpad Prism Software, version 5.04. 
We used the two-tailed Mann-Whitney U test to compare two independent groups and 
the Wilcoxon matched-pairs signed rank test to compare samples of the same persons. 
Correlations were tested using Spearman’s rank. A logistic regression model was used to 
correct for MRI measurements in the multivariate analyses. Experimental data are depicted 
as mean and standard error of the mean. P-values < 0.05 were considered signicant.
RESULTS
Low frequencies of Th1-like Th17 and not Th17 eector cells in CIS blood 
associate with rapid MS onset
To search for pro-inammatory Th subsets that are critically involved in early diagnosis 
of CDMS, we used peripheral blood mononuclear cells at time of CIS from age- and gen-
der-matched patients who remained monophasic for at least 5 years (CIS-CIS, n = 16) and 
from patients who experienced a second attack within 1 year (CIS-CDMS, n = 16; Table 1). 
Flow cytometric analysis of CD4+ T cells showed decreased Th1-like Th17 (CCR6+CXCR3+) 
frequencies in the CIS-CDMS group compared to the CIS-CIS group (median: 5.9% versus 
11.2%, p = 0.011; Fig. 1A). After correction for lesion load on MRI at baseline, using a logis-
tic regression model, the association remains signicant (OR: 0.78 per percent increase in 
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Th1-like Th17; p = 0.026). In CIS-CDMS, additional reductions in eector memory (EM) to 
central memory (CM) ratios were found for Th1-like Th17 (mean: 0.30 versus 0.50, p = 0.005; 
Fig. 1B). Similar but less strong reductions were observed for Th1 (CCR6-CXCR3+; 10.0% 
versus 12.5%, p = 0.070 and mean EM/CM ratio: 0.21 versus 0.29, p = 0.021). Frequencies 
and EM/CM ratios for Th17 (CCR6+CXCR3-) did not dier between CIS-CIS and CIS-CDMS 
(Fig. 1A and B). Th subset distribution in CIS patients was not aected after stratication 
for methylprednisolone treatment in the last 3 months prior to sampling (data not shown). 
Finally, Th1-like Th17 EM/CM ratios in CIS blood inversely correlated to anti-EBNA1 IgG 
titers (p = 0.013; Fig. 1C) and fatigue (p = 0.001; Fig. 1D), which were reported as indepen-
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Figure 1. Reduction of Th1-like Th17 eector cells in the blood of CIS patients with short time to CDMS.
CIS patients were selected based on blood sampling within 4 months after diagnosis and time between CIS and 
CDMS. ‘CIS-CDMS’ patients were diagnosed with CDMS within 1 year (n = 16; lled bars), while ‘CIS-CIS’ patients 
were not diagnosed with CDMS for at least 5 years (n = 16; shaded bars). CD4+ T cells in the blood were compared 
for (A) Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) cell distribution, as well as (B) 
eector memory (EM; CCR7-CD45RA-) to central memory (CM; CCR7+CD45RA-) cell ratios within each of these 
subsets, as determined by ow cytometry. Th1-like Th17 eector to central memory cell ratios were correlated to 
reported predictors of early CIS to CDMS transition, anti-EBNA1 IgG blood titer (C) and fatigue severity scale (FSS; 
D). * p < 0.05; ** p < 0.01.
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Eector populations of highly activated Th1-like Th17 cells are reduced 
in blood after MS diagnosis
To verify that these selective dierences in Th subsets are associated with MS diagnosis, 
we explored total frequencies of blood Th1 EM and Th1-like Th17 EM cells in treatment-na-
ive RRMS patients (n = 18, Table 1), and age-/gender-matched healthy controls (n = 19). 
Strongly reduced frequencies were found for both these subsets in RRMS (median: 1.1% 
and 0.7%) compared to CIS-CIS (1.9%, p < 0.001 and 2.8%, p < 0.0001 respectively) and 
healthy controls (2.8%, p < 0.001 and 3.3%, p < 0.0001 respectively; Fig. 2A). These frequen-
cies did not signicantly dier between the RRMS and CIS-CDMS (1.0% and 1.3%, respec-
tively) group. In RRMS, a signicant proportion of blood Th1-like Th17 cells was positive for 
both CD38 and HLA-DR (Fig. 2B), indicating a highly activated phenotype after MS diagno-
sis. This was not seen for Th1 cells (Fig. 2B). These data suggest that Th1-like Th17 eector 
cells are selectively activated in the periphery and recruited to the CNS during MS onset. 
Predominant expression of T-bet, RORγt, IFN-γ and GM-CSF, but not IL-
17A by activated blood Th1-like Th17 cells
Human CCR6+ CD4+ T cells are not only strong producers of IL-17, but also express IFN-γ 
and GM-CSF [9, 27]. To explore how these pro-inammatory cytokines are co-regulated 
in our phenotypically dened Th1-like Th17 (CCR6+CXCR3+) cells, T-bet and RORγt, as well 
as IFN-γ, GM-CSF and IL-17A expression was compared to paired Th1 (CCR6-CXCR3+) and 
Th17 (CCR6+CXCR3-) populations from healthy blood donors. Th1-like Th17 expressed both 








































































































Figure 2. Th1-like Th17 eector cells are highly activated and less present in the blood after MS diagnosis.
(A) Th1 and Th1-like Th17 eector memory (EM) frequencies in CD4+ T cells from CIS-CIS (n = 14) and CIS-CDMS (n 
= 16) as well as RRMS (n = 18) and both age- and gender-matched healthy control (HC; n = 19) blood. (B) Highly 
activated fractions of blood Th1 and Th1-like Th17 cells in CIS-CIS (n = 14), CIS-CDMS (n = 16) and RRMS (n = 18) 
patients as well as HC (n = 19), as dened by co-expression of late T-cell activation markers HLA-DR and CD38. * p
< 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
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and Th17 (p = 0.008 and p = 0.039, respectively; Fig. 3A). IFNG/IFN-γ mRNA levels were 
similar between Th1 and Th1-like Th17, while CSF2/GM-CSF mRNA levels in Th1-like Th17 
were higher than in Th1 (p = 0.008) and Th17 (p = 0.020). Th1-like Th17 cells only moder-
ately expressed IL17A mRNA (Fig. 3B). Dierences in IFN-γ, GM-CSF and IL-17A expression 
were veried at the protein level (Fig. 3C). The percentage of GM-CSF-positive cells was 
2- to 3-fold higher in Th1-like Th17 than in Th1 and Th17. IL-17A-positive cells were ~4-fold















































































































































































































































































Figure 3. Blood Th1-like Th17 cells predominantly express T-bet and RORγt, and are high IFN-γ and GM-
CSF, but low IL-17A producers.
Buy coats from nine healthy blood donors were used to assess gene expression of TBX21, RORC and FOXP3 
(A), as well as IFNG, CSF2, IL17A and TNF (B) in sorted Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like 
Th17 (CCR6+CXCR3+) memory populations. Cells were stimulated with PMA and ionomycin and mRNA levels 
were measured using quantitative PCR. (C) Flow cytometric analysis of intracellular IFN-γ, GM-CSF and IL-17A 
expression in PMA- and ionomycin-stimulated Th1, Th17 and Th1-like Th17 memory cells from the same blood 
donors (n = 7). (D) Representative dot plots and quantication of co-expression of IFN-γ with GM-CSF and IL-17A 
in Th1-like Th17 memory cells (n = 7). * p < 0.05; ** p < 0.01. 
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co-expressed with GM-CSF and not with IL-17A in Th1-like Th17 cells (Fig. 3D). These cyto-
kine proles were the same for Th subsets from CIS and RRMS blood (data not shown). TNF 
expression was comparable between Th1, Th17 and Th1-like Th17 subsets (Fig. 3B). CD226 
was higher, while CD25 and FoxP3 were lower expressed by Th1-like Th17 as compared to 
Th17 (Fig. 3A and Supplementary Table 3), which supported their pro-inammatory poten-
tial [31, 32]. Th1-like Th17 cells also showed sustained CD161 expression (Supplementary 
Table 3), reecting an ex-Th17 phenotype [33].
Pro-inammatory Th1-like Th17 cells are abundant in CSF T cell cultures 
of MS patients 
To explore the local pro-inammatory capacity of Th1-like Th17 cells in early MS, CSF 
(n = 10) and paired blood (n = 4) T cell subsets from early-stage MS patients (Table 1) were 
analyzed after short-term culturing. Th1 and Th1-like Th17 were the main populations in 
the CSF CD4+ T cell pool (Fig. 4A). Proportions of Th1-like Th17 were higher than those of 
Th1 (p = 0.020) and their equivalents in blood (2- to 3-fold increase; Fig. 4B). Similar results 
were obtained with EM/CM ratios, which were high for both subsets but most prominent in 
Th1-like Th17 cells in CSF (Fig. 4C). Within the total CSF T cell pool, Th1-like Th17 cells were 
enriched and co-produced more IFN-γ and GM-CSF compared to CCR6- and CCR6+ CD8+ T 
cells, and paired blood counterparts (Fig. 4D to G). The percentage of IFN-γ-positive cells 
was increased in CSF Th1-like Th17 versus Th1 (Fig. 4E). The enrichment of Th1-like Th17 in 
CSF compared to blood (Fig. 4A and B) was also found in T cell cultures from late-stage MS 
patients (n = 7, p = 0.016; Table 1 and Fig. 4H), suggesting that Th1-like Th17 recruitment to 
the CNS also occurs at later stages of the disease.
Ex vivo Th1-like Th17 cells are enriched in the CNS and accumulate in the 
blood after natalizumab treatment
To conrm their recruitment to the CNS, we compared ex vivo Th1 and Th1-like Th17 fre-
quencies in single-cell suspensions of 10 brain tissues and paired CSF and blood samples 
of ve patients with late-stage MS (Table 1, Fig. 5A and B). Th1 and Th1-like Th17 cells were 
over-represented, while Th17 cells were hardly seen in MS brain tissues and CSF, in contrast 
to blood. The enrichment of Th1-like Th17 was also found in CSF, but was less in brain 
tissues from two non-demented controls (Fig. 5B), suggesting that enhanced inltration of 
Th1-like Th17 cells into the brain parenchyma is associated with MS [34-36]. 
In addition to chemokine receptors and pro-inammatory cytokines [6, 7], adhesion 
molecules play a key role in migration of peripheral Th cells into the CNS, including VLA-4, 
MCAM and PSGL-1 [37]. Interestingly, VLA-4 but not MCAM and PSGL-1 was the most abun-
dant on Th1-like Th17 cells (Supplementary Table 3). In patients with RRMS (n = 14), blood 
Th1-like Th17 proportions were elevated after 6 months of treatment with natalizumab 
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(anti-VLA-4 monoclonal antibody; median pre- versus post-treatment: 7.7% versus 10.4%, 
p = 0.006; Fig. 5C and Table 1). Th1-like Th17 cells did not show dierences in EM/CM ratio 
(data not shown), but their activation state (see also Fig. 2B) was signicantly reduced after 
natalizumab therapy (Fig. 5D). Th1-like Th17 showed increased capacity to produce IFN-γ 
and GM-CSF in post- versus pre-treatment blood samples (Fig. 5E and F). These results 
show that the eects of natalizumab in MS are associated with an accumulation of Th1-like 























































































































































































































































































































Figure 4. Prevalence of pro-inammatory Th1-like Th17 cells in CIS and MS CSF compared to blood T cell 
cultures.
(A-D) Presence of Th1-like Th17 (CCR6+CXCR3+) subsets in short-term CSF T cell cultures from 10 early-stage MS 
patients (CIS, n = 7; RRMS, n = 3). CSF Th1-like Th17 were compared to Th1 cells and their equivalents in blood for 
percentages in the total CD4+ T cell pool (A and B) and for eector memory (EM) to central memory (CM) ratios 
(C) from the same patients. Similar analyses were performed for CSF Th1-like Th17 and both CCR6- and CCR6+ 
CD8+ T cell subsets within the total T cell pool (D). These T cell subsets were separated, stimulated with PMA and 
ionomycin and assessed for intracellular expression of (E) IFN-γ, (F) GM-CSF and (G) IFN-γ with GM-CSF. For each 
analysis, Th1-like Th17 subsets were compared between paired CSF and blood T cell cultures. (H) Th1-like Th17 


















































































































































Figure 5. Th1-like Th17 recruitment to the CNS and targeting by natalizumab in MS patients.
(A) Presence of Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 (CCR6+CXCR3+) cells in single-cell
suspensions from brain tissue, CSF and blood of a patient with MS, as determined by FACS. (B) Th1-like Th17
frequencies in 10 brain tissues and paired CSF and blood samples from ve dierent MS patients (lled shapes). 
Similar analyses were performed for two non-demented controls (NDC; open shapes). Each shape represents a
dierent donor. For Th1-like Th17 cells in MS blood, frequencies (n = 14; C), activation (n = 14; D) as well as pro-
inammatory capacities (n = 6; E and F) were determined before and 6 months after natalizumab treatment. T-cell 
activation was assessed by surface expression of both HLA-DR and CD38. To determine their pro-inammatory
capacity, Th1-like Th17 memory cells were isolated from pre- and post-treatment blood, stimulated with PMA and 
ionomycin, and stained for intracellular IFN-γ and GM-CSF. * p < 0.05; ** p < 0.01. 
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Targeting of VLA-4high Th17.1 cells by natalizumab in MS patients who 
respond to treatment
To assess the selectivity of natalizumab eects on pro-inammatory Th populations 
in MS patients, CCR4 was included as a surface marker in our ow cytometric panels for 
subdivision of Th1-like Th17 into recently described pathogenic Th17.1 (IFN-γhighGM-
CSFhighIL-17low) and Th17 double-positive (DP; IFN-γlowGM-CSFlowIL-17int) subpopulations 
[27, 38]. Th17.1 (CCR6+CXCR3+CCR4-) frequencies were signicantly increased in RRMS 
blood samples after both 6 and 12 months of treatment (median: 5.3% and 6.1%) versus 
pre-treatment (3.7%; n = 14, both p = 0.0002; Table 1; Fig. 6A and B). No signicant dif-
ferences were found in Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+) and Th17 DP 
(CCR6+CXCR3+CCR4+) cells (Fig. 6A and B). Importantly, this accumulation of Th17.1 was 
most pronounced in natalizumab-treated patients who were free of clinical relapses (n = 
9; pre-treatment, 3.8% versus 6m post-treatment, 6.5% and 12m post-treatment, 6.8%; p = 
0.008 and p = 0.004, respectively). As compared to patients who had relapses during treat-
ment (n = 5; pre-treatment, 3.2% versus 6m post-treatment, 4.0% and 12m post-treatment, 
4.1%; Fig. 6C). The accumulation of Th17.1 cells in the blood of clinical responders was 
validated using a second cohort (Supplementary Table 1; Supplementary Fig. 1A). 
In pre-treated RRMS blood, VLA-4 surface expression on Th17.1 (mean MFI: 2603) 
was the highest of all pro-inammatory Th subsets analyzed, including Th1 (MFI: 1328, 
p = 0.001), Th17 (MFI: 1255, p = 0.0001) and Th17 DP (MFI: 2038, p = 0.002; Fig. 6D and 
Supplementary Fig. 1B). After natalizumab treatment, VLA-4 was downregulated on all 
subsets analyzed, but this was most prominent for Th17.1 (mean reduction: 6m post-treat-
ment, 56%, 12m post-treatment, 58%), as compared to Th1 (6m post-treatment, 52%, p = 
0.038; 12m post-treatment, 54%, p = 0.005), Th17 (6m post-treatment, 37%, p = 0.003; 12m 
post-treatment, 38%, p = 0.0009) and Th17 DP (6m post-treatment, 49%, p = 0.002; 12m 
post-treatment, 50%, p = 0.002; Fig. 6E). This indicates that Th17.1 cells are preferentially 
targeted by natalizumab treatment, preventing their transmigration into the CNS of MS 
patients. 
Pathogenic Th17.1 cells have a superior capacity to transmigrate into the 
CNS in early MS
To study the CNS transmigration potential of Th17.1 in MS further, we performed dier-
ent in vitro transwell migration assays using total Th memory cell fractions. Th17.1 was the 
main Th17 subpopulation migrating across transwell lters towards inammatory media-
tor CXCL10 [39] (Fig. 7A and B). No migration was observed towards medium only (data not 
shown). Particularly Th17.1 cells did show spontaneous transmigration across human brain 
endothelial layers (hCMEC/D3), which was enhanced under CXCL10-attracting conditions 


















































































































































































































































Figure 6. Selective accumulation of Th17.1 cells in natalizumab-treated MS patients who do not experience 
clinical relapses.
Using CCR4 as an additional marker, Th1-like Th17 cells were subdivided into Th17.1 (CCR6+CXCR3+CCR4-) and 
Th17 DP (CCR6+CXCR3+CCR4+) subsets and analyzed in natalizumab-treated RRMS patients by ow cytometry 
(A). Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 and Th17 DP cells were monitored in pre- and 
both 6 and 12 months post-treatment blood samples (n = 14; B). Th17.1 proportions were separately evaluated in 
relapse-free (n = 9) and relapsing (n = 5) treatment groups (C). VLA-4 surface expression levels were determined 
on these Th subpopulations before (D) and both 6 and 12 months after (E) natalizumab treatment. * p < 0.05; ** p 
< 0.01; *** p < 0.001. MFI = mean uorescent intensity; Tx = treatment. 
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Figure 7. Enhanced CNS transmigration potential of Th17.1 cells and their recruitment to CSF in early MS.
Total Th memory cells were sorted from healthy blood and used to assess the in vitro transmigration capacities 
of Th17, Th17.1 and Th17 DP cells across transwell membranes (A and B; n = 6) and monolayers of human brain 
endothelial cells (BEC; C and D, n = 4) towards CXCL10. Each experiment was performed in quintuplicate. Th17 
subset distribution was assessed before (‘control’) and after migration towards medium or CXCL10 using FACS. (E 
and F) Ex vivo Th17, Th17.1 and Th17 DP frequencies of CCR6+ Th cells in paired CSF and blood from four early MS 
patients. (G) The presence of Th17.1 cells in blood samples from 21 CIS-CIS, 26 CIS-CDMS and 13 treatment-naive 
RRMS patients, as well as 12 healthy controls (HC), as determined by FACS. * p < 0.05.
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In addition, ex vivo ow cytometric analysis revealed an enrichment of Th17.1 versus 
Th17 and Th17 DP cells in CSF versus paired blood samples from four patients with ear-
ly-stage MS (three CIS and one RRMS; Table 1; Fig. 7E and F). Consistently, lowered Th17.1 
frequencies were found in the blood from 26 CIS-CDMS versus 21 CIS-CIS patients (p = 
0.019), as well as 13 RRMS patients versus 12 matched healthy controls (p = 0.031; Fig. 7G 
and Supplementary Table 1). Both Th17.1 and Th17 DP cells were abundant in CSF com-
pared to blood from late-stage MS patients (Supplementary Fig. 2). 
Finally, to conrm that Th17.1 is a distinct pro-inammatory Th17 subset, we evalu-
ated the expression of key regulators of Th17 dierentiation and pathogenicity. Along 
with VLA-4 (see also Fig. 6D), CD161, CD226, ABCB1 (MDR1), IL23R, STAT4, FCMR (TOSO) 
and GZMB (granzyme B; all upregulated), as well as CD25 and BATF (downregulated) were 
discriminative markers for Th17.1 (Supplementary Table 3 and Supplementary Fig. 3). The 
abundant expression of T-bet, RORγt, IFN-γ and GM-CSF in Th17.1 cells (Supplementary 
Fig. 4) conrmed the pronounced Th1 features of this Th17 subset [27]. 
Collectively, these data demonstrate the propensity of Th17.1 cells to recruit to the CNS 
and mediate disease activity in early MS. 
DISCUSSION
In this study, we demonstrate that IFN-γ- and GM-CSF-expressing Th1-like Th17 
(CCR6+CXCR3+) cells are selectively associated with early disease activity in patients with 
MS. During disease onset, highly activated and eector memory Th1-like Th17 cells are 
markedly reduced in the peripheral blood and represents the main pro-inammatory 
T-cell population within CSF. This local recruitment seemed to be preferentially targeted
by natalizumab treatment to prevent subsequent MS relapses, since a Th1-like Th17
subpopulation termed Th17.1, and no other Th subsets, predominantly accumulated in
the blood of relapse-free patients. The current work provides in-depth insights into the
pro-inammatory capacity of distinct CCR6+ Th subpopulations during the course of MS
[9], and oers new possibilities to ne-tune currently approved T-cell directed treatment
for patients with MS.
The use of both CCR6 and CXCR3 as discriminating markers for Th17 cells does not only 
reect their pro-inammatory state, but also their capability to migrate into local inam-
matory sites. Previous studies on Th17 cells in experimental autoimmune encephalomyeli-
tis and MS primarily focused on single expression of CCR6 [9], or IL-17, which is increased in 
blood and is further upregulated in CSF during a relapse [17]. Here, we demonstrated that 
additional expression of CXCR3 subdivides human CCR6+ Th17 into high (CXCR3-) and low 
(CXCR3+) producers of IL-17A. In these IL-17low producers, which were over-represented in 
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early-stage MS CSF compared to blood T cell cultures, GM-CSF is the major pro-inamma-
tory cytokine expressed together with IFN-γ. This is likely caused by their elevated levels 
of T-bet, and not RORγt, as previously reported for human Th cells [11]. The association of 
Th1-like Th17 (T-bet-dependent) and not Th17 (RORγt-dependent) with a short time to 
CDMS diagnosis is supported by the expression of T-bet, and not RORγt in CD4+ T cells 
during rapid MS onset [40]. Th1-like Th17 cells were also highly activated after MS diag-
nosis, which links to the important role of CD4+ T-cell activation in CIS progression [3]. 
This suggests that during MS disease onset, the loss of T regulatory function [41] results 
in the activation of peripheral Th1-like Th17 subsets, which inltrate the CNS to mediate 
local inammation. Indeed, memory Th cells of relapsing MS patients were more capable 
of dierentiating into Th1-like Th17 cells, albeit co-producing IFN-γ and IL-17 [35]. These 
Th cells were cultured in the presence of IL-23, prompting RORγt and subsequently IL-17 
expression [11]. In our CCR6- and CXCR3-based approach, we dened pro-inammatory 
cytokine proles of Th17 and Th1-like Th17 populations directly from the blood. This could 
explain why we identied IFN-γ/GM-CSF- and not IL-17-producing Th17 cells as the most 
pro-inammatory subset in early MS, and also agrees with the minimal inuence of IL-17 
and strong impact of GM-CSF on experimental autoimmune encephalomyelitis induction 
[13, 42, 43]. For proper analysis of cytokine production by Th1-like Th17 cells in CSF, we had 
to add IL-2 to short-term T cell cultures, inducing GM-CSF expression [11]. Th1-like Th17 
subsets co-produced more IFN-γ and GM-CSF than other T cell subsets in CSF and their 
counterparts in blood. Our nding that pro-inammatory Th1-like Th17 and especially 
Th17.1 cells were highly enriched in CSF of patients with early-stage MS is in line with their 
reduced frequencies in the blood (this study), and the increased CSF CD4 to CD14 ratios in 
CIS patients with a short time to CDMS [44]. Consistent with in situ observations in MS brain 
tissue [35], a small fraction of blood and CSF Th1-like Th17 and Th17.1 cells did co-pro-
duce IFN-γ and IL-17, but this was considerably less than their co-production of IFN-γ and 
GM-CSF. Besides Th17.1, Th17 DP (IL-17int) cells were also enriched in CSF of patients with 
late-stage MS, suggesting that local IL-17 production is mainly involved in disease progres-
sion. Nevertheless, the predominance of Th1-like Th17 cells in MS CSF and brain tissues as 
observed in this study corresponds to more recent ndings that CNS inammation in MS is 
largely mediated by inltrating IFN-γ- and not IL-17-producing Th cells [34, 36, 45]
Th1-like Th17 cells contain several features promoting their selective intrusion into the 
CNS, although local Th17 plasticity cannot be completely ruled out [46]. Th1-like Th17 cells 
produce high levels of IFN-γ, triggering CXCL10 expression by endothelial cells to favor 
CXCR3-mediated migration into the CNS [36, 47], and thereby MS disease activity [48], 
which is supported by our in vitro and ex vivo transmigration results. Additional expression 
of GM-CSF by this subset may further dysregulate the blood-brain barrier, as described 
for monocytes [49]. Prior to their extravasation, Th17 cells make use of distinct molecules 
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involved in the rolling on and adhesion to endothelial cells, which are activated by pro-in-
ammatory cytokines and chemokines [37, 50, 51]. One of these molecules is the α4β1-in-
tegrin VLA-4, which is targeted by natalizumab to cause a strong reduction of lymphocytes 
in MS CSF [52]. In addition to previous work [53], we now show that only a particular Th1-
like Th17 subpopulation termed Th17.1 accumulates in the blood from MS patients who 
clinically respond to natalizumab treatment. These selective eects may thus be useful 
for predicting freedom from MS activity [19], and understanding the potential lethal MS 
rebounds that occur in patients who have to stop this treatment due to increased risk of 
progressive multifocal leukoencephalopathy (PML) [54, 55]. MS rebounds are characterized 
by a rapid inux of pro-inammatory cells into the CNS to cause excessive inammation, 
potentially resulting in PML-immune reconstitution inammatory syndrome (IRIS) [56]. 
Although not proven yet, the marked accumulation of Th17.1 in natalizumab-treated MS 
blood puts forward their transmigration into CNS as a critical process during these compli-
cations. Out of all pro-inammatory Th subsets dened by CCR6, CXCR3 and CCR4, Th17.1 
revealed the strongest VLA-4 surface expression levels in MS blood, which explains their 
restricted targeting by natalizumab. Consistent with our results, VLA-4 levels were found 
to be higher on Th17 than on Th1 cells in MS patients, probably mediating their tracking 
into the CNS [17]. However, when we compared individual Th17 subpopulations, i.e. CCR6+ 
Th17 (CXCR3-CCR4+; IL-17high), Th17 DP (CXCR3+CCR4+; IL-17dim) and Th17.1 (CXCR3+CCR4-; 
IL-17low) [27], VLA-4 surface expression seemed to be inversely associated with their ability 
to produce IL-17, as also described for mice [57]. The predominant expression of VLA-4 on 
Th17.1 cells closely parallels the dependence of IFN-γ- and not IL-17-producing Th cells on 
this integrin for their entry into the CNS during experimental autoimmune encephalomy-
elitis [57, 58]. However, adhesion molecules other than VLA-4 must be taken into account 
for alternative transmigration routes of pro-inammatory Th17 cells as well [50], especially 
considering the rebound eects after natalizumab discontinuation in MS. 
This cross-sectional study exemplies that a more rened evaluation of chemokine 
surface receptors, pro-inammatory cytokines and adhesion molecules is warranted to 
better understand the contribution of human Th1 and Th17 to MS and other autoimmune 
and neuroinammatory diseases. Based on CCR6/CXCR3, IFN-γ/GM-CSF and VLA-4 expres-
sion, we identify Th1-like Th17 as a clinically relevant CD4+ T cell population during disease 
onset and treatment in MS patients. Future work on the localization and antigen specicity 
of these subsets in human brain lesions will be critical to determine their local impact on 
myelin and axonal loss in MS. The prominent association of Th1-like Th17 cells, in particular 
Th17.1, with MS activity suggests the possibility for more specic T cell-targeted therapies, 
and pleads for further assessment of the use of natalizumab earlier in the disease course 
of MS [59]. 
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Supplementary Table 1. Characteristics of patients and controls in additional cohorts
a14 CIS-CIS and 16 CIS-CDMS were also included in the screening cohorts (see Table 1).
b2 natalizumab-treated RRMS patients were also used for analysis of pro-inammatory cytokine expression only 
(Table 1).
cAt the time of sampling.
dAt the time of pre-treatment sampling. RRMS according to the McDonald 2010 criteria. 
eTime from CIS diagnosis to sampling.
HC = healthy control; MS = multiple sclerosis; NA = not applicable or available; NAT = natalizumab.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(A) Validation of Th17.1 accumulation in the blood of nine MS patients after natalizumab treatment.
Frequencies of Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17
DP (CCR6+CXCR3+CCR4+) cells within the CD4+ T cell pool were compared pre- and 12m post-treatment using
multicolor ow cytometry. (B) Representative gating and percentages of VLA-4+ cells within Th1, Th17, Th17.1 and 







































































Supplementary Figure 2. Flow cytometric analysis of Th17 subpopulations in paired ex vivo CSF and blood 






































































































Supplementary Figure 3. Validation of Th17.1 as a distinct Th17 subset based on the expression of key 
genes involved in Th17 dierentiation and pathogenicity.
We sorted memory Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP (CCR6+CXCR3+CCR4+) 
cells of seven healthy blood donors and compared the relative expression levels of ABCB1 (MDR1), IL23R, STAT4, 
BATF, FCMR (TOSO) and GZMB (granzyme B). For FCMR and GZMB expression analyses, Th subsets were activated 
with anti-CD3/CD28 abs for 24 h. 
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Supplementary Figure 4. Validation of Th17.1 as a distinct Th17 subset based on the expression of Th1- 
and Th17-associated pro-inammatory cytokines and transcription factors.
Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+), Th17.1 (CCR6+CXCR3+CCR4-) and Th17 DP 
(CCR6+CXCR3+CCR4+) cells were sorted from seven healthy blood donors and compared for mRNA (A) and protein 
(B) expression of IFN-γ (IFNG), GM-CSF (CSF2), IL-17A (IL17A), T-bet (TBX21) and RORγt (RORC).
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ABSTRACT
Background: Although glucocorticoids can shorten acute relapses of 
multiple sclerosis (MS), subsequent exacerbations and disease progression 
are not prevented. A reduced glucocorticoid sensitivity of CNS-homing 
pathogenic T helper (Th) cells could contribute to these limited eects in 
MS.
Objective: In this study, we analyzed whether features of glucocor-
ticoid resistance can be utilized to delineate disease-relevant Th cells in 
early MS.
Methods: The expression of key determinants of glucocorticoid sen-
sitivity, multidrug resistance protein 1 (MDR1/ABCB1) and glucocorticoid 
receptor (GR/NR3C1), was investigated in pro-inammatory Th subsets 
and compared between natalizumab-treated MS patients and healthy 
individuals. Blood, CSF and brain compartments from MS patients were 
assessed for the recruitment of glucocorticoid-resistant Th subsets using 
FACS, qPCR, immunohistochemistry and immunouorescence.
Results: An MS-associated Th subset termed Th17.1 showed a distinct 
glucocorticoid-resistant phenotype as reected by high MDR1 and low GR 
expression. This expression ratio was further elevated in Th17.1 cells that 
accumulated in the blood of MS patients treated with natalizumab, a drug 
that prevents their entry into the CNS. Pro-inammatory markers CCR6, 
IL-23R, IFN-γ and GM-CSF were increased in MDR1-expressing Th17.1 cells. 
This subset predominated the CSF of early MS patients, which was not 
seen in paired blood or in the CSF from patients with other inammatory 
and non-inammatory neurological disorders. The potential of MDR1-
expressing Th17.1 cells to inltrate brain tissue was conrmed by their 
presence in MS white matter lesions. 
Interpretation: This study reveals that glucocorticoid resistance coin-
cides with preferential CNS recruitment of pathogenic Th17.1 cells, which 
may hamper the long-term ecacy of glucocorticoids in early MS. 
3
71
Glucocorticoid-resistant CD4+ T cells in MS
INTRODUCTION
Early multiple sclerosis (MS) is characterized by waves of brain-infiltrating immune cells 
that drive inflammation within the central nervous system (CNS), resulting in demyelin-
ation and eventually neurodegeneration [1]. Glucocorticoids are broad-spectrum immu-
nosuppressive drugs that are used as standard regimen to dampen acute exacerbations 
in MS [2]. Although glucocorticoids effectively relieve clinical symptoms, these drugs do 
not halt subsequent exacerbations or disease progression [3]. Interestingly, blood cells of 
relapsing-remitting MS (RRMS) patients show reduced sensitivity to glucocorticoids [4, 5], 
which offers a limited window of opportunity for inducing long-term efficacy of this MS 
treatment. To achieve this, more insights into the underlying mechanisms of glucocorti-
coid insensitivity are required in early MS. 
Upon binding its ligand, the glucocorticoid receptor (GR/NR3C1) hyperphosphorylates, 
forms dimers with other nuclear receptors and translocates into the nucleus [2]. Within the 
nucleus, these dimers recognize GR elements in promoter regions or interact with 
tran-scription factors to transactivate or repress pro-inammatory gene expression [2]. 
Apart from binding to the GR, glucocorticoids can be excreted out of the cell by the 
multidrug resistance protein 1 (MDR1/ABCB1) [6].
In experimental autoimmune encephalitis (EAE) mice, the therapeutic ecacy of glu-
cocorticoids depends on the suppression of CNS recruitment of pro-inammatory CD4+ 
T helper (Th) cells [7, 8]. Since glucocorticoids are unable to induce long-term protective 
eects in MS, it is tempting to speculate that certain pathogenic Th cells avoid glucocor-
ticoid-mediated suppression and thereby contribute to recurrent disease activity [9]. C-C 
chemokine receptor 6 (CCR6) expression on memory Th cells promotes their recruitment 
into the CNS and is essential for the induction of EAE [10, 11]. In RRMS patients, blood-de-
rived CCR6+ and not CCR6- memory Th cells show increased pro-inammatory capacity in 
response to myelin peptides [12]. Previously, our group revealed that a human pathogenic 
CCR6+ Th subset commonly termed Th17.1 (IL-17lowIFN-γhighGM-CSFhigh) is associated with 
early MS [13-17]. Interestingly, we and others found that Th17.1 cells from healthy individu-
als express high levels of ABCB1 [13, 15], which encodes for MDR1 and links to the reduced 
glucocorticoid sensitivity found in RRMS patients [4].
In this study, we addressed how MDR1 and GR are expressed amongst memory Th sub-
sets including Th17.1 and whether this coincides with their potential to inltrate the CNS 





Treatment-naive clinically isolated syndrome (CIS) and RRMS patients were diagnosed 
based on the McDonald 2017 criteria and included at the MS Center ErasMS, Erasmus 
MC. We collected cerebrospinal uid (CSF) and blood samples from these as well as alter-
natively diagnosed patients (Supplementary Table 1). Post-mortem blood, meninges
and white matter tissues were obtained from autopsied MS donors (Netherlands Brain
Bank, Amsterdam; Supplementary Table 1) and processed as previously described [18].
Natalizumab-treated MS patients were treated for 12 months before blood sampling. The
use of primary material and experimental procedures were approved by the medical ethics 
committee of each respective center.
Antibodies and ow cytometry
Flow cytometry was performed using uorescently labeled anti-human monoclonal 
antibodies (Supplementary Table 2). For MDR1 surface staining, cells were taken up in 
RPMI 1640 containing 2% fetal calf serum (FCS) and 25 µM Cyclosporin A (Sigma-Aldrich, 
St Louis, MO, USA) or 1:500 absolute ethanol (Merck, Schiphol-Rijk, The Netherlands) as a 
vehicle control. Subsequently, MDR1 (Biolegend, London, UK) antibody was added and 
cells were incubated for 20 min at 37˚C and 5% CO2. In all experiments, viable cells were 
analyzed using Fixable Viability Stain 700 (BD Biosciences, Erembodegem, Belgium) or the 
Fixable Viability Dye eFluor 520 (Thermo Fisher Scientic, Landsmeer, The Netherlands). 
Other surface markers were stained as previously described [13]. Cells were measured 
using the LSRII-Fortessa or FACSAria-III ow cytometer and analyzed using FACSDiva soft-
ware (Version 8.0.1; BD Biosciences). 
Cell sorting 
CD4+ cells were isolated from healthy donor blood (Sanquin, Amsterdam, The 
Netherlands) using CD4 microbeads and the autoMACS Pro Separator (both Miltenyi 
Biotec, Bergisch Gladbach, Germany). From these cells, CCR6+ memory Th populations 
(CD3+CD4+CD8-CD25lowCD45RA-CCR6+) were isolated using a FACSAria-III machine. CCR6+ 
memory subsets were dened based on dierential expression of CXCR3 and CCR4; 
Th17 (CCR6+CXCR3-CCR4+), Th17 double-positive (DP; CCR6+CXCR3+CCR4+) and Th17.1 
(CCR6+CXCR3+CCR4-/dim) [14]. 
RNA isolation and quantitative PCR
RNA isolation, complementary DNA synthesis and real-time quantitative PCRs were 
performed as previously described [13]. Primer-probe sets were designed using the 
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Universal ProbeLibrary (Roche Applied Science, Penzberg, Germany). Apart from IFNG and 
CSF2, which were measured after Phorbol 12-myristate 13-acetate and ionomycin stimu-
lation, gene expression was measured in unstimulated cells [13]. An overview of all used 
primer sequences can be found in Supplementary Table 3. RNA samples containing less 
than 75 ng total RNA were excluded from the analysis.
In vitro proliferation assay
Frozen buy-derived CD4+ T cells were thawed and labeled with 0.075 µM CellTrace 
CFSE according to the manufacturer’s instructions (Thermo Fisher Scientic). After washing, 
Th17 and Th17.1 memory cells were puried using FACS, as described above. Sorted Th17 
and Th17.1 cells were plated at 250.000 cells/ml and activated with aCD3/CD28 dynabeads 
(1:5; Thermo Fisher Scientic) for 3 days. Cells were cultured in RPMI 1640 (Thermo Fisher 
Scientic) supplemented with 1% Penicillin/Streptomycin (Lonza, Verviers, Belgium), 5% 
human AB serum (Sanquin) and 75 µM methylprednisolone sodium succinate (Pzer, 
Capelle a/d IJssel, The Netherlands) or a vehicle control. To compare dierences in prolifer-
ation, the frequencies of viable, CFSE-negative cells were analyzed using ow cytometry.
Rhodamine eux and MDR1 shift assay
We combined a rhodamine eux and MDR1 shift assay to measure both the eux 
potential and MDR1 expression of each Th memory subset [15, 19]. PBMCs were taken up 
in RPMI 1640 containing 2% FCS and 0.5 µg/ml Rhodamine 123 (Rh123) or 1:2000 absolute 
ethanol as a vehicle control (both Sigma-Aldrich) at a concentration of 1×10E7 cells/ml and 
were incubated on ice for 30 min in the dark. Cells were washed with the same culture 
media and taken up in media containing 25 µM Cyclosporin A or 1:500 absolute ethanol. 
Next, MDR1 antibody was added for 2h at 37˚C and 5% CO2, after which cells were stained 
with Th subset-dening markers as described above. 
Immunohistochemistry and multiplex immunouorescence
Immunohistochemistry was performed with an automated, validated and accredited 
staining system Ventana Benchmark ULTRA using the optiview universal DAB detection 
Kit (both Ventana Medical Systems, Oro Valley, AZ, USA). In brief, after deparanization 
and heat-induced antigen retrieval, 7 µm thick brain sections were incubated with the 
antibody of interest for 32 min. This was followed by a hematoxylin II counter staining for 
12 min and the addition of a blue coloring reagent for 8 min according to the manufactur-
er’s instructions (both Ventana Medical Systems). To assess MDR1 expression on Th cells, 
immunouorescent staining for MDR1 and CD4 was performed using the automated mul-
tiplex platform Benchmark Discovery (Ventana Medical Systems). In short, brain sections 
were deparanized and antigen-retrieved with cell conditioning (CC) 1 (Ventana Medical 
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Systems) for 32 min. Tissue slides were incubated with MDR1 antibody for 32 min at 37˚C 
followed by detection with FAM (Roche Applied Science). Antibody denaturation was 
performed using CC2 (Ventana Medical Systems) for 8 min at 100˚C. Subsequently, CD4 
antibody was incubated for 32 min at 37˚C followed by detection with Cy5 (Roche Applied 
Science). Finally, slides were washed in PBS and mounted with Vectashield containing DAPI 
(Vector laboratories, Peterborough, UK). For detailed information of the used antibodies, 
see Supplementary Table 2.
Statistical analysis
Statistical tests were performed using GraphPad Prism 5 software and are described in 
each gure legend. Results are displayed as the mean, standard error of the mean or as a 
box & whiskers plot. For all tests, a p value of < 0.05 (*) was considered signicant. 
RESULTS
High ABCB1 and low NR3C1 expression denes glucocorticoid-resistant 
Th17.1 cells with enhanced pro-inammatory capacity 
Glucocorticoid sensitivity is determined by the expression of ABCB1 (MDR1) and NR3C1 
(GR) (Fig. 1A). Using a MDR1 shift assay, we found that MDR1 was predominantly expressed 
on CCR6+ versus CCR6- memory Th cells within the blood of healthy individuals (p < 0.001; 
Fig. 1B and C), indicating that high MDR1 expression is not associated with Th1 cells. After 
Figure 1 (right page). High ABCB1 and low NR3C1 expression in Th17.1 cells from healthy blood donors. 
(A) Simplistic illustration of glucocorticoid regulation within an immune cell. Glucocorticoids diuse through
the plasma membrane and bind to the glucocorticoid receptor (NR3C1/GR) within the cytoplasm. Upon binding, 
GRs form dimers and translocate into the nucleus to regulate pro-inammatory gene expression. However,
glucocorticoids can also be transported out of the cell by the multidrug resistance protein 1 (ABCB1/MDR1). 
(B) Representative FACS plot displaying the gating strategy and expression of MDR1 for CCR6– and CCR6+ 
memory Th (CD3+CD4+CD8– CD45RA–) cells. CD25high (Treg) cells were excluded from our analyses. (C) Frequencies 
of MDR1-expressing cells within paired CCR6– and CCR6+ memory Th populations from healthy blood donors
(n = 6). (D) Representative gating of functionally distinct CCR6+ Th memory cells (Th17, Th17 DP and Th17.1)
and surface expression of MDR1. (E) Frequencies of MDR1-expressing cells within each CCR6+ Th memory subset 
(n = 6). Relative expression of NR3C1 (F), as well as their ABCB1/NR3C1 ratios (G) were analyzed for paired Th17,
Th17 DP and Th17.1 cells from healthy blood using qPCR (n = 7-8). (H) In vitro glucocorticoid response of paired 
Th17 and Th17.1 cells from healthy donors (n = 6). Cells were stimulated with aCD3/CD28 in the presence of
methylprednisolone (MP; 75 μM) or a vehicle (control) for 3 days and analyzed by ow cytometry. (I) IL23R (IL-23 
receptor), IFNG (IFN-γ) and CSF2 (GM-CSF) expression relative to the housekeeping gene 18S between MDR1+
versus MDR1– Th17.1 cells from the same healthy donors (n = 7-8). * p < 0.05; ** p < 0.01; *** p < 0.001. Data were 
compared using paired t tests (C, H and I), repeated measures one-way ANOVA with a Newman-Keuls multiple
comparison test (E, F and G) and Wilcoxon paired test (I). 
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subdivision of CCR6+ Th cells into functionally distinct subsets based on CXCR3 and CCR4 
surface expression [13, 14], MDR1 was abundant on Th17.1 (IL-17negIFN-γhighGM-CSFhigh) 
compared to Th17 (IL-17highIFN-γnegGM-CSFdim) and Th17 DP (IL-17dimIFN-γlowGM-CSFdim) cells 
from the same blood donors (p < 0.001; Fig. 1D and E). Subsequently, we sorted these pop-
ulations and analyzed co-expression of MDR1 (ABCB1) with GR (NR3C1). NR3C1 was selec-
tively downregulated in Th17.1 cells (p < 0.05; Fig. 1F), resulting in strongly elevated ABCB1/
NR3C1 expression ratios (p < 0.001; Fig. 1G). In vitro experiments showed that MDR1highGRlow 
Th17.1 cells were less sensitive to glucocorticoids in comparison to paired MDR1lowGRhigh 
Th17 cells (p < 0.05; Fig. 1H). Pro-inammatory and Th17.1-associated genes IL-23 receptor 
(IL23R), IFN-γ (IFNG) and GM-CSF (CSF2) [13, 14] displayed elevated expression in MDR1+ 
versus MDR1- fractions of Th17.1 (p < 0.01 versus p < 0.05 respectively; Fig. 1I). These nd-
ings show that Th17.1 cells have a distinctive glucocorticoid-resistant phenotype, which 
probably contributes to their role in MS disease activity [13].
Th17.1 cells trapped in the blood of natalizumab-treated MS patients 
show increased ABCB1 and reduced NR3C1 expression 
In our previous study, Th17.1 cells were found to selectively accumulate in the blood 
from MS patients who clinically responded to natalizumab treatment [13]. This peripheral 
entrapment makes it possible to analyze the glucocorticoid resistance prole of Th17.1 
cells that normally inltrate the CNS during pathogenesis. After sorting of these and other 
CCR6+ memory Th cells from the blood, we found selectively increased ABCB1 expression 
in Th17.1 cells from 11 RRMS patients who clinically responded to natalizumab treatment 
versus 9 age- and gender-matched healthy controls (p < 0.05; Fig. 2A). This was not found 
in patients who experienced clinical relapses despite natalizumab therapy (non-respond-
ers; n = 6; Fig. 2A). NR3C1 was reduced in all CCR6+ Th subsets analyzed from these patients, 
which was only signicant in non-responders and mainly found in Th17.1 (Fig. 2A). As a 
result, ABCB1/NR3C1 expression ratios were enhanced especially in natalizumab respond-
ers compared to healthy controls (Fig. 2A). Similar results were obtained when analyzing 
frequencies of MDR1+ Th17.1 cells (p < 0.05), whereas their Rh123 eux potential remained 
unchanged between the groups (Fig. 2B and C). CSF-homing marker CCR6 was higher 
expressed on MDR1+ versus MDR1- Th17.1 cells from the blood of natalizumab-treated 
patients (p < 0.0001), which was not seen for CXCR3 (Fig. 2D). These data show that gluco-
corticoid-resistant Th17.1 cells have a phenotype associated with preferential recruitment 
to the CSF in MS patients.
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Figure 2. Increased frequencies of MDR1+ Th17.1 cells in the blood of natalizumab-treated MS patients 
compared to healthy controls. 
(A) ABCB1, NR3C1 and ABCB1/NR3C1 expression ratios for blood Th17, Th17 DP and Th17.1 cells of MS patients who 
clinically responded (n = 10-11) or did not respond (n = 5-7) to natalizumab, as well as age- and gender-matched 
healthy controls (n = 6-9). (B) Representative FACS plot showing Rh123 eux in Th17, Th17 DP and Th17.1 cells. 
(C) Frequencies of MDR1+ Th17, Th17 DP and Th17.1 cells within memory Th cells (top) and percentages of
Rh123-negative cells within each subset (bottom) for 11 natalizumab-treated MS patients and 5 healthy controls. 
(D) CCR6 and CXCR3 expression (MFI) on MDR1– versus MDR1+ Th17.1 cells from 11 natalizumab-treated MS
patients. * p < 0.05, ** p < 0.01, **** p < 0.0001. Data were analyzed using Kruskal-Wallis with a Dunn multiple


























































































































































































































Figure 3. Selective enrichment of MDR1+ Th17.1 cells in the CSF of treatment-naive early MS patients. 
(A) Percentages and ratios of MDR1-expressing CD4+ and CD8+ memory fractions within CD3+ T cells in the 
blood and CSF from early MS patients (n = 9). (B) Percentages of MDR1-expressing cells within paired CCR6– 
versus CCR6+ memory Th cells from early MS CSF (n = 9). (C) Top panel: percentages of CCR6+ subsets within the 
memory Th compartment in the blood (left panel, n = 14) and CSF (right panel, n = 15) from early MS patients. 
Bottom panel: same items displayed for patients with other inammatory neurological disorders (OIND) or non-
inammatory neurological disorders (NIND) (n = 4 for blood and n = 8 for CSF). (D) Percentages of MDR1+ CCR6+ 
Th subsets in the CSF (left) and MDR1+ Th17.1 frequencies in the CSF versus blood (right) from early MS patients 
(n = 9-10). (E) CCR6 and CXCR3 expression levels (MFI) on paired MDR1+ versus MDR1– Th17.1 cells from early MS 
patients (n = 7). CXCR3 expression (MFI) on CSF- and blood-derived MDR1+ Th17.1 cells from early MS patients (n 
= 7). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data were analyzed using paired t tests (A, B, D and E) 
and repeated measures one-way ANOVA with a Newman-Keuls multiple comparison test (C and D).
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MDR1+ Th17.1 cells are enriched in CSF of early MS patients and not in 
patients with other neurological disorders
Ex vivo ow cytometric analysis of paired blood and CSF samples from treatment-na-
ive early MS patients (n = 9, Supplementary Table 1) revealed a signicant rise in MDR1-
expressing CD4+ (p < 0.0001) and not CD8+ T memory cells, resulting in increased CD4/CD8 
ratios (p < 0.001) within the CSF (Fig. 3A). Similar to blood cells of natalizumab-treated MS 
patients (Fig. 2D), CCR6+ Th memory cells expressed higher levels of MDR1 compared to 
CCR6- fractions in MS CSF (p < 0.0001; Fig. 3B). Th17.1 predominated the CSF of early MS 
patients when compared to Th17 and Th17 DP cells (n = 15, Supplementary Table 1 and p 
< 0.001, Fig. 3C). This selective enrichment was not found in paired blood samples, or in 
the CSF of 8 patients with other inammatory or non-inammatory neurological disorders 
(Supplementary Table 1 and Fig. 3C). The predominance of Th17.1 cells in early MS CSF was 
even more apparent when analyzing MDR1-expressing proportions (p < 0.001; Fig. 3D). 
Within the blood of these patients, CCR6 and not CXCR3 was enriched on MDR1+ compared 
to MDR1- Th17.1 cells (p < 0.0001 and p < 0.01; Fig. 3E). MDR1+ Th17.1 cells in CSF showed 
higher CXCR3 levels than their blood counterparts (p < 0.05; Fig. 3E). The enhanced recruit-
ment of MDR1+ Th17.1 cells to MS CSF suggests that this subset has a greater capacity to 
inltrate brain tissue to promote local inammation.
MDR1-expressing CD4+ T cells are recruited to MS brain tissue and show 
a Th17.1 phenotype 
Lastly, we studied whether MDR1 is expressed on CD4+ T cells that have inltrated the 
brain of MS patients. We performed in situ analyses of post-mortem white matter tissues 
from 3 MS donors with a high number of perivascular inltrates. Immunohistochemical 
analysis for MDR1 and CD4 showed their co-existence in perivascular areas of active lesions 
(Fig. 4A and B). Besides the expected presence of MDR1 in other types of CNS-resident cells 
[20], we were able to validate the co-expression of MDR1 with CD4 using confocal micros-
copy (Fig. 4C). To address how MDR1 was expressed amongst MS brain-inltrating CCR6+ 
Th subsets, we analyzed ex vivo single-cell suspensions of post-mortem blood, meninges 
and brain white matter tissue from 8 late-stage MS donors using ow cytometry (Fig. 4D 
and E). In contrast to Th17 and Th17 DP cells, frequencies of MDR1+ Th17.1 cells were sig-
nicantly increased in brain tissue compared to blood (p < 0.001) and meninges (p < 0.05; 
both Fig. 4E). Although not signicant, Th17.1 cells also seemed to be more present in the 
meninges than in the blood and were more abundant than Th17 DP cells in brain tissue. 
Overall, these ndings demonstrate that MDR1 expression marks a subset of CNS-homing 
Th17.1 cells and support a reduced glucocorticoid sensitivity of putatively pathogenic 



































































Figure 4. Presence of MDR1+ Th17.1 cells in post-mortem white matter tissue of MS patients. 
Representative immunohistochemical staining for CD4 and MDR1 (A) as well as HLA-II, MOG and MAP2 (B) in 
formalin-xed, paran-embedded white matter tissues from 3 MS patients. (C) Co-expression of CD4 (red) and 
MDR1 (green) in DAPI (blue)-positive cells in the same tissues, as determined by immunouorescence staining. (D) 
Representative gating of ex vivo CCR6+ Th subsets and MDR1+ fractions of Th17.1 (CCR6+CXCR3+CCR4–/dim) in the 
blood, meninges and brain tissue from an MS donor. (E) Ex vivo frequencies of MDR1+ Th17, Th17 DP and Th17.1 
cells in post-mortem blood, meninges and brain tissues from 8 late-stage MS donors, as determined by FACS. A 
total of 14 brain tissues from 8 donors were analyzed. * p < 0.05 and *** p < 0.001. Data in E were compared using 
a non-repeated measurement two-way ANOVA with a post-hoc Bonferroni multiple comparison test.
3
81
Glucocorticoid-resistant CD4+ T cells in MS
DISCUSSION
In sharp contrast to late-stage MS, early phases of MS are characterized by increased 
numbers of CD4+ and not CD8+ T cells in the CSF [18, 21]. Since glucocorticoids are used to 
dampen acute MS relapses, we focused on glucocorticoid resistance features amongst dif-
ferent pathogenic CD4+ Th cell subsets. Here, we reveal that Th17.1 cells display a unique 
glucocorticoid-resistant (ABCB1highNR3C1low) phenotype, which is accompanied by a selec-
tive enrichment within the CSF of early MS and not alternatively diagnosed patients. The 
fact that this glucocorticoid-resistant, pathogenic CD4+ Th subset also localizes within MS 
white matter lesions supports our notion that Th17.1 and particularly MDR1 is a promising 
target for predicting and inducing glucocorticoid treatment ecacy during early MS. To 
our knowledge, this is the rst study that links glucocorticoid resistance to the brain-inl-
trating capacity of human Th subsets in a neurological disease such as MS. 
Several factors may be responsible for the selective upregulation of ABCB1 (MDR1) 
and downregulation of NR3C1 (GR) in Th17.1 cells. A pathogenic feature of MS is chronic 
activation of the hypothalamus–pituitary–adrenal (HPA) axis, resulting in elevated levels 
of the natural glucocorticoid cortisol [5]. It has been shown that in vivo administration of 
glucocorticoids induces MDR1 on peripheral blood lymphocytes [22], suggesting that the 
elevated cortisol levels in MS patients could give rise to the glucocorticoid-resistant phe-
notype of Th17.1. Chronic inammation was also found to upregulate MDR1 expression on 
lymphocytes via activation of the signal transducer and activator of transcription 3 (STAT3) 
protein [23]. Consistently, STAT3 drives the expression of RAR-related orphan nuclear 
receptor γt (RORγt), which inhibits glucocorticoid action [24] and is highly abundant in 
Th17.1 cells [13]. This probably also explains our nding that the MDR1+ subset of Th17.1 
expresses high levels of GM-CSF, which is directly controlled by RORγt [25]. In addition, IL-2 
is not only an important trigger of GM-CSF in Th memory cells from MS patients [26], but is 
also able to reduce GR expression [27]. In EAE, macrophage migration inhibitor factor (MIF) 
induced glucocorticoid resistance of Th cells via upregulation of T-box transcription factor 
(T-bet) [28], another Th17.1-associated transcription factor [13]. In parallel with this, we 
found that T-bet-dependent IFN-γ was upregulated in MDR1+ Th17.1 cells. Together with 
the downregulation of GR under high glucocorticoid conditions [29], these studies indi-
cate that the glucocorticoid-resistant phenotype of Th eector cells such as Th17.1 may 
be induced by combined eects of a hyperactive HPA axis and chronic inammation in 
MS patients. Alternatively, a GR-repressive isoform (GRβ) may play a role in glucocorticoid 
resistance [30]. However, the synthetic glucocorticoid methylprednisolone is used for the 
treatment of acute exacerbations in MS patients and is unable to bind to GRβ suciently, 
thus failing to repress the signaling isoform GRα [30, 31]. GRα could also be dierentially 
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regulated at the post-transcriptional level, but remains challenging to analyze on the pro-
tein level in primary Th cells. 
Apart from the role of MDR1 and GR in glucocorticoid resistance, both molecules also 
play an important role in the induction of neuroinammation. Increased GR signaling in 
pathogenic T cells protects from CNS autoimmunity, while deletion of GR abrogates this 
phenomenon in EAE [8, 32]. Deletion of ABCB1 resulted in a similar protective phenotype 
[33], likely because of its additional role in the excretion of pro-inammatory cytokines 
[34]. These studies suggest that both low GR and high MDR1 expression in brain-hom-
ing Th eector cells such as Th17.1 drive neuroinammation. Due to their involvement 
in both glucocorticoid resistance and induction of local pathology, selective targeting 
of these molecules in Th17.1 cells may enhance glucocorticoid ecacy in MS. To further 
support this hypothesis, the relationship between MDR1+ Th17.1 frequencies in the CNS 
of MS patients and glucocorticoid ecacy should be explored. Unfortunately, we had no 
access to the required patient material. A recent study showed that low vitamin D levels 
associate with glucocorticoid-resistant relapses in MS patients [35]. Although controversial 
results were obtained from clinical trials with respect to disease activity, increasing vita-
min D levels improved glucocorticoid ecacy and suppressed EAE induction in mice via 
Th-cell intrinsic upregulation of NR3C1 [35]. Since vitamin D also reduces CCR6 expression 
on human Th cells [17], this steroid hormone may be exploited to enhance the therapeutic 
ecacy of glucocorticoids in MS by sensitizing Th17.1 cells. Selective targeting of MDR1 is 
promising due to its role in glucocorticoid resistance, pro-inammatory cytokine excretion 
as well as tracking of T cells across the blood-brain barrier [36], but should also be taken 
with care since it is expressed by many other cells. In-depth analysis of Th17.1 cells by 
currently available single-cell platforms would reveal additional targets that can be used 
for the design of small-molecule therapeutics. Finally, the predominance of Th17.1 in the 
CSF of early MS and not in alternatively diagnosed patients may set the stage for its use as 
a biomarker to predict rapid disease onset. To address this, the local presence and features 
of Th17.1 cells should be compared between larger numbers of MS and control subgroups 
in the near future.
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Supplementary Table 1. Patient characteristics
aRhodamine eux and MDR1 shift assay.
bDiagnosis according to the McDonald 2017 criteria. 
cEx vivo analyses: 11 clinical responders and 7 clinical non-responders. In vitro analyses: 5 clinical responders and 
6 clinical non-responders.
dAt the time of sampling.
eTime from CIS or if applicable RRMS diagnosis to sampling.
fDiagnosis: myelopathy, ulnar neuropathy, Neuro-Behçet’s disease, neurosarcoidosis, B-cell lymphoma.
gDepicted as hour:minutes.
hPatients did not receive glucocorticoids prior to sampling.
CIS = clinically isolated syndrome; RRMS = relapsing-remitting multiple sclerosis; HC = healthy controls; NIND = 
non-inammatory neurological diseases; OIND = other inammatory neurological diseases; NTZ= natalizumab; 
NA = not applicable or available; PMD = post-mortem delay.
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Supplementary Table 2. Used antibodies for ex vivo and in situ analysis
















































































































Supplementary Table 3. Used primer sets for qPCR
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ABSTRACT 
Objective: Results from anti-CD20 therapies demonstrate that B- and 
T-cell interaction is a major driver of multiple sclerosis (MS). The local pres-
ence of B-cell follicle-like structures and oligoclonal bands in MS patients
indicates that certain B cells inltrate the central nervous system (CNS) to
mediate pathology. Which peripheral triggers underlie the development
of CNS-inltrating B cells is not fully understood.
Methods: Ex vivo ow cytometry was used to assess chemokine recep-
tor proles of B cells in blood, cerebrospinal uid, meningeal and brain 
tissues of MS patients (n = 10). Similar analyses were performed for distinct 
memory subsets in the blood of untreated and natalizumab-treated MS 
patients (n = 38). To assess T-bet(CXCR3)+ B-cell dierentiation, we cultured 
B cells from MS patients (n = 21) and healthy individuals (n = 34) under T 
helper 1- and TLR9-inducing conditions. Their CNS transmigration capacity 
was conrmed using brain endothelial monolayers. 
Results: CXC chemokine receptor 3 (CXCR3)-expressing B cells were 
enriched in dierent CNS compartments of MS patients. Treatment with 
the clinically eective drug natalizumab prevented the recruitment of 
CXCR3high IgG1+ subsets, corresponding to their increased ability to cross 
CNS barriers in vitro. Blocking of interferon-γ (IFN-γ) reduced the transmi-
gration potential and antigen-presenting function of these cells. IFN-γ-
induced B cells from MS patients showed increased T-bet expression and 
plasmablast development. Additional TLR9 triggering further upregulated 
T-bet and CXCR3, and was essential for IgG1 switching.
Interpretation: This study demonstrates that T-bethigh IgG1+ B cells
are triggered by IFN-γ and TLR9 signals, likely contributing to enhanced 
CXCR3-mediated recruitment and local reactivity in the CNS of MS patients.
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INTRODUCTION 
B cells are one of the main contributors to chronic autoimmune pathology in multi-
ple sclerosis (MS), as supported by results from large genome-wide association studies 
[1]. B-cell repertoires in the central nervous system (CNS) and the periphery are closely 
connected, suggesting that disease-relevant B-cell networks interact at both sides of the 
blood-brain barrier [2-5]. There is evidence that the benecial eects of anti-CD20 mono-
clonal antibody therapy are related to the ablation of functional B cells interacting with 
T cells [6, 7]. The meninges of MS patients contain tertiary lymphoid structures that are 
lled with B and T cells, close to cortical lesions [8]. This strongly suggests that B- and T-cell 
interaction is a major event in triggering and sustaining inammation in the CNS.
In MS, autoreactive (naive) B cells escape peripheral selection and probably receive 
specic signals from CD4+ T cells within secondary lymphoid organs to dierentiate into 
memory populations before entering the CNS [5, 9, 10]. The presence of oligoclonal bands 
(OCBs) in the cerebrospinal uid (CSF) of MS patients implies that these memory B cells 
undergo local reactivation (with the help of CD4+ T cells) to further develop into immu-
noglobulin (Ig)-producing plasmablasts and plasma cells [8, 11]. Although memory B cells 
have been recently shown to promote the dierentiation of CNS-inltrating CD4+ T cells 
in MS, little is known about how and which functional B-cell subsets are triggered in the 
periphery to inltrate the CNS and contribute to MS pathology.
In mice, the T helper 1 (Th1) cytokine interferon-γ (IFN-γ) induces the interaction 
between autoreactive B cells and CD4+ T cells to form tertiary lymphoid structures and 
promote systemic autoimmune diseases such as systemic lupus erythematosus (SLE) 
[12]. In these cases, IFN-γ induces the expression of the T-box transcription factor T-bet, 
resulting in enhanced Ig class switching and CXC chemokine receptor 3 (CXCR3) expres-
sion in murine B cells [13, 14]. Interestingly, B-cell-intrinsic T-bet expression associates with 
increased pathogenic responses [14, 15] and is induced by systemic infections [16], a major 
environmental trigger in MS [17]. Toll-like receptor 9 (TLR9), which binds to pathogen-re-
lated CpG-DNA, integrates with the B-cell receptor (BCR), CD40 and cytokine signals to 
stimulate T-bet+ B-cell development [18, 19]. Additionally, B cells from MS patients were 
previously reported to exhibit an enhanced pro-inammatory phenotype when activated 
with IFN-γ and TLR9 ligand CpG-DNA [7].
Here, we aimed to explore the CNS transmigration capacity of T-bet(CXCR3)-expressing 
B cells and which peripheral triggers are involved in the development of such popula-
tions in MS patients. We explored the recruitment of human CXCR3+ B cells to the CNS 
both ex vivo and in vitro. Furthermore, the susceptibility of blood-derived B cells from MS 
patients and healthy individuals to T-bet-inducing stimuli and how this inuences their 
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Post-mortem CSF, meninges, brain tissues and blood samples were freshly obtained 
from MS brain donors (Netherlands Brain Bank, Amsterdam, the Netherlands). The main 
cause of death was legally granted euthanasia (8 of 10 donors). The two other donors died 
from pneumonia or MS. These tissues had a very short post-mortem delay of 8.92 hours 
(interquartile range [IQR] = 8.50 – 9.50 hours) and pH of the CSF was 6.59 (IQR = 6.44 – 
6.87). All other MS patients and healthy controls were included at Erasmus Medical Center 
(Rotterdam, The Netherlands), which is a national tertiary referral center for MS patients 
(MS Center ErasMS). Patients and controls were age- and gender-matched per study group. 
Patient characteristics are summarized in Table 1. Primary material was obtained between 






































































Table 1. Characteristics of patients and controls used in this study  
aAt time of sampling
bTime from MS diagnosis to sampling
cAt time of pre-treatment sampling
dIgG subclass instead of total IgG analysis
CNS = central nervous system; MS = multiple sclerosis; HC = healthy control; NAT = natalizumab, Tx = treatment; 
IQR = interquartile range; NA = not applicable.
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approved by the medical ethics committee of the Erasmus Medical Center (Rotterdam) 
and VU University Medical Center (Amsterdam, The Netherlands). 
Mononuclear cell isolation from blood and CNS compartments
Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufactur-
er’s instructions from blood of MS patients and matched controls with the use of vacutainer 
CPT® tubes containing sodium heparin (BD Biosciences, Erembodegem, Belgium). 
PBMCs were frozen and stored in liquid nitrogen until use as previously described [20]. 
Mononuclear cells were isolated from buy coats using Ficoll-Paque Plus (GE Healthcare, 
Freiburg, Germany) and density gradient centrifugation. Blood and CSF samples from MS 
brain donors were acquired post-mortem through heart puncture and ventricle drainage, 
respectively [20]. Heart blood mononuclear cells were isolated as described for buy coat 
material. Collection tubes with CSF were centrifuged for 10 min at 500g. CSF and blood 
mononuclear cell fractions were resuspended in RPMI 1640 (Lonza, Verviers, Belgium) con-
taining 10% heat-inactivated human AB serum (Sanquin, Rotterdam, The Netherlands) and 
1% penicillin/streptomycin (Lonza) and left to rest at 37oC until further use. Meninges were 
washed in phosphate-buered saline (PBS) containing 0.1% bovine serum albumin (BSA) 
3 times, cut into pieces and incubated with Liberase (Roche Applied Science, Penzberg, 
Germany) for 1h at 37oC, after which the meninges were ltered through a cell strainer 
(45µm) and cells were washed using Ficoll-Paque Plus (GE Healthcare). Single-cell suspen-
sions from the meninges were resuspended in PBS containing 0.1% BSA until further use. 
Brain tissue samples were processed and single-cell suspensions were obtained as previ-
ously reported [21]. 
Antibodies and ow cytometry
Multicolor ow cytometric analysis was performed using uorochrome-labeled mono-
clonal anti-human antibodies (mAbs; Table 2). PBMCs were stained extracellularly for 30 
min at 4oC. Cultured B cells were stained with a xable viability stain (FVS 700) for 15 min 
at 4oC and subsequently stained for either extracellular only or both extracellular and 
intracellular markers. For intracellular staining, cells were xed with 2% paraformaldehyde 
(Merck, Schipol-Rijk, The Netherlands) and permeabilized with PBS pH 7.4 containing 0.3% 
BSA and 0.5% saponin (Sigma-Aldrich, Saint-Louis, MO) and stained with T-bet for 60 min 
at 4oC. All measurements were conducted with an LSRII-Fortessa ow cytometer and ana-
lyzed using FACS Diva software, version 8.0.1 (both BD Biosciences). Ex vivo Th17.1 (IFN-
γhighIL-17low) and Th17 (IFN-γneg) cells in blood were dened as CCR6+CXCR3+CCR4- (Th17.1) 
and CCR6+CXCR3-CCR4+ (Th17), described recently [20].  
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Human B-cell migration assays
Flow-activated cell sorting (FACS)-sorted CD27- and CD27+ memory CD19+ B cells from 
buy coat-derived PBMCs were placed on 96 wells permeable transwell plates with a 3 
µm pore size (2×105 cells/well; Corning, Amsterdam, the Netherlands). B-cell migration 
towards medium or CXC chemokine ligand (CXCL)10 (900 ng/ml; R&D Systems, Abingdon, 
UK) was analyzed after 3h in 37°C. In addition, 2,5-5×105 memory B cells were placed on 
conuent monolayers of human brain endothelial cells (hCMEC/D3) on 5 μm pore size 
transwell plates (Corning) coated with collagen, and migration was analyzed after 5 hours 
[22]. Percentages of memory B-cell subsets were compared before and after transmigra-
tion using ow cytometry.
































































































Table 2. Monoclonal anti-human antibodies used for FACS
aBiolegend, London, UK
b BD Biosciences, Erembodegem, Belgium
cMiltenyi Biotech, Leiden, The Netherlands 
dSouthern Biotech via ITK diagnostics, Uithoorn, The Netherlands
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Antigen-primed autologous B- and Th-cell co-cultures 
BCR-mediated uptake and presentation of Salmonella typhimurium (S. typhimurium) 
SL1344 was used as a model for antigen presentation, as previously demonstrated [23]. 
mAb anti-human IgG (MH16-1, Sanquin, Amsterdam, The Netherlands) was mixed with 
mAb against S. typhimurium lipopolysaccharide (LPS; 1E6, Invitrogen, Paisley, UK) and rat 
anti-mouse IgG1 antibody (RM161.1, Sanquin) to generate BCR-LPS tetrameric antibody 
complexes. Exponentially grown bacteria were washed twice with PBS, incubated with 
BCR-LPS tetrameric antibody complexes for 30 min at room temperature, and washed 
twice to remove unbound antibodies. B cells were incubated with viable anti-IgG coated 
S. typhimurium [23] at 20 bacteria per cell for 45 min at 37oC without antibiotics. Next, cells
were washed 3 times and cultured for 60 min in medium containing 100 µg/ml gentamicin 
(Invitrogen) to eliminate non-phagocytosed bacteria. B cells were co-cultured in RPMI sup-
plemented with 5% fetal calf serum, 1% (100 U/ml) penicillin, 1% (100 µg/ml) streptamycin 
(Lonza), 1% (2 mM) ultraglutamine (Lonza), 0.1% (50 µM) beta-mercaptoethanol (Sigma
Aldrich), 0.1% (20 µg/ml) apotransferrin (depleted for human IgG with protein-G sephar-
ose; Sigma Aldrich; further referred to as B-cell medium) and 10 µg/ml gentamicin together 
with autologous CD4+ T cells (magnetic activated cell sorted). B cells (1×105) and T cells
(0.5×105) were cultured in 200 µl at 37°C in the presence of 5% CO2 in 96-well round-bot-
tom plates (Greiner Bio-One; Alphen Aan Den Rijn, The Netherlands) for 6 days. Cultures
were performed in the presence of recombinant interleukin (IL)-21 (50 ng/ml; Thermo
Fisher Scientic, Landsmeer, The Netherlands), recombinant IL-2 (50 IU/ml, Miltenyi Biotec, 
Bergisch Gladbach, Germany), and with or without an anti-IFN-γ blocking antibody (MD-1, 
10 µg/ml, U-CyTech Biosciences, Utrecht, The Netherlands).
IL-21/3T3-CD40L assay for human B-cell dierentiation 
To mimic B-cell dierentiation in vitro, murine NIH3T3 broblasts expressing human 
CD40L (3T3-CD40L) [23] were irradiated at 30 Gy using a RS320 X-ray (Beckho, Eindhoven, 
The Netherlands), taken up in B-cell medium, and seeded on at bottom 96-wells plates 
(10×103 cells per well; Greiner Bio-One) to allow adherence overnight. CD19+ (total) B cells 
were isolated from buy coat-derived PBMCs using CD19 microbeads and the autoMACS 
Pro Separator (both Miltenyi Biotec). Total, naive (CD38-/dimCD27-IgG-IgA-) and memory 
(CD38-/dimCD27+IgG+) B cells were isolated from healthy and MS blood using a BD FACSAriaTM 
III cell sorter. These fractions were resuspended in B-cell medium and 20-25×103 cells were 
co-cultured with irradiated 3T3-CD40L cells and stimulated with a combination of IL-21 (50 
ng/ml; Thermo Fisher), IFN-γ (50 ng/ml; Peprotech/Bio-connect, Huissen, The Netherlands) 
and CpG-ODN (2006-G5; 10 µg/ml; InvivoGen/Bio-connect) at 37oC and 5% CO2. After 
6 and 11 days of culture, supernatants were collected and stored at -80oC until use for 
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enzyme-linked immunosorbent assay (ELISA). The cells were stained and assessed using 
ow cytometry as described above.  
IgG1 ELISA
Nunc MaxiSorp plates (Sanbio BV, Uden, The Netherlands) were coated overnight 
with anti-human IgG1 monoclonal capture antibody (1µg/ml; clone MH161-1, Sanquin, 
Amsterdam, The Netherlands) in PBS. After washing with PBS-0.02% Tween-20, the super-
natants from in vitro B-cell cultures (described above) were diluted in high-performance 
ELISA buer (HPE; Sanquin) and incubated for 60 min. Subsequently, plates were washed 
and incubated for 60 min with anti-human IgG conjugated with horseradish peroxidase, 
a monoclonal detection antibody (1 µg/ml; clone MH16-1, Sanquin). After washing, the 
ELISA was developed with MQ containing 0.11M sodium-acetate (pH 5.5), 100 µg/ml 
tetramethylbenzidine and 0.003% (vol/vol) H2O2 (all from Merck). The reaction was stopped 
by addition of 2M H2SO4 (Merck). Optical densities at 450nm were measured with a BioTek 
(Winooski, VT) Synergy 2. Background readings at 540nm were subtracted. Results were 
related to a titration curve of a serum sample of a healthy donor in each plate.
Statistical analyses
All data sets were analyzed with Graphpad Prism Software, version 7 (GraphPad 
Software, San Diego, CA) and compared using two sided Mann-Whitney U tests, Wilcoxon 
matched-pairs signed rank test, 1- or 2-way analysis of variance with Tukey post hoc test, 
Friedman paired with Dunn post hoc test, and Spearman correlation coecients (as indi-
cated in each gure legend). Experimental data are depicted as the mean ± standard error 
of the mean (SEM). Prior to statistical analyses, datasets were tested for normal distribu-
tion. Probability values <0.05 were considered signicant. 
RESULTS
CXCR3-expressing B cells are selectively enriched in distinct CNS 
compartments of MS patients 
Enhanced chemotaxis is one of the key mechanisms by which B cells can enter dis-
tinct CNS compartments of MS patients [11]. Production of the chemoattractants CXCL10, 
CXCL13 and CCL20 in the CNS has been associated with B-cell recruitment, distribution 
and reactivity in MS [24-26]. We compared the presence of B cells that express the chemo-
kine receptors that correspond to these ligands, CXCR3+ (CXCL10), CXCR5+ (CXCL13) and 
CCR6+ (CCL20), between paired blood, CSF, meningeal and brain tissues from 10 MS 
patients (Table 1). To realize this, single-cell suspensions were obtained from autopsied 
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brain compartments using a standardized protocol [21]. From these fractions, viable 
CD45+CD3-CD19+ B cells were gated and analyzed for chemokine receptor expression 
using ow cytometry (Fig. 1A). We were able to measure sucient numbers of viable B 
cells from each compartment for all donors (mean [range]: blood, 21,509 [610-98,562]; 
CSF, 12,629 [50-59,499]; meninges, 13,819 [91-36,644]; brain tissue, 2,889 [26-18,050]. The 
frequency of CXCR3+, and not CXCR5+ or CCR6+ B cells was strongly increased in ex vivo 
cell suspensions from MS brain tissues (p < 0.0001), meninges (p = 0.0003), and CSF (p 
< 0.0001) compared to blood (Fig. 1B). CXCR3-expressing T cells, including Th17.1, were 
also enriched in the CNS compartments of these donors (data not shown), supporting our 
recent observations [20]. 
Figure 1. CXCR3+ B cells are abundant in the CNS compared to blood of MS patients.  
(A) Representative FACS plots and gating of CXCR3-expressing CD19+ B cells within viable CD45+CD3- lymphocyte 
fractions derived from the blood, CSF, meninges and brain tissue of an MS patient. (B) Frequencies of CXCR3+, 
CXCR5+ and CCR6+ B cells in distinct paired compartments from MS patients. For blood, CSF and meningeal 
samples each dot represents a dierent patient. A total of 10 brain tissues from 7 dierent MS patients were used 
for the analysis of CXCR3+ B cells. Any samples with <25 viable B cells were excluded from these analyses. Data 
are presented as the mean ± SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. The p values for B were calculated by a 







































































































Reduced frequencies of CXCR3+IgG(1)+ B cells in the blood of MS patients 
are abrogated after natalizumab treatment 
To determine how CXCR3 is involved in the local attraction of dierent  B-cell popula-
tions in MS, we assessed the proportions of CXCR3-expressing naive (CD27-IgM+; IgMnaive) 
and both IgM+ memory (CD27+IgM+; IgMmem) and IgG
+ memory (CD27+IgG+) B cells in the 
peripheral blood of untreated MS patients (n = 10) and age- and gender-matched healthy 
controls (HC, n = 10; Table 1 and Fig. 2A). CXCR3-expressing IgG+ cells were reduced (p = 
0.007), whereas no dierences were seen for IgMnaive and IgMmem cells in MS versus HC blood 
(Fig. 2B). 
To address this potential migration of CXCR3+IgG+ memory B cells into the CNS, we 
analyzed the distribution of these B-cell subsets in the blood of MS patients treated with 
the anti-α4β1 integrin (VLA-4) antibody natalizumab (Table 1), a drug that eectively 
reduces MS disease activity by blocking lymphocyte recruitment to the CNS [27]. VLA-4 
was most abundantly expressed on blood IgG+ B cells from MS patients prior to natali-
zumab treatment (Fig. 2C). Elevated frequencies of both IgMmem (pre-treatment versus 
6m post-treatment p = 0.042 and 12m post-treatment p = 0.011) and IgG+ (pre-treatment 
versus 6m post-treatment p = 0.022 and 12m post-treatment p < 0.001) B cells were found 
in the blood of MS patients both 6 and 12 months after versus before treatment (Fig. 2D). 
However, only IgG+ and not IgMnaive or IgMmem B cells from MS patients treated with natali-
zumab for 12 months showed increased expression levels of CXCR3 (p < 0.01; Fig. 2E), and 
not CXCR5 or CCR6 (Fig. 2F). These ndings were validated in a second cohort of nine MS 
patients treated with natalizumab (Table 1; data not shown). Notably, CD20 expression 
levels were increased on IgG+ B cells and higher on CXCR3+ compared to CXCR3- counter-
parts in the blood of natalizumab-treated MS patients (Fig. 2G).
Figure 2 (see right page). Reduced frequencies and natalizumab-mediated accumulation of CXCR3+IgG(1)+ 
B cells in MS blood.
(A) FACS gating strategy used to dene IgMnaive (CD27
-IgM+), IgMmem (CD27
+IgM+) and IgG+ (CD27+IgG+) B-cell
subsets. (B) Gating and quantication of CXCR3-expressing IgMnaive, IgMmem and IgG
+ B-cell frequencies in the
blood of untreated MS patients (n = 10; dark blue dots) and both age-/gender-matched healthy controls (HC; n 
= 10; grey dots, see Table 1). (C) VLA-4 surface expression on IgMnaive, IgMmem and IgG
+ B cells from blood of MS
patients before natalizumab treatment (n = 9). (D) The percentage of IgMnaive, IgMmem and IgG
+ B cells in MS blood 
before (black dots) and both 6 months (marine blue dots) and 12 months (light blue dots) after natalizumab
treatment (paired samples; n = 10; see Table 1). Surface expression levels of (E) CXCR3, (F) CXCR5 and CCR6 on
IgMnaive, IgMmem and IgG
+ B cells in MS patient blood before and after natalizumab treatment  (n = 7-10). (G) CD20 
expression on IgMnaive, IgMmem and IgG
+ B cells as well as paired CXCR3- and CXCR3+ IgG+ populations in blood of 
MS patients treated with natalizumab for 12 months (n = 8).  (H-J) Gating example and quantications of IgG1+
and IgG2+ B cells expressing CXCR3 in MS patients treated with natalizumab for 12 months (n = 9). Data are
presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The p values were calculated by 
Mann-Whitney U (B), 2-way analysis of variance (C and G), Friedman paired (D-F), and Wilcoxon matched-pairs
























































































































































































































































































































Because intrathecally synthesized OCBs are restricted to the IgG1 subclass in the CSF of 
MS patients [28], we also analyzed IgG1+ B cells for their frequencies and CXCR3 expression 
in the blood of a third cohort of natalizumab-treated MS patients (Fig. 2H). IgG1+ B cells 
not only expressed higher levels of CXCR3 (p = 0.007; Fig. 2I), but also showed increased 
frequencies in post-treatment samples (p = 0.027; Fig. 2J) compared to IgG2+ B cells. The 
selective accumulation of CXCR3high IgG(1)+ B cells in the blood of natalizumab-treated 
patients underlines the potency of this subset to transmigrate into the CNS to mediate MS 
disease activity. 
CXCR3+IgG1+ B cells have an enhanced capacity to transmigrate across 
the blood-brain barrier in vitro
To functionally test the transmigration potential of CXCR3+IgG1+ B cells into the CNS, we 
sorted memory B cells from the blood and assessed in vitro migration of subsets towards 
CXCL10. Fractions of CXCR3-expressing IgMmem, IgG1
+ and IgG2+ B cells were assessed within 
the total memory pool before and after migration through transwell lters. In contrast to 
IgMmem and IgG2
+ populations, IgG1+ B cells showed prominent recruitment to CXCL10 (p < 
0.0001 before versus after migration; Fig. 3A and B). This was not seen using medium only 
(Fig. 3B). To mimic B-cell transmigration across the blood-CNS barrier, these experiments 
were repeated using cultured conuent monolayers of human brain endothelial cells [22]. 
We found a similar CXCL10-mediated migratory advantage of IgG1+ B cells (p < 0.0001; Fig. 
3A and C), which is consistent with the abundance of CXCR3 on IgG1+ compared to IgMmem 
and IgG2+ B cells in MS patients (Fig. 2G-I). These data demonstrate that CXCR3high IgG1+ B 
cells in the blood have a heightened ability to inltrate the CNS, probably accounting for 
the local IgG1 subclass restriction of OCBs in MS patients [28].
IFN-γ promotes CXCR3 expression and CD4+ T-cell activation by human 
T-bet+ B cells under T follicular helper-like culture conditions
In MS blood, the proportion of CXCR3+IgG+ B cells correlated to Th17.1 (IFN-γhighIL-17low;
r = 0.566, p = 0.0003) and not to Th17 (IFN-γneg) cells (Fig. 4A) [20]. Th cell-derived IFN-γ is 
known as a central driver of autoreactive B cells in mice [10] and also induces CXCR3 expres-
sion on human memory B cells [29]. Therefore, we aimed to better understand how the 
dierentiation and function of human CXCR3+ memory B cells is inuenced by IFN-γ before 
entering the CNS. To address this, we mimicked the eects of IFN-γ-producing T follicular 
helper (Tfh) cells on B-cell subsets in vitro. First, an IL-21-based human B- and T-cell co-cul-
ture system was used to assess whether Th1-derived IFN-γ inuenced CXCR3 expression 
on IgG+ B cells in an antigen-specic manner. Because antigen uptake by B cells is limited 
by the selectivity of the BCR, surface IgG was crosslinked with Th1-associated pathogen 
S. typhimurium for ecient internalization, processing and presentation to autologous Th
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Figure 3. Enhanced migration of CXCR3+IgG1+ B cells across transwell lters and human brain endothelial 
monolayers in vitro.  
Sorted memory B cells from healthy donor blood were assessed for selective in vitro transmigration towards 
CXCL10. (A) Representative FACS plots and (B and C) quantications of viable CXCR3-expressing IgMmem, IgG1
+
and IgG2+ B-cells migrating across transwell lters with and without conuent monolayers of human brain 
endothelial cells (BEC). Percentages of subsets within the total memory pool were compared before and after 
migration, both to medium and to CXCL10 (-BEC, n = 8; +BEC, n = 6). These experiments were performed in 
duplicate for each donor for which the average is shown. Data are presented as the mean ± SEM. *p < 0.05, **p < 


























































































































































































































































































































































































































Figure 4. T helper 1 cytokine IFN-γ is a major trigger of CXCR3+(T-bet+) B-cell dierentiation in MS.  
(A) Correlation of ex vivo CXCR3+IgG+ B cells with Th17.1 (IFN-γhighIL-17low) and Th17 (IFN-γneg) cells in MS blood
before and after natalizumab treatment (pre-Tx and post-Tx; n = 12). (B) Experimental model of Salmonella-primed 
autologous B- and T-cell co-cultures. (C-E) B cells from healthy donor blood were primed with S. typhimurium
through BCR crosslinking using a tetrameric antibody complex, as described in Subjects and Methods. This
allows BCR-mediated Salmonella uptake, processing and presentation on MHC II molecules to Th cells. IL-21 was 
added with and without an IFN-γ blocking antibody to analyze the eects on CXCR3 expression by B cells (C), 
and on the proliferation, activation and eector memory phenotype of Th cells (D and E). These experiments
were performed in two independent experiments and in duplicate for (C) four and (D and E) two dierent blood 
donors. (F) Correlation of surface CXCR3 and intracellular T-bet expression in ex vivo B cells of MS patients before 
and after natalizumab treatment (pre-Tx and post-Tx; n = 9). (G and H) Total B cells from the blood of MS patients 
(n = 9) and both age-and gender-matched healthy controls (HC; n = 10) were cultured in vitro under Tfh-like
conditions with IL-21, 3T3-CD40L cells, and with or without IFN-γ for 11 days. Representative FACS plots and
quantication of in vitro-induced T-bet+ B cells (G) and correlation of CXCR3 and T-bet expression in these cultured 
B cells (H) are shown. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
The p values were calculated by 2-way analysis of variance (ANOVA) (C), 1-way ANOVA (D and E) and Wilcoxon 
matched-pairs signed rank (G) tests. The correlation coecients and p values for A, F and H were calculated by
Spearman rank. m = months; MFI = mean uorescence of intensity; TCR = T-cell receptor.
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cells (Fig. 4B) [23, 30]. After 6 days of co-culture, we found that the induced expression of 
CXCR3 on Salmonella-containing IgG+ and not IgMnaive or IgMmem B cells was abrogated by 
the addition of an IFN-γ blocking antibody (p < 0.0001; Fig. 4C). Furthermore, blocking of 
IFN-γ impaired B cell-induced T-cell proliferation, activation and eector memory forma-
tion (Fig. 4D and E). This implies that IFN-γ additionally stimulates the antigen-presenting 
function of CXCR3+IgG+ B cells, in parallel with previous ndings in mice [31].
CXCR3 expression is under the direct control of IFN-γ-inducible transcription factor 
T-bet, a critical regulator of memory B-cell dierentiation in mice [13, 14]. Consistent with
this, intracellular T-bet positively correlated to surface CXCR3 expression in ex vivo B cells (r 
= 0.644, p = 0.0003) and showed a similar association with Th17.1 (IFN-γhighIL-17low) cells in
MS patients (Fig. 4F and data not shown) [20]. To further explore the susceptibility of B cells 
to IFN-γ in MS [7], we compared B cells from MS and matched healthy control blood for IFN-
γ-mediated T-bet induction under Tfh-like culture conditions. After 11 days of stimulation
with 3T3-CD40L cells, IL-21 and IFN-γ, T-bet was predominantly upregulated in B cells of
MS patients (p = 0.021; Fig. 4G), whereas conditions without IFN-γ did not show this. This
in vitro-induced T-bet was co-expressed with surface CXCR3 (r = 0.766, p = 0.0001; Fig. 4H),
in line with our ex vivo results (Fig. 4F). These ndings reveal that Th cell-derived IFN-γ is a
major trigger of peripheral CXCR3(T-bet)+ B cells in MS.
IFN-γ stimulates plasmablast formation and synergizes with CpG-DNA to 
establish IgG1 switching during human Tfh-like B-cell cultures
Besides IFN-γ, TLR9 ligand CpG-DNA has also been reported to induce T-bet in murine B 
cells [14, 18] and promote pro-inammatory cytokine responses of B cells from MS patients 
[7]. To assess how TLR9 signals integrate with IFN-γ to regulate human T-bet+ B-cell develop-
ment, we rst determined whether naive or memory B cells are more prone to this type of 
co-activation. Naive (CD27-IgG-) and memory (CD27+IgG+) B cells were sorted from healthy 
donor blood and stimulated with 3T3-CD40L cells, IL-21, IFN-γ and/or CpG-DNA. After 11 
days of naive B-cell cultures, both T-bet and CXCR3 expression was induced by IFN-γ, and 
further enhanced after addition of both IFN-γ and CpG-DNA (p = 0.001 and p = 0.021; Fig. 
5A). This additional eect of CpG-DNA was not found when using sorted memory B cells 
(Fig. 5B). Both IFN-γ- and CpG-DNA-induced T-bet(CXCR3)+ B cells also showed strongly 
reduced CD21 expression (data not shown), a typical feature seen for T-bet-expressing B 
cells [31]. 
During a germinal center response, naive B cells can either dierentiate into plasmab-
last or memory populations, depending on the local inammatory environment [10, 32]. 
We investigated the eects of IFN-γ and CpG-DNA on plasmablast formation and IgG 
subclass switching during IL-21-/CD40L-induced naive B-cell dierentiation. After 11 days 
of culture, sorted naive B cells from healthy donors developed into plasmablasts under 
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Figure 5. IFN-γ induces plasmablast dierentiation, whereas both IFN-γ and CpG-DNA further upregulate 
T-bet and trigger IgG1 switching in B cells of MS patients.   
(A-D) Naive (IgG-CD27-; dots) and memory (IgG+CD27+; squares) B cells were sorted from peripheral blood of 
healthy donors and were cultured under Tfh-like conditions with IL-21, 3T3-CD40L cells, with or without IFN-γ 
and/or CpG-DNA. Frequencies of T-bet+ and CXCR3+ B cells after 11 days of culture using (A) naive B cells (n = 
12) and 6 days of culture using (B) memory B cells (n = 10-12) are shown. The frequencies of (C) plasmablasts 
(CD38highCD27+; n = 12) and (D) membrane-bound (m) mIgG1+ and mIgG2+ B cells were analyzed after culturing 
naive populations for 11 days (n = 12). (E) Correlation between cellular expression and secretion of IgG1 was 
determined by FACS and ELISA (pooled stimulation conditions for 5 donors). Naive B cells from the blood of MS 
patients (n = 6; dark blue dots) and healthy controls (HC; n = 6; grey dots) were cultured under the same Tfh-like 
conditions and analyzed for (F) plasmablast (CD38highCD27+) and (G and H) CXCR3+mIgG1+ and CXCR3+mIgG2+ 
B-cell dierentiation after 11 days of culture. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p 
< 0.001. The p values for A-D and F-H were calculated by the Wilcoxon matched-pairs signed rank test. The 
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IFN-γ stimulatory conditions only (p = 0.034; Fig. 5C). IFN-γ and CpG-DNA together did 
not induce plasmablast formation, but instead triggered IgG1 and not IgG2 expression on 
dierentiating B cells (IFN-γ only versus IFN-γ + CpG-DNA: p = 0.002; Fig. 5D). Interestingly, 
this in vitro-induced IgG1 switching was subjected to dierentiation of sorted naive (Fig. 
5D) and not memory (data not shown) B cells. CpG-DNA alone did not upregulate CXCR3, 
T-bet and IgG1 in dierentiating naive B cells (data not shown), indicating that both IFN-γ
and TLR9 signaling are required for enhanced expression of these markers. To verify that
B-cell intrinsic expression also corresponds with secretion of IgG1, we performed ELISAs
on culture supernatants of these B cells. The percentage of IgG1+ B cells positively cor-
related to IgG1 secretion (r = 0.640, p = 0.016; Fig. 5E).
Finally, to address how this is regulated in MS, we isolated naive B cells from MS patients 
and performed similar culture experiments. IFN-γ-mediated plasmablast formation was 
more induced after 11 days of culture compared to matched controls (p = 0.031; Fig. 5F). 
This was not seen after stimulation with both IFN-γ and CpG-DNA. Instead, this type of 
triggering resulted in a robust induction of CXCR3+IgG1+, and not CXCR3+IgG2+ subsets in 
MS (Fig. 5G and H). Collectively, these data demonstrate that TLR9 signaling potentiates 
IFN-γ-induced T-bet and CXCR3 expression during naive B-cell dierentiation in vitro, and 
that this is important for IFN-γ-mediated formation of IgG1+ memory B cells rather than 
plasmablasts under Tfh-like circumstances in MS. 
DISCUSSION 
Evidence has accumulated that at least in the periphery, antibody-independent roles 
of B cells are driving the pathology of MS [7]. However, local production of autoantibodies 
should not be ruled out as an underlying B-cell mechanism in this disease [33]. Although 
autoreactive naive B cells are highly active in MS blood [9], the vast majority of B cells 
identied in the MS brain have undergone further maturation into antibody-producing 
cells [34, 35]. It has also been demonstrated that memory B cells of MS patients are the 
most potent antigen-presenting cells and likely have specic pro-inammatory propen-
sities, including the capacity to express enhanced levels of immune activating molecules 
[35]. This is of special interest considering the presence of meningeal B cell-rich follicle-like 
structures in MS and the adjacent subpial cortical demyelinating injury [8], which prob-
ably contributes to progressive loss of neurological function in patients with MS. Thus, 
identication of the particular B-cell subsets that can preferentially migrate into the CNS 
and clarication of how they may contribute to propagating local injury responses are of 
considerable interest in such an organ-specic disease. In this study, we demonstrate that 
integrating IFN-γ and pathogen-associated TLR9 signals are critical for the development of 
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human T-bet+ memory B cells, probably underlying their selective recruitment to the CNS 
of MS patients. 
Recent studies have shown that in MS identical B-cell clones are present in both the 
periphery and CNS [2-4]. The fact that these B-cell populations further undergo somatic 
hypermutation in the brain implies the presence of functional germinal centers within 
the CNS. Such structures have been identied in the meninges of MS patients and are 
obvious localizations to play a role here [8]. The enrichment that we observe of CXCR3+ 
B cells in paired CSF, meninges and brain tissue compartments compared to blood of MS 
patients is in line with studies that show higher levels of CXCR3 ligand CXCL10 in the CSF of 
MS patients [24]. These results are also consistent with our previous ndings that CXCR3+ 
T cells, including Th17.1, are abundant within the CNS [20, 24], suggesting a common 
CXCR3-driven lymphocyte recruitment pathway in MS [24, 36, 37]. Other studies have also 
put forward CXCR5 and its ligand CXCL13 as important contributors to B-cell recruitment 
to the CNS [3, 38]. We did not nd dierences in CXCR5-expressing B cells between CNS 
tissues and paired blood. Hence, the CXCR5/CXCL13 axis is probably related to local orga-
nization rather than recruitment of pathogenic B (and T) cells [39, 40], in a process similar 
to that in secondary lymphoid organs [41]. Although these studies indicate a role for ger-
minal center B cells within the CNS, little is known about which peripheral mechanisms 
underlie their development and local recruitment. In mice, it has been shown that in an 
autoimmune setting, IFN-γ, likely produced by activated Tfh cells, induce germinal centers 
[10], which can be found in meningeal follicle-like structures [8]. In these situations, IFN-γ 
induced B cell-intrinsic expression of T-bet, possibly resulting in enhanced Ig class switch-
ing and CXCR3 expression [13, 14]. This points to a central role of IFN-γ-associated CXCR3+ 
B-cell subsets in the meningeal process [10, 12].
While the inducing eects of peripheral B cells on autoreactive Th1 cells are currently
being elucidated [37], far less is known about the impact of Th1 cells on peripheral B-cell 
dierentiation and function in MS patients. Therefore, we were interested in the signals 
needed for B cells to dierentiate into T-bet+ cells and postulated that IFN-γ- and IL-21-
producing Tfh1 cells in germinal centers can trigger development of such B cells. In MS 
patients, B cells were found to express higher T-bet levels under Tfh1-like culture condi-
tions. Furthermore, IL-21-based B- and T-cell co-cultures revealed that CXCR3-expressing 
IgG+ memory B cells were less induced after blocking of IFN-γ, which corresponds to stud-
ies that show IFN-γ regulates CXCR3 expression in human B cells [29]. Th cell proliferation, 
activation and eector memory formation were also aected in these cultures. In line with 
our ndings, a recent study demonstrated that memory B cells induce proliferation of 
CNS-inltrating Th1 cells in MS, which was inhibited after IFN-γ abrogation [37]. Therefore, 
in MS patients, peripheral interaction of CXCR3(T-bet)+ B and IFN-γ-producing Th cells 
probably generates a feedforward loop, in which IFN-γ enhances the potency of B cells 
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as antigen-presenting cells, resulting in the activation of (IFN-γ-producing) pathogenic Th 
cells.
Furthermore, we found that naive B cells from MS patients developed into plasmab-
lasts rather than IgG1-switched memory B cells under IFN-γ-only conditions. Because T-bet 
mediates class-switching in murine B cells [13], we expected that an additional signal 
would be required for triggering such a mechanism in human B cells. Besides Tfh1 cells, 
innate TLR signaling is also critical for naive B-cell dierentiation [42]. Especially patho-
gen-associated TLR9 and its ligand CpG-DNA have been shown to promote the develop-
ment of T-bet+ B cells in mice [19, 31, 42]. Correspondingly, we found that the induction of 
MS-blood derived naive B cells with both IFN-γ and CpG-DNA resulted in the development 
of IgG1-switched, T-bethigh B cells during Tfh-like cultures. Likewise, CXCR3 surface expres-
sion was more enhanced under these conditions, reecting the high CXCR3 levels on ex 
vivo IgG1+ B cells. This additional eect of TLR9 signaling on human T-bet+ B cells in MS links 
to the role of TLR9 in driving neuroinammatory responses, including increased produc-
tion of chemokines in the CNS [43]. Moreover, CXCR3+IgG1+ B cells showed an enhanced 
transmigration potential over brain endothelial layers, and selectively accumulated in MS 
blood after natalizumab therapy. The importance of pathogenic immune cells in contrib-
uting to MS disease progression, such as CXCR3+ memory B cells, has been put forward by 
the recurrence of often-fatal clinical relapses in MS patients when discontinuing the use 
of natalizumab [27, 44, 45]. During these rebounds, Epstein-Barr virus-infected memory 
B cells that have accumulated in the blood show massive inux into brain tissues of MS 
patients [45]. Furthermore, persistent viral infections are suggested to sustain the develop-
ment of T-bet-expressing B cells [15], which further supports the enhanced dierentiation 
and local recruitment of CXCR3(T-bet)high memory B cells in an organ-specic autoimmune 
disease such as MS (Fig. 6). 
Although the exact role of (local) autoantibody production in MS is not clear, the ques-
tion whether and how T-bet+ B cells are involved this process deserves further attention. In 
SLE, T-bet+ B cells have autoreactive BCRs and are prone to dierentiate into IgG autoanti-
body producing plasmablasts [46]. Inappropriate T-bet expression in B cells also impaired 
CXCR3-mediated plasmablast dierentiation within germinal centers [14] and autoanti-
body production [13]. In our study, IFN-γ-induced and CpG-DNA-induced human CXCR3(T-
bet)high B cells showed increased IgG1 expression and secretion. This strongly suggests that 
after preferential recruitment and re-activation in the CNS, CXCR3(T-bet)highIgG1+ B cells 
are responsible for local production of IgG1 in MS (Fig. 6) [28]. Although B cells within the 
CNS of MS patients show characteristics of an antigen-driven response, the specic anti-
gens driving this response remain unknown. MS disease heterogeneity is reected by the 
identication of several candidate target antigens, including non-myelin proteins such as 
neurolament light and RAS guanyl releasing protein 2 (RASGRP2) [33, 37]. In addition to 
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this, increased Epstein-Barr nuclear antigen 1 (EBNA1)-specic IgG1 titers have been found 
in active MS, which may be explained by the interaction of B cells with pathogen-associ-
ated TLR ligands and EBNA1-specic, IFN-γ-producing T cells that cross-recognize myelin 
antigens [47]. Therefore, we propose that the relevant antigen specicity of B cells in MS 
can be found within this subset, which should be further explored in the near future. 
Taken together, not only a disrupted blood-brain barrier, but also peripheral T-bet-
mediated dierentiation and transmigration of IgG1+ memory populations could explain 
how B cells are eventually able to mediate CNS pathology in MS patients (Fig. 6). The rele-
vance of T- and B-cell interaction in tolerance breakthrough is stressed by the nding that 
antigen-specic B cells are potentially 1,000 to 10,000 times better presenters of autolo-
gous peptides to T cells than non-specic B cells [48]. We here reveal that human CXCR3(T-
bet)+ B cells are a product of T- and B-cell interaction. Similar to SLE, such populations 
probably serve as potent antigen-presenting cells in CNS-specic autoimmune diseases 
such as MS [31]. Anti-CD20 therapy exerts immediate eects and is assumed to predom-
inantly aect this function of B cells in MS patients [35]. The potential role of CXCR3(T-































Figure 6. IFN-γ and TLR9 signaling upregulate T-bet in peripheral B cells, likely driving CXCR3-mediated 
recruitment and IgG1 production in the CNS of MS patients. 
Our ndings suggest that in the secondary lymphoid organs of MS patients, IFN-γ triggers naive B cells to 
dierentiate into T-bet-expressing populations in a Tfh-dependent manner. Human T-bet+ B cells either can 
develop into plasmablasts or undergo further dierentiation into IgG1+ memory B cells mediated by TLR9 
ligation. The enhanced CXCR3 expression on both IFN-γ- and TLR9-induced IgG1+ B cells makes these subsets 
highly capable of transmigrating across the blood-brain barrier and mediate local pathology in MS.  
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expression, as shown in the current study. The development of new targeted strategies 
to inhibit T-bet function have the potential to become a double-edged sword in MS by 
suppressing pathogenic, IFN-γ-producing T (Th17.1) cells together with their counterpart 
CXCR3(T-bet)+ B cells. Small molecule inhibitors of IFN-γ signaling (jakinibs) [49] and the 
TLR/myD88 pathway [50] are already used in clinics for other inammatory diseases, and 
are promising candidates for combined suppression of IFN-γ and TLR signals to control 
pathogenic T-bet+ B cells in autoimmune diseases such as MS.
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ABSTRACT
Epstein-Barr virus (EBV) infection of B cells is associated with increased 
multiple sclerosis (MS) susceptibility. Recently, we found that CXCR3-
expressing B cells preferentially infiltrate the central nervous system of MS 
patients. In chronic virus-infected mice, these types of B cells are sustained 
and show increased antiviral responsiveness. How EBV persistence in B cells 
influences their development remains unclear. First, we analyzed ex vivo 
B-cell subsets from MS patients who received autologous bone marrow 
transplantation (n = 9), which is often accompanied by EBV reactivation. 
The frequencies of non-class-switched and class-switched memory B cells 
were reduced at 3-7 months, while only class-switched B cells returned 
back to baseline at 24-36 months post-transplantation. At these time 
points, EBV DNA load positively correlated to the frequency of CXCR3+, 
and not CXCR4+ or CXCR5+, class-switched B cells. Second, for CXCR3+ 
memory B cells trapped within the blood of MS patients treated with natal-
izumab (anti-VLA-4 antibody; n = 15), latent EBV infection corresponded 
to enhanced in vitro formation of anti-EBNA1 IgG-secreting plasma cells 
under germinal center-like conditions. These findings imply that EBV per-
sistance in B cells potentiates brain-homing and antibody-producing 
CXCR3+ subsets in MS.
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INTRODUCTION
The success of anti-CD20 therapy puts forward B cells as important players of autoim-
mune diseases including multiple sclerosis (MS) [1]. The strongest infectious risk factor for 
MS is the Epstein-Barr virus (EBV) [2, 3], a DNA γ-herpes virus that infects and persists within 
B cells using a series of programs that mimic germinal center (GC) dierentiation signals 
[4]. In MS, one of the hypotheses is that EBV remains latent within pathogenic memory 
B cells that invade the central nervous system (CNS) [3, 5]. Once in the CNS, pathogenic 
memory B cells are likely re-activated and further develop into antibody-secreting plasma 
cells to mediate local inammation [1]. IL-21 and CD40L are the main triggers of plasma 
cell dierentiation during a GC response [6, 7]. However, in murine models of autoimmune 
diseases this response seems to be dysregulated in the presence of IFN-γ [8].
IFN-γ triggering of B cells induces the T-box transcription factor T-bet, which drives the 
surface expression of CXC chemokine receptor (CXCR)3 [9]. Recently, our group found that 
CXCR3-expressing B cells are abundant in the MS CNS and selectively accumulate in the 
blood of MS patients treated with natalizumab (anti-VLA-4 mAb; NTZ) [10], an eective 
drug that prevents their inltration into the CNS. Moreover, naive B cells of untreated MS 
patients preferentially developed into CXCR3-expressing plasmablasts under IL-21-, CD40L- 
and IFN-γ-inducing conditions in vitro [10]. Interestingly, in mice, CXCR3(T-bet)-expressing 
B cells do not only show increased antiviral responses, but are also more sustained during 
chronic viral infections [11]. How EBV infection contributes to the development of patho-
genic memory B cells is poorly understood.
Here, we used two distinct MS cohorts to determine the association of B-cell EBV DNA 
load with CXCR3+ memory B-cell development. First, memory B-cell subsets were studied 
ex vivo from MS patients who received autologous bone marrow transplantation (BMT), 
which is often accompanied with EBV reactivation [12, 13]. Second, GC-like plasma cell 
dierentiation was explored in vitro for memory B cells trapped within the blood of NTZ-
treated MS patients, who are known to experience a massive local inux of EBV-infected B 
cells after treatment cessation [14].  
MATERIALS AND METHODS
Patients
Characteristics of patients used in this study are summarized in Supplementary Table 1. 
For the analysis of EBV infection in relation to ex vivo B-cell subsets, we used 9 MS patients 
who had undergone autologous BMT as previously described [15]. In short, CD34+ stem 
cells were isolated from bone marrow and cryopreserved until use. These patients obtained 
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a vigorous T cell depletion regimen consisting of ATG (anti-thymocyte globulin) and total 
body irradiation before treatment with the preserved stem cells [15]. For each patient, 
thawed peripheral blood mononuclear cells (PBMCs) were analyzed before and both 3-7 
and 24-36 months after BMT. For the analysis of EBV load in relation to CXCR3+ B-cell dif-
ferentiation in vitro, we used thawed PBMCs of MS patients treated with NTZ (anti-VLA-4 
antibody; 1-4y post-treatment) [10]. These patients were both age- and gender-matched 
with healthy controls. Study protocols were approved by the medical ethics committee of 
the Erasmus Medical Center (Rotterdam, The Netherlands) and all patients gave written 
informed consent [15, 16]. 
Cell isolation, antibodies and ow cytometry
PBMCs were isolated from blood of patients using Ficoll®-Paque Plus (GE Healthcare,
Freiburg, Germany) and density centrifugation or with vacutainer CPT® tubes (BD
Biosciences, Erembodegem, Belgium) and stored in liquid nitrogen until use as earlier 
reported [10]. FACS was performed on PBMCs using monoclonal antibodies as indicated in 
Supplementary Table 2. Cells were stained extracellularly for 30 min at 4oC. Prior to extra-
cellular staining, cultured memory B cells were labelled with a viability stain (FVS700) for 
the analysis of viable cells. All measurements were performed on a LSRII-Fortessa machine 
and analyzed using FACS Diva software, version 8.0.1 (both BD Biosciences). B-cell subsets 
were separated using a FACSAria III cell sorter (BD Biosciences) for qPCR analysis or in vitro 
cultures.
DNA isolation and EBV load qPCR
DNA was extracted using a GenEluteTM Mammalian Genomic DNA Miniprep Kit accord-
ing to the manufacturer’s instructions (Sigma-Aldrich via Merck, Kenilworth, New Jersey, 
USA). EBV DNA load was determined using a multiplex RQ-PCR assay using a FAM-labeled 
probe specic for BALF5 (the EBV DNA polymerase; Eurogentec, Liège, Belgium) and a 
VIC-labeled probe specic for reference gene beta-2 microglobulin (B2M; Thermo Fisher 
Scientic, Landsmeer, The Netherlands) [17, 18]. Primer and probe sequences and used 
concentrations are shown in Supplementary Table 3. We added 5 µl (200 ng) DNA to 20µl 
reaction mixture containing primers and probes for BALF5 and B2M supplemented with 
TaqManTM Universal Master Mix II, no UNG (Applied BiosystemsTM, Thermo Fisher Scientic). 
Samples were run on a QuantStudioTM 5 machine (Applied BiosystemsTM, Thermo Fisher 
Scientic) using the following thermal cycle protocol: 10 min at 95oC followed by 50 cycles 
of 15 s at 95oC and 1 min at 60oC.
EBV genome copies per 1×106 cells were calculated using standard curves for BALF5 
and B2M as analyzed and generated by the QuantStudioTM Design and Analysis software 
version 1.4.1. The standard curves were made by serial dilutions of Namalwa DNA [17] 
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containing 404 (stock concentration: 132 ng/µl DNA; assuming that 1 cell contains 6.6 pg 
DNA and each Namalwa cell contains two integrated EBV genomes), 104 , 103, 200, 40, 10, 4 
and 1 EBV genome per µl H2O. The quantity of EBV DNA in sorted B cells was extrapolated 
from these curves using CT values measured in each experiment. All samples were mea-
sured in duplicate. 
In vitro memory B-cell dierentiation assay
Sorted CD27+ memory B cells were cultured under GC-like conditions as previously 
described [10]. In short, irradiated 3T3-CD40L cells were seeded on at-bottom 96-well 
plates. We added 5×104 memory B cells per well in the presence of human recombinant 
IL-21 (50 ng/ml; Thermo Fisher Scientic) with and without human recombinant IFN-γ 
(50 ng/ml; Peprotech/Bio-Connect, Huissen, The Netherlands). After 6 days of culture, 
supernatants were collected and stored at -80oC until use for an EBNA1 IgG enzyme-linked 
immunosorbent assay (ELISA). The cultured cells were removed and extracellularly stained 
using ow cytometry as described above. 
Anti-EBNA1 IgG ELISA
A commercially available ELISA kit (IBL international, Hamburg, Germany) was used to 
quantify anti-EBNA1 IgG antibodies in memory B-cell culture supernatants. 50 µL of each 
supplied standard and culture supernatants were added to the plate and incubated for 60 
min at room temperature (RT). After washing, samples were incubated with rabbit peroxi-
dase-conjugated IgG for 30 min at RT. Each well was incubated with TMB substrate solution 
for 20 min at RT and the reaction was stopped with TMB solution. Optical densities were 
measured at 450nm using a BioTek Synergy 2 machine (Winooski, Vermont, USA). Data 
were analyzed by following the manufacturer’s instructions. A cut-o value for culture 
supernatants was determined based on the average from cultured naive mature B cells (n 
= 8). Results above ≥1.59 U/ml were considered positive, which was the case for 13 out of 
21 samples. 
Statistical analysis
Statistical analyses on datasets were carried out using GraphPad Prism Software, 
version 8 (GraphPad Software, San Diego, CA) and indicated in gure legends. Data are 





EBV load corresponds to CXCR3 expression in class-switched memory B 
cells of BMT-treated MS patients
To address the specic relation between EBV load and CXCR3+ B-cell induction, we 
explored the distribution, EBV load and chemokine receptor proles of ex vivo B-cell sub-
sets within the blood of 9 MS patients after autologous BMT (Supplementary Table 1) [15]. 
The proportions of transitional (CD38highCD27-) B cells were increased at 3-7 months and 
reduced to baseline levels at 24-36 months, while those of naive mature (CD38-/dimIgM+CD27-) 
B cells remained unaltered post-BMT (Fig. 1A and B). Both Ig class-switched (IgM-IgD-) and 
non-class-switched (IgM+CD27+) memory B cells were decreased at 3-7 months, and only 
class-switched B cells returned to baseline levels at 24-36 months post-BMT (Fig. 1A and B). 
After purifying these subsets, high EBV copy numbers were measured for class-switched B 
cells at 3-7 months post-BMT (Fig. 1C), at the timeframe in which low numbers of memory 
B cells are present in the blood. This is in line with previous studies using allogeneic stem 
cell transplants [19, 20]. EBV levels in class-switched B cells were increased for 5 patients 
and reduced for 4 patients when comparing 3-7 months post- to pre-BMT samples. These 
changes in EBV load strongly corresponded to the expression of CXCR3 (Fig. 2A and B). 
Taking all individual samples into account, we found a positive correlation between EBV 
load and CXCR3+, but not CXCR4+ or CXCR5+ fractions of class-switched B cells (Fig. 2C and 
D). Despite the lower levels of EBV, similar trends were observed in non-class-switched B 
cells (Supplementary Fig. 1A). In contrast to non-class-switched B cells, EBV load positively 
correlated to the expression of activation markers CD69 and CD95 in class-switched B cells 
(Supplementary Fig. 1B). Notably, three out of four BMT-treated patients whose memory B 
cells showed decreased EBV and CXCR3 levels, showed stable or improved disability scores 
during 36 months follow-up as reected by expanded disability status scale (EDSS) score 
and ambulatory index (AI, Fig. 2E) [15]. In BMT-treated patients with an increase in memory 
B cell EBV and CXCR3 levels, an increased disability was observed in four out of ve and ve 
out of ve participants, respectively.
Overall, these ndings implicate that the high EBV levels found after autologous BMT 
in MS patients induces the development of CXCR3+ memory B cells and is possibly related 
to clinical worsening. CXCR3 upregulation through EBV infection may be caused by a dis-
turbed immune system [21], and contribute to the increased recruitment of pathogenic B 
cells and the formation of follicle-like structures in the MS CNS [10, 22]. 
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Figure 1. Reconstitution and EBV load of B-cell subsets in the blood of autologous BMT-treated MS 
patients. 
(A) FACS gating strategy used to dene transitional (CD38highCD27–; Btrans), naive mature (CD27
–IgM+; Bnm), non-
class-switched memory (CD27+IgM+; NCS Bmem) and class-switched memory (IgM
–IgD–; CS Bmem) within blood
CD19+ B cells. (B) Quantication of B-cell subset frequencies in the blood of MS patients before (black dots) and 
both 3-7 months (dark grey dots) and 24-36 months (light grey dots) after receiving autologous BMT (paired
samples; n = 9; Supplementary Table 1). (C) EBV DNA load in sorted Bnm, NCS Bmem and CS Bmem cells before and
both 3-7 and 24-36 months after BMT (n = 9; copies / 1×106 cells).  FACS data were measured and B cell subsets
were sorted in ve independent experiments, with paired time points for 1-2 patients per experiment. EBV DNA 
load was determined in three independent experiments, with paired time points for 3-5 patients per experiment. 
Data are presented as the mean ± SEM. ** p <0.01 and * p <0.05. The p values in B were calculated by repeated






























































































































































































































































































Figure 2. The association between EBV load and chemokine receptor expression in class-switched B cells 
of BMT-treated MS patients. 
(A) Representative FACS plots of CXCR3-expressing CS Bmem cells from an MS patient before and both 3-7 months 
and 24-36 months after autologous BMT. EBV copy numbers and frequencies of CXCR3
+ (B) as well as CXCR5+ (C) 
fractions were determined for CS Bmem cells of 9 BMT-treated MS patients. (D) EBV copy numbers were correlated 
to CXCR3+, CXCR4+ and CXCR5+ fractions of CS Bmem cells. Data were collected in the same number of experiments 
as depicted in Figure 1. (E) EDSS and AI changes after BMT treatment (∆ pre- vs 36 months post-BMT) for patients 
showing increased (n = 5) and decreased (n = 4) memory B-cell EBV loads. ** p <0.01. The p values were calculated 
by repeated measures one-way analysis of variance with Tukey post hoc test (B and C) and correlation coecient 
by Pearson rank (D).  
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EBVhigh memory B cells of NTZ-treated MS patients preferentially develop 
into CXCR3+ plasma cells 
EBV mainly persists within GC-derived memory B cells, which subsequently dierentiate 
into antibody-secreting plasma cells [4]. After NTZ treatment, MS patients show increased 
numbers of CXCR3+ memory B cells in the blood, which are normally recruited and fur-
ther dierentiate into plasma cells in the CNS [10, 23]. Hence, blood samples from these 
patients oer a unique opportunity to assess the relation between latent EBV infection and 
plasma cell development of potentially CNS-inltrating memory B cells. To determine this, 
we screened EBV load in dierent blood samples from 15 MS patients treated with NTZ for 
1 to 4 years. Of these patients, one showed an increase, one a decrease and the remainder 
a stable EDSS-score over the course of 36 months after sampling (Supplementary Table 1). 
Ten samples with >1000 copies per 1×106 cells (EBVhigh) and eight samples with <500 copies 
per 1×106 cells (EBVlow) were selected for our in vitro dierentiation study. CD27+ memory B 
cells were cultured under IL-21- and CD40L-stimulating (GC-like) conditions for 6 days and 
dierentiation into plasma cells (CD38highCD27highCD138+) was compared with and without 
the addition of IFN-γ (Fig. 3A and B). Under these circumstances, total and CXCR3+ plasma 
cells were found to be more induced in the EBVhigh versus the EBVlow group, which was 
most pronounced in cultures containing IFN-γ (p = 0.023 and p = 0.011, respectively; Fig. 
3C and D). For 9 out of 10 samples from the EBVhigh group, CXCR3+ plasma cell frequencies 
were higher under IFN-γ-inducing conditions than those from a healthy reference group 
(n = 6; dotted line), which was the case for 2 out of 6 samples from the EBVlow group. B-cell 
EBV load correlated to CXCR3+ plasma cell outgrowth in IL-21- and IFN-γ-induced samples 
(Fig. 3E). This agrees with a mouse study showing that enhanced CXCR3 expression results 
in aberrant plasma cell development within GCs [9]. Both surface CXCR3 and intracellular 
T-bet levels were further triggered by IFN-γ during these cultures, but were not dierent
between EBVhigh and EBVlow groups (Supplementary Fig. 2A). Finally, the ability of in vitro-in-
duced plasma cells to secrete anti-EBNA1 IgG positively correlated with the expression of
CXCR3 (Fig. 3F) and T-bet (Supplementary Fig. 2B).
CONCLUDING REMARKS
In this study, we reveal that high EBV load is associated with 1) early emergence of 
CXCR3+ class-switched memory B cells from autologous BMT-treated MS patients, and 
2) enhanced in vitro generation of CXCR3+ plasma cells from memory B cells trapped in
the blood of NTZ-treated MS patients. Although we did not show the dependence of
memory B-cell development on CXCR3 in these settings, there is a clear relation between






























































































































































































































Figure 3. In vitro plasma cell formation of memory B cells from NTZ-treated MS patients with dierent 
B-cell EBV load. 
(A) Experimental setup of the GC-like memory B-cell dierentiation assay. CD27+ memory B cells (Bmem) were
sorted from dierent blood samples of a total of 15 NTZ-treated MS patients (Supplementary Table 1) and
cultured under IL-21-/CD40L-inducing (GC-like) conditions for 6 days. (B) Representative gating strategy for
the analysis of in vitro-dierentiated plasma cells within viable CD19+ cells after 6 days of culturing. Plasma cell
development was analyzed for NTZ-treated MS patients with high and low B-cell EBV load (n = 6-10) under
conditions with and without IFN-γ (C and D). Dotted lines indicate the mean frequencies of each population
analyzed for simultaneous in vitro cultures with memory B cells of 6 age- and gender-matched healthy controls. 
In vitro cultures and FACS data were collected in six independent experiments, with 1-2 EBVhigh and 1-2 EBVlow MS 
patients, as well as 1 healthy control per experiment. (E) Correlation between EBV copy numbers and fractions
of in vitro-induced CXCR3+ plasma cells. (F) Correlation between anti-EBNA1 IgG secretion and CXCR3 surface
expression by in vitro-dierentiated plasma cells. anti-EBNA1 IgG was measured in four independent experiments 
and each sample was measured in duplicate. Data are presented as the mean ± SEM. * p <0.05. The p values were 
calculated by Mann-Whitney U (D) and correlation coecients by Spearman rank (E and F) tests. 
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in virus-infected mice. Based on our ndings, EBV load is related to the development of 
CXCR3+ memory B cells into plasma cells, while the expression of CXCR3 by these plasma 
cells seems to enhance their ability to secrete anti-EBNA1 antibodies. This may not only 
link to the predictive value and intrathecal detection of anti-EBV antibodies [25, 26], but 
also add to the ongoing debate about the local presence of EBV-infected B cells in MS [27]. 
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aSecondary progressive MS patients who had received an autologous bone marrow transplantation [15].
bAt start of treatment.
cTime from MS diagnosis to start of treatment.
dThis patient discontinued natalizumab at 24 months of treatment.
BMT = bone marrow transplant; MS = multiple sclerosis; EDSS = expanded disability status score; AI = ambulatory 








































































Supplementary Table 2. Monoclonal antibodies used for FACS analysis
Supplementary Table 3. Primers and probes used for qPCR
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Impact of Epstein-Barr virus infection on CXCR3+ B-cell development
Supplementary Figure 1. Correlations of EBV load to chemokine receptor expressions on NCS Bmem cells 
and activation markers on CS and NCS Bmem cells. 
EBV copy numbers were correlated to CXCR3, CXCR4 and CXCR5 surface expression in NCS Bmem cells (A), and to 
surface expression of CD69 and CD95 in both CS and NCS Bmem cells (B) of 9 BMT-treated MS patients. Data were 
collected in the same number of experiments as depicted in Figure 1. The p values and correlation coecients 
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Supplementary Figure 2. T-bet and CXCR3 expression is induced by IFN-γ and anti-EBNA1 IgG levels 
correlate to T-bet expression in CD38highCD27high cells during in vitro cultures. 
(A) Surface expression of T-bet and CXCR3 on total CD19+ B cells and CD38highCD27high cells were analyzed for
NTZ-treated MS patients with high (n = 10) and low (n = 7) B-cell EBV load cultured under GC-like conditions with 
and without IFN-γ. Dotted lines indicate the mean frequencies of T-bet and CXCR3 analyzed for age-/gender-
matched healthy controls (n = 6). (B) Correlation between anti-EBNA1 IgG and the surface expression of T-bet on 
CD38highCD27high cells. Data were collected in the same number of experiments as depicted in Figure 3. Data are 
presented as the mean ± SEM. ** p <0.01 and * p <0.05. The p values were calculated by Wilcoxon matched-pairs 
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ABSTRACT
Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare, 
but severe autoimmune diseases characterized by inammation of the 
optic nerve(s) and/or spinal cord. Although naive B cells are considered key 
players by escaping central tolerance checkpoints, it remains unclear how 
their composition and outgrowth dier in patients with NMOSD. Under 
complete treatment-naive circumstances, we found that naive mature/
transitional B-cell ratios were reduced in the blood of 10 patients with 
aquaporin-4 (AQP4) IgG-positive disease (NMOSD) as compared to 11 both 
age- and gender-matched healthy controls, 8 patients with myelin oligo-
dendrocyte glycoprotein-IgG-associated disorder (MOGAD) and 10 multi-
ple sclerosis patients. This was the result of increased proportions of tran-
sitional B cells, which were the highest in NMOSD patients with relapses 
and strongly diminished after corticosteroid treatment. For puried naive 
mature B cells of 7 NMOSD and MOGAD patients with relapses, TLR9 ligand 
synergized with IFN-γ to enhance plasmablast formation during germinal 
center-like cultures. This was not seen for 11 patients without relapses and 
9 healthy controls. In the NMOSD group, in vitro plasmablast formation 
corresponded to total and anti-AQP4 IgG secretion, of which the latter only 
for relapsing cases. These data demonstrate that naive B-cell homeostasis 
is dierent and targeted by corticosteroids in NMOSD patients. This also 
supports further exploration of naive B cells for use in TLR9-dependent in 
vitro platforms in order to predict NMOSD activity. 
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INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSD) are rare and convey a range of 
severe clinical presentations caused by inammation with preferential involvement of the 
optic nerves and spinal cord [1]. Although the exact cause of these divergent presenta-
tions remains poorly understood, the dominant role of the B-cell lineage is undisputed 
[2]. In approximately 75% of NMOSD patients, IgG antibodies are found that target the 
neuronal water channel protein aquaporin-4 (AQP4) [3]. Furthermore, 30-40% of AQP4-
IgG-negative NMOSD patients test positive for antibodies against myelin oligodendrocyte 
glycoprotein (MOG) [4, 5], which are associated with a distinct entity termed MOG-IgG-
associated disorder (MOGAD).
There are signicant dierences in clinical features between AQP4-IgG-positive NMOSD 
and MOGAD [6-8], including a higher frequency of and worse recovery from relapses in 
AQP4-IgG-positive NMOSD. Relapses are commonly treated with corticosteroids in both 
entities. To prevent relapses, AQP4-IgG-positive NMOSD patients and relapsing patients 
with MOGAD are usually treated with maintenance therapy. Currently, no biomarkers are 
available to accurately predict relapses and guide treatment decisions. This could be due 
to the fact that previous studies on the immunopathogenesis of NMOSD primarily used 
patients treated with corticosteroids or other maintenance therapy, thereby possibly oblit-
erating disease-relevant B-cell subsets.
Recent ndings reveal that AQP4-specic B cells are already present in naive popu-
lations that escape early tolerance checkpoints [9, 10]. Normally, self-reactive clones are 
counterselected during early B-cell development in the bone marrow (central tolerance) 
and during subsequent maturation of transitional into naive mature B cells after entering 
the circulation (peripheral tolerance). In patients with AQP4-IgG-positive NMOSD, naive 
mature B cells escape both these checkpoints and likely develop into antibody-secreting 
cells in a germinal center-dependent manner [9-11]. In systemic autoimmune disease, 
which coexists in ~20% of AQP4-IgG-positive NMOSD patients [12], IL-21, IFN-γ and TLR9-
ligand CpG-ODN serve as key triggers of autoreactive germinal center B cells expressing 
T-box transcription factor T-bet [13, 14].
In this study, we aimed to dene the impact of AQP4-IgG serostatus, steroid treatment
and relapse occurrence on naive B-cell development in NMOSD. The composition of the 
naive B-cell pool within the blood was compared between NMOSD, MOGAD and MS 
groups with and without corticosteroid treatment, as well as matched healthy controls. 
Furthermore, naive B-cell outgrowth into (anti-AQP4 or -MOG) IgG-secreting plasmablasts 




MATERIALS AND METHODS 
Participants
We included 10 treatment-naive AQP4-IgG-positive NMOSD patients [15] and 8 treat-
ment-naive patients with MOGAD (all with optic neuritis and/or transverse myelitis). These 
patients did not get immune suppressive therapy before blood sampling; no steroids 
within 1 month and no other maintenance treatment within 3 months. Additionally, 5 
patients with AQP4-IgG-positive NMOSD and 4 patients with MOGAD were included who 
received corticosteroids (i.e. oral prednisone or intravenous methylprednisolone) within 
1 month prior to sampling. In the corticosteroid-treated MOGAD group, 2 patients had 
an NMOSD phenotype, 1 patient presented with acute disseminated encephalomyelitis 
and 1 patient was diagnosed with encephalitis. None of the patients included in this study 
received therapy with prolonged immune suppressive activity such as anti-CD20 or any 
other B cell-directed monoclonal antibodies before sampling. Patient characteristics are 
shown in Table 1. 
Ex vivo B-cell subset frequencies were compared to age- and gender-matched treat-
ment-naive multiple sclerosis (MS) patients (n = 10) as well as healthy controls (n = 20). 
As a reference group for corticosteroid-treated patients, we included 8 clinically isolated 
syndrome (CIS) patients treated with methylprednisolone within 1 month before sampling 
and diagnosed according to the McDonald 2017 criteria. For the NMOSD and MOGAD 
groups, serum was collected at the same time as peripheral blood mononuclear cells. An 
NMOSD relapse was dened as a new episode of disease activity at least 3 months sepa-
rated from the previous disease episode. All subjects gave written informed consent, and 
the study was approved by the medical ethics committee of Erasmus MC. 
Total IgG ELISA
IgG concentrations in supernatants were determined by ELISA using at-bottom 
96-well half-area plates (Corning, Tewksbury, USA) coated overnight at 4°C with goat 
anti-human Ig (1 mg/ml; Southern Biotech, Birmingham, USA). Plates were washed with 
PBS/0.05%Tween-20 to remove unbound antibody and blocked with PBS/5%FCS for 2 h at 
room temperature. Sample and a human IgG standard (Sigma-Aldrich/Merck, Darmstadt, 
Germany) were added for 1.5 h at room temperature. Subsequently, plates were washed 
with PBS/0.05%Tween-20 and bound IgG was detected by peroxidase-conjugated goat 
anti-human IgG (Thermo Fisher Scientic, Landsmeer, The Netherlands). TMB Substrate 
(Thermo Fisher Scientic) was used to reveal peroxidase activity. The reaction was stopped 
with H2SO4 and OD was measured at 450 nm.
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Table 1. Patient characteristics
# At time of sample collection.
* Steroid treatment within 1 month before sampling (all patients were at least not treated with maintenance
medication for 3 months).
§ All AQP4-IgG and MOG-IgG serum titers were measured within the same experiment using ΔMFI.
ADEM = acute disseminated encephalomyelitis; BS = brainstem (area postrema or cranial nerves); E = encephalitis; 
MP = methylprednisolone (intravenous); ND, not determined; ON = optic neuritis; bilateral = both eyes; P = 
prednisone (oral); TM = transverse myelitis. 
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AQP4- and MOG-IgG cell-based assays 
For determination of AQP4- and MOG-IgG levels in sera and culture supernatants, 
standardized cell based assays were used as previously described [5, 6, 16]. In short, 
either HEK293T transfectants with EGFP-tagged AQP4-M23 or 1:1 mixtures of LN18 cells 
transfected with and without full length human MOG were incubated with the sample 
and stained with goat anti-human secondary antibody (IgG labeled with APC; Jackson 
ImmunoResearch, Amsterdam, The Netherlands). Our AQP4-IgG cell-based assays showed 
a mean transfection eciency (GFP+) of approximately 35%. Mean uorescence intensity 
(MFI) representing the amount of AQP4- or MOG-IgG bound to the cell surface was com-
pared between transfected (GFP+) and untransfected (GFP-) cells within the same experi-
ment using ow cytometry.
Cell isolation, antibodies and ow cytometry
Peripheral blood mononuclear cells were collected using Vacutainer CPT® tubes con-
taining sodium heparin according to the manufacturer’s instructions (BD Biosciences, 
Erembodegem, Belgium). After centrifugation, cells were taken up in RPMI 1640 (Lonza, 
Basel, Switzerland) containing 40% fetal calf serum (Lonza) and 20% dimethyl sulfoxide 
(Sigma-Aldrich, St Louis, MO) and stored in liquid nitrogen until further use. Ex vivo naive 
mature (CD19+CD38dim/-CD27-IgG-IgA-) B cells were puried for in vitro cultures using a BD 
FACSAria III cell sorter. For immunophenotyping, cells were incubated with Fixable Viability 
Stain 700 (BD Biosciences) for 15 min and monoclonal antibodies for 30 min at 4°C. The 
following FACS antibodies were used: CD24 (BV605, ML5), CD27 (BV421, M-T271), IgD (PE-
CF594, IA6), IgG (APC-H7, G18-145; BD Biosciences), CD19 (BV785, HIB19), CD38 (PE-Cy7, 
HIT2), IgM (BV510, MHM-88), T-bet (PE-Cy7, 4B10; Biolegend, London, UK) and IgA (FITC, 
IS11-8E10; Miltenyi Biotec, Bergisch Gladbach, Germany). For intracellular T-bet staining, 
cells were xed with 2% paraformaldehyde (Merck, Schiphol-Rijk, the Netherlands) and 
permeabilized using PBS pH7.4 containing 0.3% BSA and 0.5% saponin (Sigma-Aldrich). All 
measurements were conducted with an LSRII-Fortessa ow cytometer and analyzed using 
FACS Diva software, version 8.0.1 (BD Biosciences). For both ex vivo and in vitro analyses, we 
rst gated on viable CD19+ B cells.
Germinal center-like B-cell dierentiation assay
Germinal center-like B cell cultures were performed as recently described [17]. In short, 
irradiated murine 3T3 broblasts expressing human CD40L were co-cultured with sorted 
naive mature (CD27-CD38dim/-IgG-IgA-) B cells in the presence of IL-21 (50 ng/ml; Thermo 
Fisher Scientic) with and without IFN-γ (50 ng/ml; Peprotech, Huissen, The Netherlands) 
and CpG-ODN (10 μg/ml; InvivoGen, San Diego, USA). After 11 days of culturing, cells were 
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stained for ow cytometry and supernatants were stored and analyzed for the presence of 
AQP4- and MOG-IgG.
Statistical analysis
Statistical analysis was performed using Graphpad Prism Software, version 5.04. 
Kruskal-Wallis and Dunn’s post-hoc tests were performed for comparing multiple groups. 
Mann-Whitney U-tests were used for comparing two groups. Paired datasets were assessed 
using Wilcoxon signed-rank tests. Correlations between variables were tested using the 
Spearman rank or Pearson coecients, depending on results of the D’Agostino & Pearson 
omnibus normality test. Percentages and MFI were displayed as the mean. p values < 0.05 
were considered statistically signicant.
RESULTS
Naive mature/transitional B-cell ratios are reduced in the blood of 
treatment-naive AQP4-IgG-positive NMOSD patients 
First, we assessed the proportions of naive and memory B-cell subsets in the blood of 
NMOSD patients without any form of previous immune suppressive treatment. Because 
the female-to-male ratio is higher in AQP4- than MOG-IgG-associated disease (see Table 
1) [5], we selected healthy controls who were age- and gender-matched either to treat-
ment-naive patients with NMOSD (n = 11) or MOGAD (n = 9). The proportion of transitional 
B cells (CD38++CD27-) and not naive mature (CD38dim/-CD27-IgM+) B cells [18, 19] was ele-
vated in NMOSD versus healthy controls (mean 16.2% versus 5.6% for transitional B cells
and 47.3% versus 41.5% for naive mature B cells, respectively), which resulted in lowered
naive mature/transitional B-cell ratios (Fig. 1A and B). This classication of naive B cells was 
conrmed using IgD and CD24 (Supplementary Fig. 1). No dierences were seen between
the MOGAD and healthy control group (Fig. 1C and D). Two out of three NMOSD patients
with relapses showed extremely high frequencies of transitional B cells (35% and 44% of
the total B-cell pool, Fig. 1B). Naive mature/transitional B-cell ratios were lower in NMOSD
compared to MOGAD (p < 0.01; Fig. 1F).
Germinal center-independent natural eector (CD38dim/-CD27+IgM+IgD+) memory B 
cells [20] were signicantly reduced in the NMOSD versus healthy control group (lowest 
in two relapsing cases with the highest percentage of transitional B cells; Supplementary 
Fig. 2A and B). A similar trend was found in the MOGAD group (Supplementary Fig. 2B). 
The proportions of germinal center-dependent IgM-only B cells (CD38dim/-CD27+IgM+IgD-) 
and IgG+ (both CD27+ and CD27-) B cells [20] (Supplementary Fig. 2B) or plasmablasts 
















































































































































































































Figure 1. Transitional and naive mature B-cell frequencies in the blood of dierent NMOSD, MOGAD, MS 
and healthy control groups.
Representative gating, proportions and ratios of transitional (CD38++CD27-) and naive mature (CD38dim/-CD27-) 
B cells from blood of treatment-naive patients with NMOSD (n = 10; A,B) or MOGAD (n = 8; C,D). The fractions 
of transitional and naive mature B cells and their ratios were compared to a separate age- and gender-matched 
healthy control group (for NMOSD, n = 11; for MOGAD, n = 9). (E) Gating example for the detection of transitional 
and naive mature B cells in the blood from corticosteroid-treated patients with NMOSD or MOGAD (CS-treated). 
(F) Naive mature/transitional B-cell ratios in the blood of treatment-naive NMOSD or MOGAD, CS-treated NMOSD 
or MOGAD (n = 9), treatment-naive MS (n = 10) and healthy control (HC; n = 20) groups. (G) Correlation of naive 
mature/transitional B-cell ratios to time since start of CS treatment in NMOSD and MOGAD patients
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populations and ratios correlated to AQP4- or MOG-IgG serum levels (Table 1) in the 
NMOSD groups (data not shown).
Corticosteroid treatment corresponds to increased naive mature/
transitional B-cell ratios in AQP4- and MOG-IgG-positive disease 
To study the impact of corticosteroids as a standard treatment of acute relapses, we 
compared our results to B-cell subsets from the blood of 9 AQP4-IgG or MOG-IgG-positive 
patients who only received corticosteroids and no other forms of immunosuppressive 
treatment. In this group, naive mature/transitional B-cell ratios were signicantly elevated 
(fold change versus NMOSD: 14.8, p < 0.0001; Fig. 1E and F), which correlated positively 
with time since start of corticosteroid treatment (r = 0.86 and p = 0.002, Fig. 1G). These 
elevated ratios were the result of an almost complete absence of transitional B cells (Fig. 
1E, Supplementary Fig. 4). The association of corticosteroid treatment with transitional and 
not naive mature B cells was conrmed in an additional cohort of patients with a clinically 
isolated syndrome (Supplementary Fig. 5). In the steroid-treated NMOSD and MOGAD 
group, the proportion of natural eector B cells was similar to healthy controls and cor-
related to time since start of treatment (r = 0.71, p = 0.02; Supplementary Fig. 2C and D). 
Corticosteroid treatment did not aect plasmablast, IgM-only and IgG+ (CD27-/CD27+) 
B-cell frequencies (Supplementary Fig. 3B and data not shown). 
TLR9 ligand synergizes with IFN-γ to promote naive mature B cell to 
plasmablast formation only for AQP4- or MOG-IgG-positive patients with 
relapses
To assess how the B-cell germinal center-like dierentiation pathway is regulated in 
NMOSD, we puried naive mature B cells from the peripheral blood of 9 AQP4-IgG-positive 
patients, 9 MOG-IgG-positive patients and 9 healthy controls and cultured these popula-
tions in the presence of IL-21 and CD40L-3T3 cells with and without IFN-γ and TLR9 ligand 
CpG-ODN. The percentage of viable CD38++CD27++ plasmablasts was analyzed after 11 
days using ow cytometry (Fig. 2A). To further substantiate the clinical relevance of this 
model, we explored the functional association of in vitro-generated plasmablasts with dis-
ease activity within the continuum of relapse risk. 
For all tested subjects, IFN-γ induced the development of plasmablasts (Fig. 2B), 
which was similar between the groups. However, in both NMOSD and MOGAD patients 
with relapses (n = 7), the addition of CpG-ODN to IFN-γ-containing cultures signicantly 
increased plasmablast formation (Fig. 2B; mean, IFN-γ: 19.8%, IFN-γ + CpG: 34.9%, p = 
0.0156). The opposite was found in patients without relapses (n = 11; IFN-γ: 15.8%; IFN-γ 
+ CpG: 12.8%, p = 0.0137). Although disease duration was longer for relapsing compared 
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Figure 2. In vitro plasmablast outgrowth for naive mature B cells from subgroups with and without relapses 
under dierent germinal center-like conditions.
(A) Representative gating of viable plasmablasts (CD38++CD27++) cultured from naive mature B cells of an NMOSD 
patient with and without relapses. Cells were triggered with CD40L-3T3, IL-21, IFN-γ and/or TLR9 ligand CpG-
ODN for 11 days. Both the percentage of in vitro-generated plasmablasts (B) and intracellular T-bet expression
(C) were determined for cultured naive mature B cells from the blood of NMOSD or MOGAD subgroups with (n
= 7) or without relapses (n = 11), as well as healthy controls (n = 9). For 1 patient with MOGAD, we only obtained 
sucient cell numbers to analyze plasmablast frequencies and not T-bet expression.
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experienced their rst relapse within a median time of 10 months since onset. In 6 out of 
7 relapsing patients, immune suppressive treatment was initiated after the rst relapse, 
whereas 6 out of 11 monophasic patients were treated from onset onwards. For naive 
mature B cells of healthy controls, these frequencies were identical for both conditions 
(IFN-γ: 20.9%, IFN-γ + CpG: 20.4%). Intracellular T-bet levels were upregulated by IFN-γ and 
further induced by CpG-ODN (Fig. 2C). Since this was comparable between the groups, 
other factors probably mediate the observed eect of CpG-ODN on in vitro plasmab-
last formation. The proportions of ex vivo B-cell subsets and plasmablasts did not dier 
between the groups with or without relapses (Supplementary Fig. 6). 
In both the NMOSD and MOGAD group, in vitro secretion of total IgG was signicantly 
increased after the addition of CpG-ODN (Fig. 3A and Supplementary Fig. 7). For the 
NMOSD group, this positively correlated with in vitro plasmablast formation (Fig. 3B). The 
increase in both plasmablast formation and IgG secretion was the most pronounced in the 
2 NMOSD patients with relapses (Fig. 3B). We detected anti-AQP4 IgG in naive mature B-cell 
culture supernatants of all 3 relapsing but in none of 6 non-relapsing NMOSD patients (Fig. 
3C). Anti-AQP4 IgG secretion was enhanced by CpG-ODN for 2 out of 3 relapsing patients; 
for one relapsing case with very high levels in culture (ΔMFI, IFN-γ: 24442, IFN-γ + CpG: 
34725, negative control: 33) and one relapsing case with very low levels in culture (ΔMFI, 
IFN-γ: 57, IFN-γ + CpG: 94, negative control: 54). In culture supernatants of naive mature 
B cells of 4 relapsing and 4 non-relapsing patients with MOGAD, anti-MOG IgG could not 
be detected (Fig. 3C; ΔMFI, positive control: 7322). In this group, total IgG levels did not 
correlate with in vitro plasmablast formation (Fig. 3B).
DISCUSSION
AQP4-IgG production by peripheral B cells is an important driver of NMOSD [21-23]. 
Since central B-cell tolerance mechanisms are defective in NMOSD [10, 24], the selection 
of AQP4-specic B cells is already disturbed at the earliest stage in the bone marrow. We 
now show that the composition and functional outgrowth of circulating naive B cells is 
dierent in NMOSD patients, which seems to be linked to corticosteroid treatment, relapse 
occurrence and AQP4-IgG secretion.
The selective enrichment of transitional B cells in the blood of AQP4-IgG-positive 
NMOSD patients is likely caused by higher fractions of poly- and autoreactive clones 
that escaped selection within the bone marrow [10]. We now nd that transitional B cells 
are almost completely absent in the blood of corticosteroid-treated patients. Since the 
patients described by Cotzomi et al. received immunotherapy including corticosteroids, 
AQP4-specic B cells and other unique clones may have been missed in their analysis. This 
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eect of steroids on transitional B cells is probably explained by their lack of multidrug 
resistance receptor 1 [25], a glycoprotein that pumps a wide range of substances including 
corticosteroids out of the cell [26]. Transitional B cells were abrogated by steroid treat-
ment in patients with NMOSD and MOGAD. This correlated to time since start of treatment 
in clinically isolated syndrome patients as well, implicating that corticosteroids have a 
generic impact on these early B-cell emigrants. 
In a previous study, the proportion of circulating CD27+ memory B cells was found 
to be reduced in NMOSD patients [11]. We nd that frequencies of germinal center-in-
dependent CD27+IgM+IgD+ memory B cells are lower in NMOSD patients and recovered 
after corticosteroid treatment. These data suggest that AQP4-specic naive mature B cells 
preferentially enter the germinal center to undergo proliferation and somatic hypermu-
tation. Consistent with this, under germinal center-like conditions in vitro, AQP4-specic 
































































































































































Figure 3. IgG secretion by in vitro-generated plasmablasts using naive mature B cells from subgroups with 
and without relapses. 
(A) Total IgG secretion was measured in germinal center-like cultures with naive mature B cells from patients with 
NMOSD (n = 7) or MOGAD (n = 6; 11 days). In each subgroup, two patients had relapsing disease (open symbols). 
Data were compared between IFN-γ- and both IFN-γ- and CpG-ODN-inducing conditions (A) and correlated to in 
vitro plasmablast (CD38++CD27++) formation (B). (C) Detection of anti-AQP4-IgG and -MOG-IgG in naive mature 
B-cell culture supernatants (11 days) for patients with NMOSD or MOGAD. AQP4-IgG levels were elevated in IFN-
γ-containing cultures with CpG-ODN for 2 NMOSD patients with relapses.
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antigen [9], and somatic hypermutation was shown to be essential for generating AQP4-
specic antibodies [10]. We did not nd any increase in circulating memory B-cell subsets, 
including those lacking CD27 expression [11]. This implies that within germinal centers, 
AQP4-specic naive B cells develop into plasmablasts rather than memory B cells. Indeed, 
some studies showed that ex vivo circulating plasmablasts are expanded in NMOSD, which 
seemed to be irrespective of steroid usage [11, 27]. In the current study, no dierences in 
ex vivo CD38++CD27++ plasmablasts were found, similar to the observations by Wilson et al. 
The vulnerability of plasmablasts for freeze-thaw cycles [28] can be a confounding factor, 
although this was similar for all subjects in this study. Another factor is that plasmablasts 
probably further mature and reside within the bone marrow or inamed tissues to pro-
duce AQP4-specic antibodies [9, 29]. 
Whereas the ability of ex vivo plasmablasts to produce AQP4-IgG is highly controversial 
[9, 27], the development of naive B cells into antibody-secreting cells has become widely 
accepted. In the study by Cotzomi et al., none of the recombinant anti-AQP4 IgGs that 
reverted back to unmutated precursors were able to bind to AQP4, indicating that naive 
mature B cells need to enter germinal centers to develop into anti-AQP4 IgG producers. 
Recently, we found that IFN-γ induces naive mature B cells to develop into plasmablasts 
during germinal center-like cultures [17]. The same is true for naive mature B cells of 
NMOSD patients (this study). However, in contrast to MS patients [17], the addition of CpG-
ODN had an inducing eect on in vitro plasmablast outgrowth for NMOSD patients with 
recorded relapses. This dierence in in vitro naive mature B-cell outgrowth is likely related 
to the impaired central B-cell tolerance found in NMOSD and not in MS [10]. Based on the 
data in this study it is tempting to speculate that the elevated frequencies of (autoreactive) 
transitional B cells in patients with a high relapse risk causes preferential development 
of naive mature B cells into AQP4-IgG-secreting plasmablasts within secondary lymphoid 
organs. However, our ndings should be interpreted cautiously due to low patient num-
bers and inherent dierences in the clinical course between NMOSD, MOGAD and MS. 
CpG-ODN alone is known to suppress [30], but synergizes with IFN-γ to potentiate 
autoreactive T-bet+ B cells [31]. T-bet expression does not seem to mediate the dierence 
in IFN-γ- and CpG-ODN-induced plasmablast induction in vitro between relapsing and 
non-relapsing NMOSD groups. An intriguing scenario may be that IFN-γ enhances IL-6 
production by B cells [32], leading to TLR9 upregulation [33]. TLR ligation has been previ-
ously associated with the activation of transcription factor X-box binding protein 1 (XBP-1; 
[34], which enhances IgG secretion [35] and links to the IL-6-driven survival of AQP4-IgG-
secreting plasmablasts [27]. 
To our knowledge, this is the rst study that assessed the phenotype and respon-
siveness of naive B cells from NMOSD patients without immunomodulatory therapy and 
compared these to MOGAD, MS and healthy control groups. The impact of steroids on 
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transitional but not on naive mature B cells may be a mechanistic explanation why NMOSD 
relapses recur after discontinuation of corticosteroids. Our ndings provide a rationale for 
exploring the underlying mechanisms of naive B-cell development in patients with active 
or stable disease. This study also supports further assessment of CpG-ODN-mediated out-
growth of naive B cells under germinal center-like, IFN-γ-containing in vitro conditions as a 
new approach to predict NMOSD relapses. 
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Supplementary Figure 2. Presence of ex vivo memory B-cell subsets in the blood of untreated and CS-
treated NMOSD, MOGAD, MS and HC subgroups.
Gating strategy for the identication of IgM-only (CD27+IgM+IgD-), natural eector (CD27+IgM+IgD+) and IgG+ 
(both CD27- and CD27+) memory B cells from the blood of a treatment-naive (A) and a corticosteroid (CS)-treated 
(C) AQP4-IgG positive NMOSD patient. Fractions were compared between NMOSD (n = 10) and MOGAD (n = 8)
and age- and gender-matched healthy controls (HC) for each group (for NMOSD, n = 11; for MOGAD, n = 9; B). 
(D) Fractions of natural eector memory B cells in CS-naive NMOSD, MOGAD, MS, and HC, as well as CS-treated
NMOSD and MOGAD groups and their correlation to time since start of CS treatment.
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Supplementary Figure 3. Frequencies of ex vivo plasmablasts in the blood of untreated and CS-treated 
NMOSD, MOGAD, MS and HC subgroups. 
Representative gating and frequencies of circulating plasmablasts (CD38++CD27++) in treatment-naive (A) and 
corticosteroid (CS)-treated (B) NMOSD and MOGAD patients. Fractions of ex vivo plasmablasts within the total 
CD19+ pool were compared between CS-naive NMOSD (n = 10), CS-naive MOGAD (n = 8), CS-treated NMOSD 

















































Supplementary Figure 4. Composition of the naive B-cell pool in the blood of untreated and CS-treated 
NMOSD, MOGAD, MS and HC subgroups. 
Proportions of circulating transitional and naive mature B cells within the total CD19+ pool were assessed in CS-








































































































Supplementary Figure 5. The impact of CS treatment on the presence of transitional and naive mature B 
cells in the blood. 
Proportions of circulating transitional and naive mature B cells were correlated to time since start of CS treatment 
in NMOSD or MOGAD (n = 9; A) and clinically isolated syndrome (CIS, n = 8; B) groups.
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Supplementary Figure 6. Presence of ex vivo B-cell subsets in relapsing and non-relapsing NMOSD and 
MOGAD subgroups. 
Proportions of naive and memory B-cell subsets as well as plasmablasts (CD38++CD27++) were analyzed in the 


























Supplementary Figure 7. Validation of the differences in IgG secretion by in vitro-
generated plasmablasts between NMOSD and MOGAD subgroups. 
Plasmablasts were generated from naive mature B cells of a relapsing (solid box) and non-relapsing (open 
box) NMOSD and MOGAD patient under IFN-γ and/or CpG-ODN-inducing germinal center-like conditions. IgG 




Partly adapted from “B and T cells driving multiple sclerosis: 








In multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), patho-
genic lymphocytes are triggered in the periphery to inltrate the central nervous system 
(CNS) and cause local inammation and demyelination. Anti-CD20 therapy has proven to 
be clinically successful in both MS [1-3] and NMOSD [4, 5]. Although this underscores the 
fact that B cells play a key role in these CNS demyelinating diseases, the exact triggers, 
subsets and eector mechanisms contributing to dierences in the pathogenesis are 
unclear. Defects in early B-cell tolerance checkpoints may already skew the dierentiation 
of pathogenic B cells within the periphery. In MS, peripheral tolerance is awed, while dis-
turbances in both central and peripheral tolerance mechanisms are seen in aquaporin 4 
(AQP4)-IgG-positive NMOSD [6, 7]. Furthermore, the impact of B-cell depletion therapies 
on the antigen-presenting cell function of B cells indicates that interaction with T cells is an 
important driver of disease activity in MS [1, 8], which may also account for NMOSD. This 
interaction prompts the development of disease-inducing B and T cells through several 
mechanisms including antigen presentation, co-stimulation and cytokine production [4, 
6]. Additionally, pathogenic B cells may exert their eects through secretion of autoanti-
bodies. In contrast to MS, where the target of (auto)antibodies remain largely unknown, 
the vast majority of NMOSD patients have antibodies in the blood that are specic against 
AQP4 and myelin oligodendrocyte glycoprotein (MOG), both of which are expressed in the 
CNS [9]. 
In addition, disease-inducing B and T cells are likely generated through increased 
responsiveness to certain pathogenic triggers. The type and extent to which these cells 
respond to such triggers could inuence dierential pathogenesis in MS and NMOSD. 
The strongest known pathogen associated with MS development is the Epstein-Barr virus 
(EBV), a human DNA herpesvirus that infects B cells [10, 11]. However, evidence for this 
association with MS mostly comes from epidemiological studies [11-13] and it remains 
incompletely understood how EBV is involved in the immunopathogenesis [14, 15]. EBV 
infection is a risk factor for many other types of autoimmune diseases, including systemic 
lupus erythematosus (SLE) and Sjogren’s syndrome [10]. Interestingly, these systemic 
autoimmune diseases coincide with AQP4-IgG-positive disease in a subgroup of NMOSD 
patients [16]. Although a recent serological study has demonstrated possible persistence 
and active replication of EBV in NMOSD [17], there is currently no proof that EBV infection 
plays a role in this disease. 
In MS, the inltration of pro-inammatory lymphocyte subsets into the CNS signies 
relapsing disease, while compartmentalized CNS inammation, as seen during disease 
progression, seems to be driven by tissue-resident populations [18-20]. Since there is a 
clear association of relapse occurrence and radiological disease activity early in MS with 
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the severity of disability progression later in MS [21], it is crucial to understand which exact 
cells invade the CNS and what triggers these cells to instigate local pathology. Similarly, 
in NMOSD, it is important to understand if similar triggers in the periphery enable the 
formation of plasmablasts/plasma cells and how this aects their production of disease-in-
ducing antibodies that are recruited to the CNS.
In this chapter, we integrate the ndings in this thesis with current knowledge on 
which and how lymphocyte subsets contribute to disease activity in MS and NMOSD. The 
development of such subsets probably involves one or more of the following processes: 
1) peripheral escape of pathogenic B cells, 2) mutual activation of pathogenic B and T cells 
within peripheral germinal centers, and 3) re-activation of inltrating B and T cells within 
the CNS (with the focus on MS). For MS, we aimed to understand how both B and CD4+ T 
cells develop into CNS-homing subsets. To assess this, we performed in-depth analyses of 
their phenotype in several CNS compartments and compared functional characteristics 
in the blood from well-dened patient groups. For NMOSD, we focused on how naive B 
cells as key players in the disease develop into antibody-producing cells and whether this 
diers amongst serological and corticosteroid-treated subgroups including MS. 
IMPAIRED PERIPHERAL CONTROL OF PATHOGENIC B 
CELLS DURING CNS DEMYELINATING DISEASE
In diseases such as MS and NMOSD, the crosstalk between B and T cells is likely dis-
turbed, eventually causing pathogenic instead of protective immunity. This may already 
start during the early selection of transitional and/or naive mature autoreactive B cells. 
In Chapter 6, we found that in contrast to MS patients and matched healthy controls, the 
proportion of transitional B cells is enhanced in the blood of treatment-naive AQP4-IgG-
positive NMOSD patients, which resulted in a reduced naive mature/transitional B-cell 
ratio. This was the highest for two patients with relapsing disease. This nding suggests 
that disturbed B-cell tolerance already occurs early in the bone marrow and only in this 
NMOSD patient group. In a very recent study [7], Cotzomi et al. showed that both the fre-
quencies of polyreactive transitional and naive mature B cells are increased in the blood 
of AQP4-IgG-positive NMOSD patients. This indicates that also peripheral tolerance check-
points are defective in NMOSD [7]. Additionally, we found that corticosteroid treatment 
of NMOSD patients resulted in a strong reduction in circulating transitional B cells, which 
was not seen for other subsets (Chapter 6). Since steroids are commonly used to treat 
acute relapses, depletion of transitional B cells may interfere with the development of 
autoantibody-secreting cells in this disease. In contrast to NMOSD, only peripheral B-cell 




of polyreactive naive mature but not transitional B cells in the blood [6, 7, 22, 23]. Although 
the exact cause remains to be determined, the lack of peripheral control of B-cell devel-
opment in both NMOSD and MS may be explained by chronic T-cell stimulation and/or 
dysfunction of CD4+ T regulatory cells (Tregs) (Figs. 1 and 2). 
Although many theories have been proposed how EBV can inuence MS pathogenesis 
[24], one hypothesis is that, due to the chronic nature of this infection, continuous antigen 
presentation by B cells leads to functionally impaired, so-called ‘exhausted’ T cells [25, 26]. 
This, together with the impact of HLA and other risk alleles [27], may result in inappropri-
ate T cell-mediated control of EBV-infected (pathogenic) B cells in genetically susceptible 
individuals. Consistent with this, peripheral CD8+ cytotoxic T cells (CTLs) show decreased 
responses to EBV and not to cytomegalovirus (CMV) antigens during the MS course [26]. 
EBV antigens can also induce Tregs capable of suppressing eector T-cell responses to 
recall antigens [28], as seen for other persistent infections such as lymphocytic choriome-
ningitis virus [29, 30]. 
However, forkhead box P3 (FOXP3+) Tregs have also been described to control infec-
tions [31], implying that additional T cell-intrinsic defects are involved. For example, in MS 
patients, certain Treg populations that are enriched in the blood show increased IFN-γ and 
reduced FOXP3 levels. This may not only result in less suppression of eector T cells [32-
34], but possibly also in an impaired removal of pathogenic B cells, as described for other 
autoimmune diseases [6, 35, 36]. AQP4-specic Tregs are reduced in the blood of NMOSD 
patients and have decreased FOXP3 expression, which suggests that such processes also 
occur in this disease [37, 38]. Especially for MS and NMOSD, the direct impact of function-
ally defective Tregs on (pathogenic) B-cell development still has to be proven.
THE GERMINAL CENTER AS A B- AND T-CELL POWER-
HOUSE DRIVING CNS DEMYELINATING DISEASE 
Th cells as inducers of pathogenic memory B cells and plasmablasts/
plasma cells
After their escape from peripheral tolerance checkpoints, naive B cells possibly interact 
with CD4+ Th cells in germinal centers (GCs) to develop into memory and/or plasmablast/
plasma cells that trigger CNS demyelinating disease through autoimmune-related pro-
cesses. In MS patients, it is very likely that naive B cells recognize a yet unknown antigen 
and enter GCs to become pathogenic memory B cells that are prone to inltrate the CNS. 
In the CNS, B cells are probably re-activated to further mature into antibody-secreting cells 
and trigger local inammation (Fig. 1). Within peripheral lymphoid organs, IL-21 produced 
by T follicular helper (Tfh) cells is crucial for GC formation and plasma cell dierentiation 
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Figure 1. Simplied model of the key pathogenic events involving human B- and T-cell subsets driving MS 
disease activity. 
In MS patients, B- and T-cells interact in the periphery and central nervous system (CNS) to contribute to disease 
pathogenesis. In this hypothetical model, we put forward three important pathogenic events involving B 
and T cells that drive the disease course of MS. In secondary lymphoid organs, B-cell tolerance defects in MS 
patients allow EBV-infected B cells to escape from suppression by CD8+ CTLs and T regulatory (Treg) cells (1). 
Subsequently, these activated B cells enter germinal centers (GCs) and interact with follicular Th(17.1) cells to 
further dierentiate into pathogenic memory B cells. Under the inuence of IL-21, CD40L, IFN-γ and TLR9 and/
or HLA-II signaling, B cells develop into CXCR3(T-bet)-expressing memory cells, which in turn activate Th eector 
cells (2). Especially Th17.1 cells inltrate the CNS of MS patients by distinct expression of chemokine receptors 
(CXCR3, CCR6), adhesion molecules (VLA-4) as well as pro-inammatory cytokines (IFN-γ, GM-CSF). (3) Within the 
CNS, Th17.1 cells and CXCR3(T-bet)+ memory B cells probably crosstalk in follicle-like structures, resulting in clonal 
expansion and eventually inammation and demyelination. CXCR3(T-bet)+ memory B cells further dierentiate 






















































[39]. However, in an autoimmune setting, additional production of IFN-γ by Tfh cells elicits 
autoimmune GCs, which has become evident from studies in SLE [40-42]. Similarly, Toll-like 
receptor 9 (TLR9) signaling promotes IgG class-switching and autoantibody production 
[43, 44]. In mice, both IFN-γ and TLR9 ligation induces the expression of the T-box transcrip-
tion factor T-bet, which triggers CXC chemokine receptor 3 (CXCR3) [45, 46]. In Chapter 4, 
we demonstrate that naive B cells from MS patients are dierentially inuenced by IFN-γ 
and TLR9 ligand CpG-ODN during in vitro GC-like cultures. IFN-γ stimulated the develop-
ment of plasmablasts, whereas IFN-γ together with CpG-ODN triggered the dierentiation 
of IgG1+ memory B cells. Furthermore, TLR9 triggering was crucial for T-bet and CXCR3+ 
expression on B cells during IFN-γ-mediated GC-like cultures of naive B cells (Chapter 4). 
This seemed to be more pronounced for naive B cells of MS patients. The synergistic in vitro 
eects of IFN-γ and CpG-ODN on T-bet/CXCR3 induction and B-cell dierentiation were not 
seen when culturing puried memory B cells (Chapter 4), indicating that these triggers are 
important for the fate of naive B cells. Although not studied in this thesis, pathogenic B-cell 
responses during autoimmunity probably rely on both IFN-γ and TLR-mediated induction 
of T-bet [41, 46-48]. This is also reected by the increased pro-inammatory response of B 
cells from MS patients to IFN-γ and TLR9 triggering [49]. Previously, B cell-intrinsic deletion 
of the IFN-γ receptor has been shown to impair autoimmune GC formation and systemic 
autoimmunity [41]. Ongoing work by our group reveals that in human B cells carrying a MS 
risk SNP in the coding region of IFNGR2 [50, 51], signal transducer and activator of transcrip-
tion (STAT)1 is highly phosphorylated and stimulates T-bet as well as IRF1 gene expression 
under IFN-γ-stimulating conditions (Fig. 3). Hence, this suggests that risk variants related 
to IFN-γ signaling, such as IFNGR2 but also for example IFI30, may contribute to increased 
responsiveness and functionality of pathogenic B cells. Since T-bet has been shown to reg-
ulate IgG class-switching in other autoimmune diseases [44], our results further suggest 
that IFN-γ and TLR9 work in concert to enhance T-bet-mediated IgG1 class-switching in 
MS patients. 
In NMOSD patients, naive B-cell populations already seem to be specic for AQP4 
and develop into AQP4-IgG-secreting cells probably in a germinal center-dependent, but 
antigen-independent manner within peripheral lymphoid organs (Fig. 2) [7, 52, 53]. Since 
NMOSD has been associated with other systemic autoimmune diseases [16], IFN-γ and 
CpG-ODN could potentiate these autoreactive naive B cells to become pathogenic AQP4- 
or MOG-IgG producing plasmablasts. In contrast to MS, in vitro plasmablast formation was 
enhanced under IFN-γ and CpG-ODN-stimulating GC-like culture conditions using naive 
mature B cells from NMOSD patients with high disease activity (Chapter 6). These dier-
ences in outgrowth may be related to the early central tolerance defects found in AQP4-
IgG-positive NMOSD, possibly making AQP4-specic naive B cells more prone to develop 






























Figure 2. Simplied model of key peripheral processes driving the production of autoantibodies in AQP4-
IgG-positive NMOSD and MOGAD. 
In NMOSD and MOGAD patients, B- and T-cells interact in the periphery to induce the dierentiation of AQP4- or 
MOG-specic antibodies, which subsequently enter the CNS to mediate local damage. B cells escape both central 
(1) and peripheral (via Tregs; 2) tolerance checkpoints. These autoreactive naive B cells interact with Th cells in
germinal centers to dierentiate into AQP4-IgG- or MOG-IgG-producing plasma cells (3). AQP4-IgG and MOG-IgG 




pronounced for AQP4-IgG-positive patients with relapses in GC-like cultures containing 
IFN-γ and CpG-ODN (Chapter 6). This indicates that in vitro formed plasmablasts have the 
ability to produce potentially pathogenic autoantibodies. Intriguingly, for NMOSD patients, 
the expression of T-bet during such cultures seemed to increase irrespective of whether 
these patients had relapses or not (Chapter 6). An alternative, T-bet-independent, mech-
anism that could play a role in both IFN-γ and CpG-ODN-driven plasmablast formation in 
NMOSD could be increased TLR9 expression on naive B cells during relapsing disease [54]. 
IL-6 may be a pro-inammatory cytokine driving this expression [54, 55], which is elevated 
in serum during relapses [56, 57] and promotes plasmablast development [58, 59] and 
anti-AQP4 antibody production [60] in NMOSD patients. Accumulating evidence shows 
that the majority of anti-AQP4 antibodies are produced in the periphery and not within 
the CNS [61, 62]. Subsequently, these autoantibodies inltrate the CNS to directly induce 
















































































Figure 3. IFN-γ enhances STAT1 phosphorylation in human B cells carrying the coding MS risk variant 
IFNGR2.
(A) Western blotting and quantication of phosphorylated STAT1 (pSTAT1) expression in human B-LCLs 
stimulated with or without IFN-γ for 24 hours. A B cell line (MC116) homozygous for the IFNGR2 risk allele (G; 
risk) was compared to a B cell line (Karpas422) that did not contain the risk allele (non-risk). For each B cell line an 
internal replicate of n = 4-6 was used. (B) TBX21 (T-bet) and IRF1 gene expression in B cells from clinically isolated 
(CIS) MS patients stimulated with IFN-γ for 24 hours. CIS patients were grouped based on risk allele carriage (non-
risk, A/A; heterozygous risk, G/A; homozygous risk, G/G; n = 4 in each case).
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disorder (MOGAD; Fig 2.) [65, 66], although Chapter 6 does show a rst clue that B-cell 
development is dierentially regulated between AQP4-IgG-positive NMOSD and MOGAD. 
In sharp contrast to MS, we did not nd dierences in CXCR3 expression on memory B cells 
of NMOSD or MOGAD patients (data not shown). Therefore, as a result of CXCR3 upregula-
tion, memory B cells are possibly more prone to inltrate and develop into antibody-pro-
ducing plasmablasts/plasma cells in the MS CNS. 
In Chapter 4, we found that CXCR3+ B cells are enriched in CSF, meninges and brain 
tissues of MS patients. Further analysis of these cells in the blood of natalizumab-treated 
MS patients revealed that particularly IgG(1)+ memory B cells express high levels of CXCR3 
and accumulate 6- and 12-months after treatment. CXCR3+IgG1+ memory B cells also pref-
erentially migrated towards CXCL10 in human brain endothelial in vitro transmigration 
assays (Chapter 4). Together with our in vitro culture data, this suggests that in the periph-
ery, naive B cells are triggered by IFN-γ and TLR9 signaling to develop into CNS-inltrating 
CXCR3(T-bet)-expressing IgG+ B cells in MS. Notably, CD20 was also found to be enriched 
on such IFN-γ-inducible CXCR3(T-bet)-expressing IgG+ B cells in MS blood (Chapter 4). 
Since anti-CD20 therapy has been shown to be eective in reducing relapses in MS, T-bet-
expressing B cells could potentially be an important therapeutic target.
T-bet does not only elicit IgG class-switching, but also enhances antiviral responsive-
ness of B cells in mice [44, 45, 67]. Furthermore, in mice, persistent viral infections sustain 
the development of these types of B cells [46, 67]. To determine whether a persistent virus 
such as EBV is an additional player in the formation of CXCR3(T-bet)-expressing B cells, we 
analyzed EBV DNA load and related this to CXCR3 surface expression in blood B cell sub-
sets of MS patients treated with autologous bone-marrow transplantation (BMT; Chapter 
5). Autologous BMT is often accompanied by EBV reactivation and thus provides a unique 
setting where the impact of EBV can be followed during B-cell development [68, 69]. 
We found that increased EBV load associated with enhanced CXCR3 expression in class-
switched memory B cells of MS patients treated with autologous BMT (Chapter 5). A more 
pronounced progression of disability was found in the majority of BMT-treated MS patients 
whose memory B cells showed heightened EBV and CXCR3 levels. This was reected by an 
increased expanded disability status scale score as well as ambulation index (Chapter 5). 
EBV is known to reside lifelong within memory B cells [70]. In MS, EBV is hypothesized to 
infect autoreactive B cells and mimic T-cell help for GC-dependent dierentiation into such 
EBV-infected memory B cells [25, 71-73]. Furthermore, EBV-reactivated B cells have been 
found to be enriched in lesions of MS patients after natalizumab withdrawal [74], which 
often result in severe MS rebound aects [75]. Together with our data, this implies that EBV 
infection could lead to the formation of GC-derived CXCR3+ (EBVhigh) pathogenic memory B 
cells capable of entering the CNS, which is possibly related to sustained clinical worsening 




B cells as inducers of pathogenic brain-homing memory Th cells
Synchronously, within peripheral GCs, T-bet-expressing memory B cells are ideal can-
didates to trigger CNS-inltrating Th cells in MS patients (Fig. 1). In mice, T-bet promotes 
the antigen-presenting cell function of memory B cells [76]. In Chapter 4, we found that 
blocking of IFN-γ not only interfered with CXCR3 expression on human B cells, but also 
suppressed human Th cell activation, proliferation and eector memory skewing during 
autologous co-cultures. It has already been shown that memory B cells in general serve as 
potent antigen-presenting cells to drive MS disease activity by stimulating brain-homing 
Th cells [8, 49]. Although no link with T-bet has been described yet, the presence of the 
major risk locus HLA-DRB1*1501 in B cells seems to be critical for inducing these types 
of Th cells [8]. These brain-homing Th cells show features of both Th1 and Th17 by co-ex-
pressing CCR6 and CXCR3 [8]. In Chapters 2 and 3, we explored how such subsets are 
associated with disease activity and their CNS-inltrating capacity in MS. In Chapter 2, 
we used peripheral blood from treatment-naive patients with clinically isolated syndrome 
(CIS, the earliest clinical presentation of MS) and RRMS. We subdivided the CIS group 
into patients who remained CIS for at least 5 years (CIS-CIS) and patients who rapidly 
developed clinically denite MS (CIS-CDMS). Th1-like Th17 (CCR6+CXCR3+) and not Th17 
(CCR6+CXCR3-) cell proportions were reduced, but showed a highly activated phenotype 
in both CIS-CDMS and RRMS blood. This is supported by a study that shows CD4+ T cells 
in the periphery are already activated very early in CIS patients with a high risk of devel-
oping MS [77]. During this early disease phase, CD4+ T cells are thought to be involved 
in disrupting the blood-brain barrier (BBB) function [78-80]. The dierential expression of 
chemokine receptors, integrins and pro-inammatory cytokines by such cells have been 
argued to mediate this disruption and subsequently allow their inltration into the CNS 
[81, 82]. Therefore, in Chapter 2, we determined whether Th1-like Th17 cells have the abil-
ity to migrate to the CNS by rst using CSF paired with blood from CIS and RRMS patients 
(Chapter 2). Although Th1-like Th17 cells were enriched in CSF from these patients, the 
short-term cultures in the presence of IL-2 used here likely skewed the phenotype of these 
cells. To eliminate this probable confounder, we next performed ex vivo analyses of Th1-like 
Th17 cells derived from various CNS tissues and conrmed their local enrichment in MS 
patients (Chapter 2). 
Chemokine receptors such as CCR6 and CXCR3 are also co-expressed with integrin 
α4β1 (VLA-4), which allows inltrating T-cell populations to bind to vascular cell adhesion 
protein 1 (VCAM-1) on brain endothelial cells [83]. Using peripheral blood of MS patients 
treated with natalizumab (anti-VLA-4 mAb), we further subdivided Th1-like Th17 into 
recently described pathogenic Th17.1 and Th17 double-positive (DP) cells based on the 
dierential expression of CCR4 (Chapter 2) [84]. Th17.1 (CCR6+CXCR3+CCR4-) cells accumu-
lated in the blood of MS patients who clinically responded to natalizumab treatment. This 
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was not seen for Th17 (CCR6+CXCR3-CCR4+), Th17 DP (CCR6+CXCR3+CCR4+) or Th1 (CCR6-
CXCR3+CCR4-) cells. Consistent with this, ex vivo analysis showed that Th17.1 cells were 
enriched in CSF versus paired blood from 4 CIS patients (Chapter 2). In Chapter 3, we 
conrmed this enrichment in the CSF of 9 CIS and RRMS patients. Additionally, we showed 
that Th17.1 is the predominant Th subset in CSF of early MS patients, but not in CSF of 
patients with other inammatory or non-inammatory neurological disorders (Chapter 
3) and late-stage MS patients (Chapter 2). Th17.1 cells also had an increased capacity to 
inltrate the brain, as shown in i n vitro human brain endothelial transmigration assays 
(Chapter 2) as well as ex vivo and in situ using post-mortem MS brain tissues (Chapter 3).
Besides for an increased ability to inltrate the CNS, T h17.1 cells show pathogenic 
potential in early MS disease through dierential pro-inammatory cy tokine and gene 
expression proles. T h17.1 cells have increased co-production of IFN-γ and granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) as compared to the classical Th17 
cells (Chapter 2). Although we see little IL-17A produced by these cells, work by others 
does indicate that Th17 cells co-express IL-17A and IFN-γ within brain tissues of MS patients 
[85]. The dierences could be due to the fact that in this study, Th cells were cultured in 
the presence of IL-23 and therefore induces RORγt-mediated IL-17A expression [86]. We 
directly sorted the dierent T h subsets from the blood and stimulated these cells with 
PMA/ionomycin to assess their pro-inammatory cytokine proles. Moreover, the patho-
genicity of Th17.1 is further exemplied by their dual expression of T-bet and RORγt as well 
as high levels of genes such as IL23R, ABCB1 (MDR1; multidrug resistance), FCMR (TOSO; 
anti-apoptotic) and GZMB (granzyme B; cytotoxicity) (Chapter 2) [87-89]. In Chapter 3, 
we demonstrate that Th17.1 cells trapped in the blood of natalizumab-treated MS patients 
have increased ABCB1 and reduced NR3C1 (glucocorticoid receptor) expression. This, along 
with the enrichment of MDR1+ Th17.1 cells within CSF of early MS patients, indicates that 
glucocorticoid-resistant Th17.1 cells are recruited to the CNS to mediate early disease 
activity in MS. Glucocorticoids are broad range immunosuppressive drugs that are used to 
dampen acute relapses in MS [90]. However, relapses and disease progression are not pre-
vented. In Chapter 3, we also found that ex vivo Th17.1 cells present in meninges and brain 
tissues of end-stage MS patients have a glucocorticoid-resistant phenotype (MDR1high). 
This could explain why such therapies may not always be eective and puts forward MDR1 
as a potential therapeutic target on these cells to increase ecacy of glucocorticoids. 
The fact that granzyme B is abundantly expressed in Th17.1 cells provides new insights 
into the role of CD4+ cytotoxic cells during MS disease progression [91]. Although the causal 
MS autoantigen is still unknown, an indirect factor that could be involved in the develop-
ment of such cytotoxic Th cells in MS is the inadequate control of EBV-infected B cells by 
CD8+ CTLs [11, 73]. As mentioned above, antiviral CD8+ CTLs become exhausted during 




CD8+ T cell responses are decreased in MS patients [26]. Normally, CD8+ CTL responses 
are compensated by the induction of CD4+ cytotoxic T cells to keep persistent infections 
under control [92]. Following EBV infection, CD4+ cytotoxic T cells produce high levels of 
granzyme B, perforin, IFN-γ and IL-2 [93, 94]. This links to the fact that EBV-specic and 
myelin-reactive CD4+ T cells from MS patients produce high levels of IFN-γ and IL-2 [95] and 
strongly respond to B cells presenting myelin peptides [96]. Since CXCR3(T-bet)-expressing 
B cells are potent antigen-presenting cells [47, 76] and EBV infection alters B cell-intrinsic 
processing and presentation of endogenous antigens [73], one may speculate that chronic 
antigen presentation by EBV-infected B cells leads to CD8+ CTL exhaustion. Consistent with 
this assumption, in Chapter 5, we found that increased EBV load in reconstituting memory 
B cells from BMT-treated MS patients is associated with CXCR3 and not CXCR4 or CXCR5 
expression. Furthermore, we show that in MS patient blood, frequencies of (IFN-γhighIL-
17Alow) Th17.1 cells correlated to CXCR3+IgG+ B cells (Chapter 4). Although not directly 
proven in the current thesis, we argue that based on these and other studies, EBVhigh B cells 
and especially those expressing T-bet and CXCR3 probably escape from control by EBV-
specic CD8+ CTLs and interact with IFN-γ-producing Th17.1 cells within germinal centers 
of peripheral lymphoid organs. This would then promote pathogenic B and CD4+ T cells to 
inltrate the CNS and cause local inammation in MS [97, 98].  
LOCAL REACTIVATION AND EFFECTOR FUNCTION OF 
CNS-INFILTRATING B AND T CELLS IN MS
Although CD4+ Th cells are in general outnumbered by CD8+ CTLs in brain lesions as 
investigated in autopsy studies [18, 20], their role as triggers of local pathology should 
not be overlooked in MS. This is consistent with the enrichment of CD4+ Th cells in white 
matter lesions with active demyelination [18]. It has also been shown that in contrast to 
CD8+ CTLs, brain-associated CD4+ Th-cell clonotypes are reduced in MS blood, indicat-
ing selective recruitment (as described above) [99]. In addition to this, the fact that CD4+ 
Th17.1 cells have cytotoxic potential and co-express IFN-γ and GM-CSF (Chapter 2) may 
imply that these cells serve as the rst triggers in disrupting the permeability of the BBB 
during the early stage of MS [100, 101]. This will then allow many other cells including 
B and CD8+ T cells to inltrate the CNS (Fig. 1). Similarly, to CD4+ T cells, identical B cell 
clones have been found in the periphery and dierent CNS compartments of MS patients 
[102, 103], supporting their local recruitment [99]. B cells can predominantly be found in 
the perivascular space and associate with active white matter lesions in autopsy cases 
with acute and relapsing remitting MS [18] as well as in the meninges [103]. Within the 
meninges, B- and T cell-rich follicle-like structures are present that localize next to cortical 
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lesions, presumably mediating progressive loss of neurological function in MS [104, 105]. 
Interestingly, in MS brain-inltrating CD4+ T cells are able to express and respond to IL-21 
[106], the cytokine that that drives follicular T- and B-cell responses. Furthermore, IFN-γ 
triggering of B cells promotes ectopic follicle formation in autoimmune mice [40, 41]. Put 
together, it can at least be assumed that besides perivascular spaces in white matter, the 
formation of such structures, containing germinal centers, serve as a niche for B cells inter-
acting with IFN-γ-/IL-21-producing CD4+ T (Th17.1) cells to become reactivated in the MS 
CNS (Fig. 1). We found that both Th17.1 and CXCR3(T-bet)-expressing B cells are enriched 
in the meninges and brain tissue derived from end-stage MS patients (Chapters 2, 3 and 
4). Such pathogenic T- and B-cell subsets can lead to local damage in several ways. IFN-γ 
produced associates with the presence of demyelinating lesions in the CNS [107-109] and 
activates microglia and macrophages to cause damage to oligodendrocytes [110-112]. The 
same may be true for pro-inammatory cytokine GM-CSF, which can be produced by inl-
trating Th cells (Chapter 2) and B cells [110]. B cells have also been found to have increased 
production of TNF-α and IL-6 [49, 113], which could add to local lymphocyte activation and 
inammation. 
Aside from serving as antigen presenters and cytokine producers, the antibody-se-
creting function of B cells may play an additional role in mediating local inammation 
in MS. In Chapter 4, we have shown that during GC Tfh-like naive B-cell cultures, IFN-γ 
drives the dierentiation of IgG-producing plasmablasts in MS. Furthermore, high EBV 
load in memory B cells derived from natalizumab-treated MS patients corresponded to 
an increased potential to develop into CXCR3+ plasma cells capable of producing anti-
EBNA1 IgGs during these same cultures (Chapter 5). This suggests that EBV load not only 
inuences their CNS-homing capacity, but also their local dierentiation and function as 
professional antibody-secreting cells (Chapter 5). Consistently, both meninges and brain 
tissues of MS patients are enriched with plasma cells [114, 115] and there is an abundant 
presence of oligoclonal bands in MS CSF [49, 116]. Also supporting the local dierentiation 
of B cells into antibody-secreting cells is that anti-CD20 therapies in MS target bulk B cells 
(CD20+) and not plasmablasts/plasma cells (CD20-). Although the (auto)antigen specicity 
and eector function of locally produced antibodies remain unclear, we have shown that 
T-bet-expressing B cells display increased IgG1 switching (Chapter 4) and thus we argue
that IgG secreted by inltrating T-bet-expressing plasmablasts/plasma cells recognize yet
unknown antigens in the CNS to mediate local inammation in the MS brain [44, 46].
Several antigenic targets have been proposed to contribute to MS pathology. Next to 
myelin, which is one of the most intensively studied antigens [117], also EBV antigens are 
considered as major candidates. EBNA1-specic IgG antibodies are predictive for early MS 
disease activity [118] and are present in CSF from MS patients and not in controls [119, 120]. 




plasma cells correlated with the production of anti-EBNA1-IgG during GC-like memory 
B-cell cultures. Whether EBV is only recognized in the periphery or also present in the CNS 
and how this contributes to local pathology in MS is still under debate in the eld [15, 74, 
121-124]. The fact that EBV load corresponds to brain-homing memory B cells and their 
ability to develop into anti-EBNA1 IgG-secreting plasma cells in vitro at least adds to these 
controversies. Some studies imply that reactivated B cells in ectopic meningeal follicles 
[125, 126] present EBV peptides to activate EBNA1-specic CD4+ T cells that are cross-reac-
tive to myelin antigens [95, 127, 128]. Currently, also other candidate B- and T-cell antigenic 
targets are being proposed to be relevant for MS, such as sperm-associated antigen 16, 
neurolament light chain, RAS guanyl-releasing protein 2, αB-crystallin and GDP-l-fucose 
synthase [8, 129-132]. Whether our identied brain-inltrating B and Th-cell subsets in MS 
dierentially respond to these candidate antigens remains to be determined in the near 
future. 
CONCLUDING REMARKS
In this chapter, we have summarized the ndings within this thesis and discussed 
potential triggers and mechanisms through which interacting B and T cells could drive 
the pathogenesis of CNS demyelinating disease. In our presented models, we emphasize 
the dierences in selection and outgrowth of naive B cells between MS and NMOSD sub-
groups, probably as the result of impaired control by chronically exhausted CD8+ CTLs or 
functionally impaired Treg cells. The dierent mechanisms of IFN-γ- and CpG-dependent 
B-cell dierentiation under GC-like conditions may distinguish these two types of CNS 
demyelinating diseases. Furthermore, the specicity of autoantibodies in the majority of 
NMOSD patients is known and is thought to arise from autoreactive naive B cells in the 
periphery. These autoreactive naive B cells likely interact with eector Th cells in periph-
eral germinal centers to induce the development of plasmablasts/plasma cells, which 
secrete autoantibodies that enter the CNS to inict local pathogenesis in NMOSD patients. 
Although the exact (auto)antigen in MS is unknown, the disease pathology likely involves 
GC-dependent interaction of B cells with IFN-γ-producing Th cells within lymphoid organs, 
which creates a feedforward loop resulting in the development of highly pathogenic sub-
sets. Subsequently, these subsets break through blood-CNS barriers and, together with 
inltrating CD8+ CTLs, are locally reactivated to cause inammation and demyelination. 
Although denite proof is still lacking, these pathogenic events in MS are likely mediated 
by persistent infections such as EBV. We speculate that at least for this CNS demyelinat-
ing disease, EBVhigh memory B cells escape from peripheral CD8+ CTL-mediated control 
to induce cytotoxic IFN-γhigh Th17.1 development in genetically susceptible individuals. 
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In turn, Th cell-derived IFN-γ along with pathogen-associated triggers (e.g. EBV and CpG-
ODN) enhance CXCR3 and T-bet expression in memory B cells, making them prone to inl-
trate, further mature and respond to local antigens in the CNS (Fig. 1). 
FUTURE PERSPECTIVES 
Although the clinical course of MS and NMOSD is dierent and complex, both involve B 
and T cells that are directed at damaging the CNS. This thesis has made advances in iden-
tifying the phenotype and triggering of CNS-inltrating B and T cells in MS (Chapters 2, 3 
and 4). However, one remaining question is how do the functional programs of Th17.1 and 
CXCR3(T-bet)+ B cells dier between patient subgroups and controls? Further expansion 
on the single cell transcriptome and proteome of such subsets from various subgroups 
of patients (e.g. RRMS vs SPMS vs PPMS) versus controls should be undertaken to answer 
this question. In addition, isolating these exact subsets and using autologous co-culture 
systems (as described in Chapter 4) with antigens such as myelin or EBV could provide 
more insights into their antigen-specic interaction. Gaining further knowledge into their 
functional characteristics will also help to determine whether these subsets can be used 
as biomarkers to predict onset, progression and/or therapy ecacy. Since TLR9 trigger-
ing of naive B cells in NMOSD patients links to relapse occurrence, it would be interesting 
to see whether similar eects are seen in MS patients with high or low disease activity. 
Furthermore, the fact that T-bet-expressing B cells are induced with dual IFN-γ and TLR9 
stimulation and that T-bet is highly expressed by IFN-γ-producing Th17.1 cells as well 
suggests that targeting such cells in a ‘hit two birds with one stone’ approach may be a 
potential therapeutic strategy to further investigate. Small molecule inhibitors of the IFN-γ 
signaling (jakinibs) [133, 134] and TLR/myD88 pathway [135] are currently being used for 
treating other inammatory diseases. Such targeted treatments may be applied for com-
bined suppression of IFN-γ and TLR signals in B cells, thereby preventing their develop-
ment as well as their induction of pathogenic T cells in MS. 
Another remaining question is whether and how EBVhigh B cells play a role in the 
exhaustion of specic CD8+ CTLs and the induction of cytotoxic CD4+ T cells. In our view, 
more in-depth insights into how infections and genetic burden dene the CNS-inltrating 
potential and antigen specicity of such subsets should be the next step to take in the 
near future. This includes phenotypical analysis of EBV-specic CTLs using tetramers and 
exhaustion markers (e.g. CD160, PD-1, CD244, TIM-3, LAG-3) as well as assessing their 
function (cytokine production, cytotoxicity). Synchronously, EBV DNA load within B cells 
from patients and controls can be correlated to the exhaustion status of CD8+ CTLs. As 




CD4+ Th cells compensate to keep viral infections under control [92]. Since such cytotoxic 
Th populations have been associated with MS progression [91], a third question is whether 
these show similar characteristics to Th17.1 cells and whether EBV reactivity of such 
brain-inltrating Th17.1 cells are enhanced in MS. Similar to CD8+ CTL analysis, tetramer 
staining could be used to assess the phenotypical characteristics of potentially cytotoxic 
EBV-specic CD4+ T cells. Alternatively, stimulating bulk CD4+ T cells with EBV peptide 
mixes can be used to assess their phenotype and cytokine producing capacity. 
As for NMOSD patients, it would be interesting to determine whether Th17 cells that are 
involved in NMOSD [136] show a Th17.1 cell phenotype and are dierentially involved in 
inducing AQP4- or MOG-specic B-cell responses. Firstly, to decipher the distribution and 
dierent roles of Th17 (Th17.1, Th17 DP) subsets in NMOSD and MOGAD patients, periph-
eral blood from these dierent patient subgroups should be phenotyped to compare such 
distinct subsets. Secondly, as mentioned for MS, stimulating naive B cells in autologous 
co-cultures with CD4+ Th cells (or Th17.1 cells) can be used to assess their proliferation and 
dierentiation capacity. Lastly, TLR9 induces plasmablast formation in NMOSD patients 
with relapses and could potentially be used to predict relapses. Thus, measuring TLR9 
expression in B cells along with further investigating the use of CpG-ODN containing 
GC-like cultures of B cells to predict relapses from dierent NMOSD subgroups should be 
done in the near future. 
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APC Antigen presenting cell
AQP4  Aquaporin 4
ASC Antibody secreting cell
BBB Blood-brain barrier 
BCL-6  B-cell lymphoma 6
BCR B-cell receptor
BMT Bone marrow transplantation
CDMS  Clinically denite multiple sclerosis
CIS Clinically isolated syndrome
CD40L  CD40 ligand
CMV  Cytomegalovirus




CTL Cytotoxic T cell
CCR CC chemokine receptor
CXCR  CXC chemokine receptor
CXCL  CXC chemokine ligand
DP Double positive
DNA  Deoxyribonucleic acid
EAE Experimental autoimmune encephalomyelitis
EBV Epstein-Barr virus
EBNA1  EBV nuclear antigen 1
EDSS  Expanded disability status scale
ELISA  Enzyme-linked immunosorbent assay
FOXP3  Forkhead box P3
FACS  Fluorescence activating cell sorting
GC Germinal center
GM-CSF  Granulocyte-macrophage colony-stimulating factor
HLA-II  Human leukocyte antigen
HSC Hematopoietic stem cells
IFN-γ  Interferon gamma
IL Interleukin
Ig Immunoglobulin




MOG  Myelin oligodendrocyte glycoprotein
MRI Magnetic resonance imaging 
mRNA  Messenger ribonucleic acid
MS Multiple sclerosis
NCS Non-class-switched
NMOSD  Neuromyelitis optica spectrum disorder
NTZ/NAT Natalizumab
PBMCs  Peripheral blood mononuclear cells
RQ-PCR  Real-time quantitative PCR
RRMS  Relapsing remitting multiple sclerosis
SLE Systemic lupus erythematosus
STAT  Signal transducer and activator of transcription
TCR T-cell receptor
Th T helper
Tfh T follicular helper
Treg T regulatory
TLR Toll-like receptor
TNF Tumor necrosis factor
T-bet T-box transcription factor




The adaptive immune response plays a central role in both multiple sclerosis (MS) and 
neuromyelitis optica spectrum disorders (NMOSD). This has become evident from both 
genetic studies and B-cell depletion therapies in MS (discussed in Chapter 1) that show 
the involvement of both B and CD4+ T helper (Th) cells. B-cell depletion therapies further 
indicate that the interaction between B and CD4+ Th cells is a key mechanism driving MS 
disease activity. Additionally, both antibody-dependent and/or -independent functions 
of B cells contribute to the pathogenesis, which may dier between each disease entity. 
Deciphering which functionally distinct disease-relevant lymphocyte subsets are triggered 
to drive MS and NMOSD will help to better predict the early disease course and treatment 
response in patients. 
It is well known that CD4+ eector Th cells play a crucial role in the pathogenesis of 
MS. However, which exact eector Th subset shows increased pathogenicity in the earliest 
phases of MS is not fully understood. In Chapter 2, we used chemokine receptor expression 
proles to study the presence of Th1 (CCR6-CXCR3+), Th17 (CCR6+CXCR3-) and Th1-like Th17 
(CCR6+CXCR3+) cells in the peripheral blood of clinically isolated syndrome (CIS) patients 
who remained CIS for more than 5 years (CIS-CIS) and patients who developed clinically 
denite MS (CDMS) within 1 year (CIS-CDMS). The results were compared to relapsing 
remitting MS (RRMS) and matched healthy controls. Selectively reduced percentages of 
circulating Th1-like Th17 cells were found in CIS-CDMS and RRMS patients. In addition, 
Th1-like Th17 cells were enriched and co-produced high levels of IFN-γ and GM-CSF in 
the CSF of these patients. To further dene the role of Th1-like Th17 cells, we used CCR4 
as a marker to subdivide these populations into Th17 DP (CCR6+CXCR3+CCR4+) and Th17.1 
(CCR6+CXCR3+CCR4-/dim). This corresponded to distinct pro-inammatory cytokine proles 
for each subset (Th17: IL-17AhighGM-CSFlow, Th17 DP: IL-17AlowGM-CSFlowIFN-γlow, Th17.1: 
IFN-γhighGM-CSFhighIL-17Alow). Th17.1 cells showed the highest VLA-4 expression out of all 
Th subsets evaluated, which coincided with their selective accumulation in the blood of 
MS patients who clinically responded to natalizumab (anti-VLA-4 mAb) treatment. The 
fact that Th17.1 cells were prevented from migrating to the central nervous system (CNS) 
by natalizumab suggests that this subset has preferential transmigration abilities. This 
was shown in Chapter 2 by using in vitro transmigration assays and analyzing CSF from 
4 treatment-naive CIS and RRMS patients ex vivo. Besides for transmigration, Th17.1 cells 
showed enhanced pathogenicity through the expression of ABCB1 (MDR1), FCMR (TOSO) 
and GZMB (granzyme B), which are associated with steroid resistance, anti-apoptosis and 
cytotoxicity respectively.
MDR1 expression in Th17.1 cells was of particular interest as glucocorticoids are used as 
a standard treatment for acute MS relapses. This treatment does not prevent recurrent dis-
ease activity or disease progression in MS. To further determine whether such Th17.1 cells 




(ABCB1) and glucocorticoid receptor (NR3C1) amongst eector Th subsets in early-stage 
MS patients and controls in Chapter 3. Th17.1 cells that were trapped in the blood of RRMS 
patients treated with natalizumab (Chapter 2) showed increased ABCB1 and reduced 
NR3C1 levels as compared to healthy controls. MDR1+ Th17.1 cells were conrmed to be 
enriched in the CSF of 15 treatment-naive CIS and RRMS patients and not in patients with 
other inammatory or non-inammatory neurological disorders. The proportion of these 
cells were also increased in post-mortem brain tissues compared to blood of 8 late-stage 
MS patients. These results indicate that the glucocorticoid-resistant phenotype of Th17.1 
cells corresponds to their preferential recruitment to the CNS of MS patients. 
IFN-γ, which is produced the highest by Th17.1 cells as compared to other Th subsets, 
has been shown to induce autoimmune germinal centers and CXCR3 expression in B cells 
from mice. In Chapter 4, we gained insight into which peripheral B-cell subsets are capa-
ble of inltrating the MS brain and which peripheral triggers inuence their development. 
First, we phenotyped B cells derived from ex vivo post-mortem single-cell suspensions 
of CNS compartments paired with blood from end-stage MS patients using ow cytom-
etry. We observed an enrichment of CXCR3+ B cells in CSF, meninges and brain tissues 
of these patients. Next, we used blood from MS patients before and after natalizumab 
treatment to assess whether distinct subsets were prevented from migrating into the CNS. 
CXCR3highIgG1+ memory B cells appeared to accumulate after 6- and 12-months of treat-
ment. Their increased transmigration potential was further conrmed in vitro using human 
brain endothelial monolayers. Lastly, we used an in vitro culture system containing IFN-γ 
and/or CpG-ODN to mimic germinal center responses. IFN-γ and CpG-ODN synergized to 
enhance CXCR3(T-bet)-expression of dierentiating naive and not memory B cells. Both 
IFN-γ and CpG-ODN-induced T-bet expression was required for IgG1 switching, which 
correlated to the secretion of IgG1. Altogether, these data indicate that CXCR3-mediated 
transmigration and local reactivity of memory B cells in the CNS of MS patients may be 
attributed to IFN-γ and TLR9 triggering of T-bet. 
Chronic viral infections have also been described to sustain the development of T-bet+ 
B cells. Epidemiological studies show Epstein-Barr virus (EBV) infection is a strong contrib-
uting factor in MS. However, little is known about how such a persistent virus inuences 
the development of CXCR3(T-bet)+ B cells. In Chapter 5, we used peripheral blood from MS 
patients treated with bone marrow transplantation (BMT) to rst determine whether there 
is an association between CXCR3 expression and EBV infection in memory B cell subsets. 
We showed that EBV DNA load correlated with CXCR3, and not CXCR4 or CXCR5 expres-
sion in class-switched memory B cells in post-BMT blood samples. Next, we investigated 
whether high or low EBV DNA load impacted CXCR3+ memory B cell development into 
plasmablasts in vitro. Memory B cells from EBVhigh natalizumab-treated MS patients had an 
increased ability to dierentiate into CXCR3+ plasma cells during IFN-γ germinal center-like 
cultures as compared to EBVlow patients and healthy controls. The percentages of CXCR3+ 
plasma cells correlated with EBV DNA load, whereas the expression of CXCR3 on plasma 
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cells correlated with the production of anti-EBNA1 during these cultures. Although direct 
proof is not shown, these ndings imply that EBV plays a role in the brain-homing capacity 
of pathogenic B cells and their local production of anti-EBNA1 in MS. 
Both central and peripheral B cell tolerance defects have been found in NMOSD, which 
is in contrast to MS. Since little is known about the composition and outgrowth of such 
early naive B cells in dierent subgroups of NMOSD, we determined the proportions of 
naive mature and transitional B cells within the blood of treatment-naive and corticoste-
roid-treated AQP4-IgG-positive NMOSD and MOG-IgG-positive (MOGAD) patients as well 
as treatment-naive MS patients and healthy controls in Chapter 6. The ratio of circulat-
ing naive mature/transitional B cells was reduced in treatment-naive AQP4-IgG-positive 
NMOSD compared to other groups. In patients who had undergone steroid treatment, this 
ratio was increased as a result of decreased frequencies of transitional B cells. In addition, 
the enhanced naive mature/transitional B cell ratios correlated to time of treatment. To 
further assess the outgrowth of naive B cells into IgG-secreting plasmablasts, we used the 
same germinal center-like culture system as in Chapter 4 to induce plasmablast formation 
in vitro. Stimulation of naive B cells with both IFN-γ and CpG-ODN triggered plasmablast 
formation in AQP4-IgG-positive NMOSD and MOGAD patients with relapses, which was in 
contrast to patients without relapses and matched healthy controls. Interestingly, for AQP4-
IgG-positive patients, in vitro secretion of total IgG was increased for CpG-ODN-containing 
conditions and was even more elevated in the relapsing cases. Furthermore, AQP4-specic 
IgG secretion was only found for relapsing patients. These in vitro dierences were not 
seen for naive B cells from MOGAD patients. This study indicates that steroid treatment 
dierently aects the proportions of naive and transitional B cells and provides rst hints 
towards the use of TLR9-mediated germinal center-like cultures to predict NMOSD disease 
activity.
In Chapter 7, we brought the results from the above mentioned studies together and 
highlighted the similarities and dierences between MS and NMOSD. Furthermore, we 
proposed two models of how B and/or Th cells play dierent roles in the immunopatho-
genesis of each of these diseases. Primarily, in NMOSD patients, autoreactive B cells that 
have escaped early tolerance checkpoints interact with Th cells in the periphery to enter 
germinal centers and develop into AQP4- or MOG-specic IgG producing plasmablasts. 
These autoantibodies are capable of entering the CNS to induce local damage. In the 
case of MS, Th17.1 cells possibly interact with B cells within germinal centers in secondary 
lymphoid organs to produce brain-homing populations that further interact in the CNS to 





Het aangeleerde of verworven immuunrespons speelt een centrale rol in zowel mul-
tipele sclerose (MS) als neuromyelitis optica spectrum ziekten (NMOSD). Dit blijkt uit 
resultaten verkregen uit genetisch en B-cel depletie onderzoek in mensen met MS (zie 
Hoofdstuk 1). Hierin is aangetoond dat B en CD4+  T helper (Th) cellen zich anders gedra-
gen in mensen met MS in vergelijking met gezonde individuen. B-cel depletie studies 
geven verder aan dat de interactie tussen B en CD4+ Th cellen een belangrijke drijfveer 
is van het ziekteproces in MS. Zowel antilichaam-afhankelijke als onafhankelijke functies 
van B cellen dragen bij aan de pathogenese van MS en NMOSD, welke kunnen verschillen 
per ziektebeeld. Wij denken dat het ontcijferen van zowel humane B als CD4+ Th cellen die 
bepalend zijn voor ziekteactiviteit in MS en NMOSD zal helpen om het beloop van deze 
ziekten in de toekomst beter te kunnen voorspellen en behandelen.
Het is bekend dat CD4+ eector Th cellen een essentiële rol spelen in de pathogenese 
van MS. Wat echter niet precies bekend is, is welke eector Th subset zorgt voor verhoogde 
ziekteactiviteit in de vroege fase van MS. Om dit te achterhalen hebben we chemokine 
receptor expressie proelen gebruikt om de aanwezigheid van Th1 (CCR6-CXCR3+), Th17 
(CCR6+CXCR3-) en zogenaamde ‘Th1-like’ Th17 (CCR6+CXCR3+) cellen te bestuderen in het 
perifere bloed van patiënten met een klinisch geïsoleerd syndroom (‘CIS’), de vroegste 
fase van MS (Hoofstuk 2). Voor deze studie maakten we onderscheid in patiënten die 
geen (CIS-CIS) en wel (CIS-CDMS) een tweede neurologische aanval kregen en hiermee de 
diagnose MS. De resultaten hiervan zijn vergeleken met Th subsets uit relapsing-remitting 
MS (RRMS) patiënten die overeen kwamen in leeftijd en geslacht met gezonde donoren. 
De frequenties van circulerende, ‘Th1-like’ Th17 cellen bleken signicant lager in zowel de 
CIS-CDMS als de RRMS groep. Deze ‘Th1-like’ Th17 cellen waren verrijkt en produceerden 
hoge hoeveelheden aan IFN-γ en GM-CSF in het liquor van deze patiënten. Vervolgens 
gebruikten we CCR4 als derde marker om deze ‘Th1-like’ Th17 populatie onder te verdelen 
in ‘Th17 DP’ (CCR6+CXCR3+CCR4+) en ‘Th17.1’ (CCR6+CXCR3+CCR4-/dim) cellen. Deze subsets 
onderscheidden zich op basis van specieke pro-inammatoire cytokine proelen (Th17: 
IL-17AhoogIFN-γnegGM-CSFmid, Th17 DP: IL-17AmidIFN-γlaagGM-CSFlaag, Th17.1: IL-17AlaagIFN-
γhoogGM-CSFhoog). De Th17.1 cel bracht VLA-4 het hoogst tot expressie van alle Th subsets 
die onderzocht werden. Dit kwam overeen met hun selectieve ophoping in het bloed 
van MS patiënten die klinisch goed reageerden op behandeling met natalizumab (VLA-4 
antilcihaam). Het feit dat de Th17.1 cel ophoopt in het bloed van natalizumab-behandelde 
patiënten suggereert dat deze subset in staat is preferentieel de bloed-brein barrière te 
passeren. Dit werd in Hoofdstuk 2 aangetoond door middel van in vitro transmigratie 
assays en ex vivo analyses van liquoren verkregen uit 4 onbehandelde CIS en RRMS 
patiënten. Het ziekte-inducerend vermogen van Th17.1 cellen werd verder gekenmerkt 
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door selectieve expressie van ABCB1 (MDR1), FCMR (TOSO) en GZMB (granzym B), oftewel 
genen die respectievelijk te maken hebben met resistentie tegen glucocorticoïden, rem-
ming van apoptose en cytotoxiciteit. 
De expressie van MDR1 in Th17.1 cellen is interessant omdat glucocorticoïd stan-
daard wordt gebruikt als behandeling voor acute aanvallen in MS. Echter, deze behan-
deling voorkomt niet dat ziekteactiviteit zich herhaalt of dat de ziekte verergert in deze 
patiënten. Om te bepalen of Th17.1 cellen een verminderde gevoeligheid hebben voor 
glucocorticoïden en hoe dit relateert aan hun brein-inltrerend vermogen in MS, hebben 
we eerst de expressie van zowel MDR1(ABCB1) als de glucocorticoïd receptor (NR3C1) uit 
eector Th subsets in patiënten in een vroeg stadium van MS vergeleken met gezonde 
donoren (Hoofdstuk 3). ABCB1 werd hoger en NR3C1 werd lager tot expressie gebracht in 
Th17.1 cellen die ophoopten in het bloed van natalizumab-behandelde RRMS patiënten 
(Hoofdstuk 2) in vergelijking met gezonde controles. Daarnaast tonen we in dit hoofdstuk 
aan dat MDR1+ Th17.1 cellen verrijkt zijn in het liquor verkregen uit 15 onbehandelde CIS 
en RRMS patiënten in tegenstelling tot patiënten met andere inammatoire en niet-in-
ammatoire neurologische aandoeningen. De relatieve hoeveelheden van deze cellen 
waren ook verhoogd in post-mortem hersenweefsel in vergelijking met gepaard bloed 
van 8 patiënten met eind-stadium MS. Deze resultaten geven aan dat glucocorticoïd-resis-
tente Th17.1 cellen meer in staat zijn het brein van MS patiënten binnen te dringen.  
Het feit dat Th17.1 cellen hoge hoeveelheden aan IFN-γ produceren is relevant, omdat 
in muis modellen is laten zien dat deze cytokine betrokken is bij zowel de ontwikkeling 
van autoimmuun-gerelateerde kiemcentra als de expressie van T-bet en CXCR3 door B 
cellen. In Hoofdstuk 4 laten we zien welke perifere B-cel subsets in staat zijn om het brein 
van MS patiënten binnen te dringen en welke perifere signalen hun ontwikkeling beïnv-
loeden. Allereerst hebben we ex vivo B cellen uit verschillende breincompartimenten en 
het bloed van eind-stadium MS patiënten gefenotypeerd met behulp van ow cytometrie. 
Wij zagen een toename van CXCR3+ B cellen in het liquor, de hersenvliezen en het hersen-
weefsel ten opzichte van gepaard bloed van deze patiënten. Daarna gebruikten we het 
bloed van vroege MS patiënten voor en na behandeling met natalizumab om te bepalen 
of de migratie van dit soort subsets naar o.a. het centrale zenuwstelsel (CZS) geremd werd. 
Inderdaad, CXCR3+ geheugen B cellen, en met name de IgG1+ populatie die CXCR3 zeer 
hoog tot expressie brengt, bleken op te hopen in het bloed van deze patiënten na 6 en 12 
maanden van behandeling. Het verhoogde brein-inltrerende vermogen van deze B-cel 
subsets werd verder in vitro bewezen aan de hand van bloed-brein barrière transmigratie 
assays. Vervolgens hebben we een in vitro kweeksysteem gebruikt die een kiemcentrum 
reactie met dit soort B cellen nabootst. Enkel naïeve en niet geheugen B cellen lieten een 
verhoogde CXCR3 en T-bet expressie zien na toevoeging van IFN-γ als TLR9 ligand CpG-




verhoogde expressie en uitscheiding van IgG1. Aan de hand van deze data kunnen we 
concluderen dat voornamelijk CXCR3(T-bet)+ B cellen aangezet worden om het CZS binnen 
te treden en via IgG1 expressie waarschijnlijk beter kunnen reageren op lokaal aanwezige 
(maar op dit moment nog onbekende) antigenen.    
Muizen studies laten ook zien dat chronische virale infecties in toom worden gehouden 
door T-bet+ B cellen. Epstein-Barr virus (EBV) infectie is een sterke risicofactor voor het 
ontwikkelen van MS. EBV houdt zich schuil in de geheugen B cel, maar het is onbekend 
of dit virus een rol speelt in de ontwikkeling van CXCR3(T-bet)+ B cellen. Aangezien EBV-
reactivatie een veelvoorkomend verschijnsel is na beenmergtransplantatie (BMT), geb-
ruikten we het bloed van MS patiënten met een autologe BMT om dit te onderzoeken 
(Hoofdstuk 5). We toonden aan dat 3 tot 7 maanden na BMT, EBV DNA belading in deze 
cellen positief correleerde met CXCR3 en niet met CXCR4 of CXCR5 expressie op geheugen 
B cellen. Vervolgens onderzochten we of de mate van EBV belading in geheugen B cellen 
van invloed was op de dierentiatie naar CXCR3+ plasma cellen in vitro. Hiervoor maakten 
we gebruik van de ophoping van CXCR3+ geheugen B cellen die we zagen in het perifere 
bloed van natalizumab-behandelde MS patiënten (Hoofdstuk 4). Geheugen B cellen van
patiënten met hoge EBV belading bleken zich meer te ontwikkelen naar CXCR3+ plasma 
cellen dan die van patiënten met een lage EBV belading en gezonde controles. Het per-
centage CXCR3+ plasma cellen correleerde met EBV DNA belading, terwijl de expressie van 
CXCR3 op plasma cellen correleerde met de productie van EBNA1-speciek IgG. Alhoewel 
direct bewijs nog geleverd moet worden, geven deze bevindingen eerste aanwijzingen dat 
een EBV infectie bijdraagt aan het brein-inltrerend en (EBNA1-speciek) IgG-producerend 
vermogen van geheugen B cellen in MS. 
In tegenstelling tot MS, worden er in patiënten met NMOSD defecten gevonden in de 
selectie van autoreactieve B cellen in het beenmerg (centrale tolerantie). Recent is aange-
toond dat deze Bcellen in de vroege fase van hun ontwikkeling speciciteit vertonen tegen 
AQP4, het autoantigeen in een groot deel van NMOSD patiënten. Er is nog weinig bekend 
over de perifere ontwikkeling van naïeve B cellen in patiënten met AQP4-IgG-positieve 
NMOSD. In Hoofdstuk 6 hebben we de relatieve hoeveelheden van transitionele en 
naïef mature B cellen in het bloed vergeleken tussen zowel onbehandelde als glucocorti-
coïd-behandelde AQP4-IgG-positieve NMOSD en MOG-IgG-positieve (MOGAD) patiënten, 
MS patiënten en gezonde controles. De relatieve verhouding tussen naïef mature cellen en 
transitionele B cellen was verlaagd in onbehandelde NMOSD patiënten. Deze verhouding 
was juist verhoogd in glucocorticoïd-behandelde patiënten. Dit correleerde met de tijd 
sinds de start van behandeling en werd veroorzaakt door de afwezigheid van transitionele 
B cellen in het bloed. Om de uitgroei van deze naïeve B cellen tot antilichaam-producer-
ende cellen te onderzoeken, gebruikten we dezelfde kweeksystemen als in Hoofdstuk 4 en 
5. Het stimuleren van naïef mature B cellen met zowel IFN-γ als CpG-ODN zette de vorming 
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van antilichaam-producerende cellen aan. Dit was alleen het geval voor NMOSD en MOGAD 
patiënten met periodes van aanvallen en niet voor gezonde donoren (Hoofdstuk 6) of 
voor patiënten met MS (Hoofdstuk 4). Ditzelfde gold voor de uitscheiding van totaal IgG, 
met name voor naïef mature B cellen van NMOSD patiënten. Verder werd AQP4-speciek 
IgG alleen gedetecteerd tijdens kweken met B cellen van actieve NMOSD patiënten, ter-
wijl MOG-speciek IgG afwezig bleek in dezelfde kweken voor MOGAD patiënten met en 
zonder aanvallen. Deze studie laat zien dat de naïeve B-cel populatie selectief beïnvloed 
wordt door steroïd behandeling en geeft een eerste aanleiding tot verder onderzoek naar 
het gebruik van dit soort cellen in CpG-ODN-bevattende kweeksystemen om ziekteactivi-
teit in patiënten met NMOSD te kunnen voorspellen.
De resultaten van de bovengenoemde studies worden bediscussieerd in Hoofdstuk 
7, met daarin de overeenkomsten en verschillen van B-cel ontwikkeling tussen MS en 
NMOSD. Op basis hiervan brengen we twee modellen naar voren die laten zien hoe de 
interactie tussen B en Th cellen mogelijk een rol speelt in de pathogenese van beide ziek-
tes. In het geval van NMOSD, ontsnappen autoreactieve naïeve B cellen aan selectie in het 
beenmerg, waarna ze een interactie hebben met Th cellen in de kiemcentra van secundaire 
lymfoïde organen. Hierna ontwikkelen deze cellen zich onder invloed van IFN-γ en CpG-
ODN tot plasmablasten/plasma cellen, waarna autoantilichamen zoals AQP4-speciek IgG 
het CZS binnendringen om lokale schade te veroorzaken. In het geval van MS, ontsnappen 
B en Th cellen aan selectie in de periferie om zich te ontwikkelen tot brein-inltrerende 





From a small village in Lesotho to growing up in Taiwan, returning to South Africa for 
my Bachelor's degree and finally ending up in The Netherlands. Here I embarked upon a 
PhD journey I never thought I would begin but have so enjoyed and now it has come to 
an end. My research during this time has only confirmed the love I have for both the 
immunology and neuroscience fields with perfectly combining them in a thesis about 
central nervous system demyelinating diseases. Completing my PhD project would 
have never been possible without the help and support of many people who I would 
like to thank below. 
Dr. M.M. van Luijn, dear Marvin, while doing my Master’s internship under your supervi-
sion you asked me whether I ever considered to do a PhD. I told you straight away that I was 
unsure about this and that it is out of my comfort zone especially because my knowledge 
on immunology and MS was so little at the time. To which you answered ‘I will convince 
you otherwise’, and so you did when you presented me with this very challenging but 
interesting project about the role of EBV and B cells in MS. Oh, how things have changed 
over the course of the years with ‘small’ side projects leading to great publications and ever 
so slightly changing the course of my project with EBV taking a bit of a backseat. In the end 
though all my various projects had a connection in one way or another, mainly through 
CXCR3(T-bet)! Thank you for seeing the potential in me to do a PhD and for mentoring me 
these last couple of years (and a few more years to come!). You have taught me an immense 
amount about immunology, flow cytometry and MS. I admire your work ethic and how 
you seem to so easily and enthusiastically write articles, grants and especially rebuttals. 
Although, sometimes difficult to understand your line of thoughts, your feedback has 
helped my writing skills grow with each manuscript presenting its own challenges, yet you 
guided me through. Your enthusiasm and passion to unravel the different Th and B cell 
subsets that play a role in MS has inspired and driven me forward and has broadened my 
own interest to continue with research in the MS field!
Prof. dr. R.Q. Hintzen, dear Rogier, I want to thank you for taking me on as an intern and 
allowing me to continue my PhD in the MS(NIB) group. I am grateful for your encourage-
ment and, although sometimes confusing, but useful meetings we had throughout my 
PhD. Just over halfway through my PhD you passed away and couldn’t experience the end 
of this journey. Your extreme drive to solve MS has inspired me (and the NIB group) and I 
hope through the completion of this thesis that we have answered some of your burning 
questions. You were always very keen on having a chat about South Africa right before 
any of our meetings started, in which you always mentioned the beautiful flower gardens 
and wine routes that you wished to have visited. Although your Africa trip ended up being 
Tanzania instead of South Africa, I will also always remember the excitement with which 
you told me about the lions in the tree and immediately showing me the photo of this. 
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Prof. dr. P.D. Katsikis and Prof. dr. P.A.E. Sillevis Smitt, dear both Peters, thank you very 
much for your willingness to be my promotors under these extenuating circumstances. I 
appreciate the time, feedback and help you have both given me in order to complete my 
thesis book.  
I would like to thank my reading (sub)committee members, Prof. dr. Jon Laman, Prof. dr. 
Bart Jacobs and Prof. dr. Rudi Hendriks for your time and both positive and critical feedback 
on my thesis manuscript. I am also grateful to Prof. dr. Marieke van Ham, Prof. dr. Inge 
Huitinga and Prof. dr. Heinz Wiendl for being part of my PhD committee. I look forward to 
discussing the contents of my thesis with you! Here I would also like to say thank you to 
Marieke for our collaborations during my project and I hope to continue our collaborations 
with you in the future. To all other collaborators I would also like to say thank you for your 
input on our various articles together. 
The NIB group (Marvin included), writing one single paragraph to cover all of you will 
not do you justice so I will try and write a small (crisp and clear) paragraph for each of you 
as you all played such dierent roles in helping me through my PhD. Collectively, I can say 
that having travelled extensively throughout my life, I am so glad I managed to meet a 
group like you where I feel right at home. All of you were present at my Master’s graduation 
(like a third family) when my parents couldn’t be there. You all have also helped me to 
improve my Dutch through meetings, lunches etc. although I have yet to prove that to you 
by speaking it in your presence.
Marie-José, from day one we could comfortably chat about many things, including our 
love for food and trying out various dierent restaurants (many tips coming from you). 
Thank you very much for making me feel so at ease in the group, your moral support 
throughout my PhD and for helping me whenever Annet was unavailable. Being the orga-
nizer in the group you were always willing to organize birthday gifts, order antibodies/
reagents needed for my experiments and sometimes doing it even on your day o because 
it was a rush order – this was very much appreciated! You also taught me how to culture 
and take care of my “babies” in the lab, which at the beginning I kept forgetting about. Our 
many train rides to and from Delft have also been appreciated, especially if I had a dicult 
and long day and could let o some steam. During the rst COVID-19 lockdown, our visits 
meant so much to me, especially because it was during the last year of my PhD when I 
needed a lot of encouragement to get through all the writing.  Your support throughout, 
in many shapes and forms, has denitely helped me reach this end goal!   
Annet, you were/are always willing to help me with an experiment no matter how big 
or small, complicated, or simple. I cannot thank you enough for all the help you have given 
me over the years both inside and outside of the lab. You have taught me so much in the 
lab, starting from multicolour ow cytometry all the way to DNA isolation, qPCR and the 




of experiments for the Th17.1 Brain paper that I realized we work so well together in the 
lab, being able to start an experiment and take over so easily from each other whenever 
needed – like a well-oiled machine. During this time you had my back and supported me 
through the early mornings, late nights and even having 6 weeks to tackle a new protocol 
using transmigration assays that we have never used before. I admire your patience and 
the calmness with which you do each experiment (although sometimes it seems like chaos 
when last minute changes do happen, sorry for those..). I could not have completed this 
PhD without your support, experimental insights and even at times help with calculations. 
I am so happy to have you as my paranymph!
Liza, we have gotten to know each other well, being in the same group, during con-
ferences and the last 2-3 years when we were oce roommates. How I enjoyed our brain-
storm sessions, chats, laughs, helping each other through dicult times and sharing cute 
nephew and niece videos. I would also never have found my way in dierent cities and 
conference venues without you (I was always following you like a sheep ;)). You have also 
taught me a lot about B cells and in the end, we could joke and maybe convince the others 
that B cells are just as important as T cells in MS! We ended up writing our thesis books 
alongside each other and for this I am grateful, especially for your help, understanding and 
encouragements through both the good and more dicult times. Thank you for agreeing 
to be one of my paranymphs! We denitely have to have a nice big celebration when all 
the restrictions are lifted. I wish you lots of success in your new career path and do not be 
a stranger! 
Steven, where should I begin, maybe with a speedvac tease.. Thank you for providing 
me with ample material and allowing me to joke with you from time to time, making me 
laugh each time. You took over from me and expanded our research on Th17.1 cells. I am 
happy to see that you have been able to gather some nice results and a great publication 
that conrm our hypothesis (MDR1 rocks!). T hank you for your critical insights into my 
projects and for less serious coee moments away from the lab as a small break to escape 
reality. I wish you success in completing your PhD project. Remember to take a breath 
now and then, you will get your publications (with almost another publication on the way 
already - at the time of writing this ;)) and have an awesome thesis book! 
Dr. J.J.F.M. Smolders, dear Joost, I still find it difficult to figure out when you are being 
sarcastic or serious! I do appreciate your enthusiasm and insight into the projects I had 
ongoing when you joined our group. Also thank you for reading and giving me such 
positive feedback on my thesis book. Your positive attitude and thoughts on sometimes 
difficult/negative results has helped me throughout this last year to gain back my own 
positivity. You have now also peaked my interest on CD8 T cells and I hope to continue 
some side-line research on them. 
To my students, Ilse, Larissa and Caroline, thank you for your help in my various studies!
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To the new and old members of the ErasMS center, and to name a few Roos, Yuyi, 
Arlette, Katelijn, Beatrijs and Dorine, thank you for your contributions to my/our articles. 
Without your continued supply of patient material and looking up information, these studies 
would never have been possible. With this I would also like to thank the MS and NMO patients 
for taking part in our studies! Gijs and Peter-Paul, thank you for your help and collaborations 
throughout my PhD project. Gijs, especially at the beginning of my PhD, thank you for our 
conversations and your thoughts about how EBV infection is involved in MS.  
The IMN group, Anne, Ruth, Wouter, Willem-Jan and Sander, thank you for all the enjoy-
able lunch chats, coee moments and your support on all the dierent things I have gone 
through during the last few years inside and outside the lab. In addition to this, we share 
the same space in the lab and have had many moments to laugh about when doing com-
pletely dierent experiments side by side. Anne, I appreciated the many early mornings 
when you arrived with your cheerful good morning and sometimes startling me when I 
was so deep in thought that I didn’t realize someone else was in the lab so early!   
Fabian, we had many laughs and serious conversations during the course of our PhD 
projects. Thank you for your encouragement, advice and for showing me how passionate 
someone can be about the work they do. I wish you success with completing your thesis 
book, you are almost there! 
Manzhi, thank you (Xiè Xiè Ni) for always being honest and saying exactly what you 
think! I respect the fact that you can carry on with your research while your baby son is 
in China with your husband, this must be incredibly dicult for you. We started approxi-
mately at the same time with our PhDs and are ending very close to each other, thank you 
for your wisdom and many chats we had! You will accomplish great things in life, and you 
are almost there as well with your thesis book. 
Iris and Dew, both of you are now ocially Doctors!!! Dew, I will always respect how 
hard you worked for your PhD and always with a smile on your face! I also never could 
understand how you managed to work through the many chats Iris and I had in our oce. 
Iris, as you mentioned in your thesis book, I should also write this to you in Dutch to prac-
tice, but as always, my excuse is it is not good enough so I will spare you the grammar and 
spelling mistakes. I miss our chats very much since you left and also, your support and jokes 
about me opening the door way too loudly (keeping a tally to remind me that I owe you 
and Dew sushi when it got over a certain limit!). Thank you for being the friend I needed at 
every corner throughout my PhD (even when you left you were always a WhatsApp away!) 
and I know we will continue to be friends outside of our work! 
Marie-Joan, you are one of the most bubbly and positive people I know (you remind 
me a lot of my mom with your personality). I have really enjoyed our occasional chats in 
your oce (thank you for the support) and you could always brighten up my day when we 




To the two sort machine operators Harm and Peter, I am very thankful for your help. 
Almost all my studies required the sort machine in one way or another and I could always 
rely on your willingness to start early, nish late and sort simple or complicated cell 
populations! 
To all the new and old fellow PhD students, Erika, Javad, Manhaz, Christiaan, Astrid, 
Olivia, both Martijn’s, Emma, Benjamin, Jorn, Paul, Ling, Verna, Ziye, Britt, Christina, Anne, 
Wida, Xiaofei, Malou, Martine, Marjolein, Wida, thank you each for your individual support 
and as a group fun PhD retreats! 
To the many colleagues at the Department of Immunology (workgroup leaders, 
Postdocs and technicians), we have in one way or another crossed each other’s paths, be it 
“borrowing” antibodies from diagnostics, lab days, Christmas/New Year’s dinners, lunches, 
birthday celebrations, remaining logged in on analysis computers for long periods of time 
(sorry for this...). Thank you all in contributing in your own way in supporting me through 
my PhD project! A special thanks to Jane and Corine for the interest and many chats!  
To Bibi and Danielle, I am grateful for your help in formatting my thesis book and 
for easily adapting the numerous changes I kept throwing your way. This has definitely 
helped in saving me time! 
Last but not least I would like to thank my friends and family outside of academia.
Stephie Houlberg and Rie Kanaya, thank you for your continued support from afar and 
for your understanding that if I take weeks before responding to your WhatsApp messages 
or e-mails that you are still important friends to me and that I am thinking of you! I appre-
ciate that our friendships are so strong that when we have not spoken in months or seen 
each other in years that when we do get to see each other it feels like no time has passed. 
Mamma, “ek kan, ek wil, ek sal” – my hele lewe se Ma dit vir my maar ek het dit die 
meeste waardeer terwyl ek my PhD gedoen het, veral aan die einde. Baie dankie vir Ma se 
ontsettend baie aanmoediging en positiwiteit deur hierdie “journey” van my. Al verstaan 
Ma glad nie wat aangaan in die Projek van my nie, Ma vra altyd hoe dit gaan en hoe almal 
is. Al irriteer dit vir my wanneer Mamma vir my se moenie worrie nie, aan die einde is 
Ma meestal reg dat dinge altyd sal uitwerk soos dit moet. Pappa, maak nie saak hoe ver 
my veld van studie/werk afwyk van Pappa s’n nie, Pappa het altyd moeite gedoen om te 
probeer verstaan presies wat dit is wat ek navors (ten minste het ons projekbestuur in 
gemeen 😊😊). Ek moes selfs aanvanklik een of twee keer vir Pappa wys wat my PhD projek 
behels deur middel van ’n aanbieding. Dankie vir die aanmoediging om hierdie sprong te 
neem asook die geleentheid te bied en die ondersteuning om oorsee te kan studeer. Dit 
sou nie moontlik gewees het sonder Pappa se hulp nie. Ek weet dat opvoeding vir Pappa 
baie belangrik is en ek waardeer dit dat Pappa my ondersteun het om so ver te kon kom. 
Karien, Gideon, Bailey en baba Leah, baie dankie vir die steun en amper daaglikse fotos 
van Leah (veral in my laaste jaar of twee) en ook die video chats – dit het my baie gehelp 
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om haar glimlaggie en vrolike persoonlikheid te sien en ook hoe sy so mooi opgroei. Dit 
het ook gehelp om my aan te moedig om klaar te maak so dat Christiaan en ek ook ’n 
familie kan begin. Karien ook vreeslik baie dankie vir die mooi “cover” en “inside pages” van 
my boek, jy het so `n onsetend mooi kreatiwiteit en talent wat ek dink jou baie ver gaan 
bring in die lewe. Ek kry baie komplemente oor my oorbelle van jou wat ek daagliks dra!  
Oupa en Ouma Visser, elke keer as ek met Ouma praat dan vra Ouma of ons al ’n terapie 
onwikkel het om MS te stop, ongelukkig het ons nog nie so ver gekom nie. Maar ons het 
darem klein stappies al geneem om meer te verstaan wat gebeur in die siekte aktiwiteit 
van MS. Oupa ek onthou nog hoe ons baie aande op die stoep gesit het en gepraat het oor 
my belangstelling en wat ek een dag wil doen, een ding was virseker ek wou nie physics 
doen nie (maar dit het terug gekom op ’n klein manier tydens my studie). Van Oupa het ek 
geleer om vas te byt en enige ding kan n werklikheid word as jy net wil. Altwee baie dankie 
vir julle ondersteuning van al die pad uit Moorreesburg!
Oupa James, eendag het Oupa vir my iets gesê wat in my gedagtes gebly het “mense 
versamel altyd iets, dit kan geld wees, dit kan familie wees, dit kan materialistiese goed 
wees of kennis” in my geval is dit kennis en dit het Oupa ook goed geweet (alhoewel Oupa 
gedink het ek moes n “lawyer” geword het)! Ek het ook altyd vir Oupa gesê as ek ooit my 
PhD klaar maak sal dit met die van Langelaar naam wees omdat ons dit nie kan aandra in 
ons familie nie. Baie dankie vir al Oupa se ondersteuning en wyse woorde deurgaans! 
My schoonfamilie and Nuggy, without your support and willingness to take me on as 
your extra daughter, I would never have been able to come to the Netherlands to join 
Christiaan. I am so happy we met you in Taiwan. I will also never forget how small the world 
is when we returned to South Africa and my dad came home to say he works in the same 
building as Rene without even knowing where he was working at that time. Hellen, you 
were always ready for a chat when I returned home during the days we were still living with 
you. Thank you so much for your encouragement and long chats!! Rene, you are always 
ready with some wise words, we even went through a couple of coaching sessions while 
you were in Australia. Thank you both for always listening and being there when I needed 
it the most and Rene for helping me with my Dutch summary (although it has changed 
alot now). My sister in-law, Meylin, quite a challenging name when parts of my thesis 
involves the word myelin, every time I typed this word, I would type your name first! Thank 
you for your continued support and the sometimes random conversations we have had to 
take my mind off of the PhD. Although that was difficult, I always wanting to vent about 
various things, but you were always there ready with a listening ear or a glass of red wine! 
The moments I enjoyed the most were when we started jogging and then after a couple of 
minutes we decide naahh and just walk the rest of the way while dad runs ahead of us (I am 




to time in Markelo….). You are a very positive person by nature and I am very happy that 
you managed to find your own passion by now working at the World Animal Protection 
agency – I wish you continued success in this career path! Ook bedankt aan oma Hulleman 
voor de interesse en aanmoediging.
To my husband Christiaan, thank you for listening to my joyous moments, frustrations 
and long stories (with one ear open and the other covered by headphones while playing 
X-box)! Your enormous amount of support and wanting to come up with solutions to my 
problems has helped me through this journey. When the day came that you started your 
PhD, I thought finally I have a companion that understands all the ups and downs of doing 
a PhD. But so wrong was I, because from day one I could see the passion and joy you have 
for your own project. Your positivity during your project has inspired me and helped me 
to put a positive spin on difficult situations. You are almost there with completing your 
thesis – hang in there and I know you will do great at your defence! I could go on and write 
a whole book about our journey starting from way back when we met in Taiwan, surviving 
a time of long distance and then finally me joining you in The Netherlands. Hopefully from 
here on we can hop from country to country together as a family . Thank you again for 
all your patience and understanding with early mornings and long nights throughout this 
time. Ek is onsettend lief vir jou!
To end with I would like to dedicate this thesis to Oupa James van Langelaar (94) and 
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